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Abstract 
 
Mucus is a dynamic gel network primarily composed of water. The principal 
“non-water” component of mucus is mucin, a macromolecular glycoprotein largely 
responsible for the viscoelastic gel nature of mucus. Recent evidence indicates that 
some inhaled antibiotics are bound by mucus components and their biological 
activity reduced.  
This thesis focussed upon the mucin binding of a panel of epithelial sodium 
channel (ENaC) blockers that have been studied as experimental therapeutic agents 
for cystic fibrosis (CF). Using porcine gastric mucin (PGM) as a model system the 
directional transport of FL-Na, FITC dextran probes (4-70 kDa) and two ENaC blockers 
was determined using Franz diffusion cells. Size-dependent restriction of dextran 
transport was accompanied by a large disparity in the passage of two structurally 
similar ENaC blockers with differing lipophilic character. A 96-well ultrafiltration assay 
was developed to study mucin-binding of 12 related ENaC blockers of two main 
structural groups: quaternary amine compounds (QQA) and non-quaternary amine 
(NQQA) analogues. The extent of binding was variable within sub-groups and 
correlated well with Log P o/w. Other physical parameters (e.g. rotatable bond 
number, PSA) served as good correlates only for QQA structures. In contrast, the 
apical-basolateral transport of ENaC blockers across restrictive Calu-3 monolayers 
was not clearly predicated by solute hydrophobicity. Saturation Transfer Difference 
(STD)-NMR spectroscopy was used to gather structural details of mucin-drug 
interactions. These studies provide the first evidence that STD-NMR can be used to 
identify discrete molecular regions that participate in interactions with mucin.  
In conclusion, these data indicate that some inhaled drugs undergo reversible 
interactions with mucus. This finding could have wide implications for the design of 
new inhaled therapies for lung diseases where binding to supraphysiological amounts 
of airway mucus may modulate drug disposition and clinical response. 
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Chapter 1 : General Introduction 
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1.1 Pulmonary Delivery  
Pulmonary delivery of drugs has become an attractive target of scientific and biomedical 
interest in the health care and research area thanks to capability of lung of absorbing 
pharmaceuticals either for local transport or for systemic delivery. The lungs provide a 
huge surface area of alveoli, of approximately 70-140 m2 in adult humans, (1) with a rich 
capillary network which acts as an excellent absorbing surface for administration of 
drugs.  
The first to demonstrate that the lungs were naturally permeable to peptides   was    in 
1925 when Gansslen (2) discovered the possibility to lower blood glucose in diabetic 
subject following inhalation of insulin, 51-amiino-acid peptide (5.7 kDa). Later in 1989, 
Patton, McCabe (3) showed that human growth hormone (hGH), 192-amino-acid protein 
(22 kDa), following instillation into the rats’ lungs was absorbed into the systemic 
circulation. 
Initially, pulmonary delivery seemed to be complicated and unreliable due to its 
unknown long-term safety. Things changed in 1990 when a startup company (Nektar) 
started the development of inhaled insulin, and is now being continued by a variety of 
companies (4). Particularly for drugs with poor oral absorption such as peptides and 
proteins (5), the pulmonary route promises a progressive alternative way of reaching the 
systemic circulation (thereby avoiding painful injections). Compared to the 
gastrointestinal tract and liver, in the lungs drug-metabolizing enzymes are in much 
lower concentrations (6) (7)  and the inhaled drug are less likely to be degraded than if 
they had been delivered orally. This huge advances in aerosol technology allows to 
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control deposition, to deliver aerosols at the correct part of the inspirational cycle and 
increase reliability of deposition pattern. Thanks to advancement in application, 
nowadays pulmonary drug delivery is useful to treat several disease diabetes (8), bone 
disorders (9), tuberculosis (10), migraine acute lung injury and others.  
Currently, inhalation therapy is the best option for lung diseases like asthma, cystic 
fibrosis, and COPD. The most commonly used aerosols, designed for local drug delivery 
in the therapy of lung diseases contain bronchodilators used to improve mucociliary 
clearance in COPD (11), or glucocorticoids that are applied directly to the lung for therapy 
of obstructive airway and inflammatory diseases. Pulmonary delivery is also used for 
local delivery of aerosolized aminoglycosides such as tobramycin, for the treatment of 
pulmonary infection by P. aeruginosa (12).  
 
1.1.1 Anatomy of the pulmonary tract 
The pulmonary tract includes tracheo-bronchial tree, which resembles an inverted tree, 
bronchus, bronchiole and alveolus. The trachea has an inner diameter of about 25 
millimetres and a length of about 10 to 16 centimetres, is made of about 20 rings of 
tough cartilage rings with a membrane in between. The trachea is nearly but not quite 
cylindrical, being flattened posteriorly, in fact the back part of each ring is made of 
smooth muscle and connective tissue. The point where trachea branches in bronchus is 
called carina (Figure 1.1). 
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The lung anatomy can be described with the Weibel model, which is the simplest model 
of human lung developed in 1963. Weibel represented the lung anatomy as a system of 
23-fold bifurcating tubes, called generations, based on the dimension of the airways. 
Weibel divided the lung into two zones: conducting zone and respiratory zone. The only 
function for the conductive zone is to direct air into the lung. Gas exchange occur only at 
the respiratory zone inside alveoli. 
In the Weibel model, the trachea is indicated as generation 0 (G=0), this is a straight duct 
and at its end is divided in right and left mainstem bronchus that serve the right and left 
Figure 1.1 Trachea anatomy 
The trachea begins immediately below the larynx. Around the trachea wall there is a series of 16 
to 20 C-shape cartilage rings. Rings encircle the front part of the trachea but are open where the 
trachea lies next to the esophagus. The tracheal rings are joined together by anular ligaments. 
The trachea bifurcates into the primary bronchi  and the cartilaginous ridge at the site of the 
tracheal bifurcation is called Carina. Taken from Healthy lifestyle, 2013. Human Anatomy Trachea. 
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lung respectively. Bronchi successively branch into increasingly narrow and short 
bronchioles until G=16. At this point the respiratory tract is still surrounded by cartilage. 
After G=16 bronchioles no longer have cartilage around. After a total of about 23 
divisions, the bronchioles end at alveolar ducts. At the end of each alveolar duct, there 
are clusters of alveoli (air sacs), which is the site where gas exchange occurs (Figure 1.2 
(13).  
 
Figure 1.2 The Weibel model of lung anatomy 
The airway structures of Weibel’s model branches in 23 generations with the trachea 
representing the G=0. The lung is divided into two zones: the conductive zone comprising 
covering G=0 to 16 (including trachea, bronchi and bronchioles) and the transitory and 
respiratory zone from G=17 to 23 (including respiratory bronchioles, alveolar ducts and 
alveolar sacs). Taken from (13). 
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1.2 Barriers of the pulmonary route 
 1.2.1 Formulation challenges 
A very controlled aerosol creation process is required to achieve highly controlled drug 
doses in fine droplets or particle clouds. The complexity of pulmonary delivery derives 
from the need to quickly convert formulations into fixed-dose aerosol clouds and to 
deliver these in a minimum number of inspirations. Particles of the aerosol clouds should 
be neither too large (to avoid deposit primarily in the upper airways, mouth and throat), 
nor too small (exhalation risk). 
One of the most important design variables for an aerosol formulation is the particle size. 
Aerosol sizes, expressed as aerodynamic diameters, depends on the area of distribution  
and should preferably be 3-7 μm for tracheobronchial deposition, or 1-3 μm for  
deposition in the lower pulmonary regions (14). The design of the particles should be so 
accurate to make sure it will reach a specific region of the respiratory tract. 
The deposition of a particles depends on the flow velocity, particle size, density and rate 
of breathing so mainly occurs near the bifurcations of large conducting airways where 
air velocities are high. Gravitation sedimentation occurs for the deposition in the small 
conducting airway of particles with diameter of 1-5 μm, while with diameter of 0.5 μm 
or less, acquire a random Brownian motion which can result in particle deposition in 
small airways and alveoli where air velocities are very low. 
Another barrier for particle deposition in aerosol therapy is the physical interactions of 
particles such as van der Waals (due to electromagnetic nature of particles), or 
mechanical interlocking, depending of the roughness surface, (15) (Figure 1.3).  
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The physical-chemical stability and pharmaceutical properties (e.g. dissolution) of the 
active pharmaceutical ingredient may be enhanced with the use excipients which act to 
improve formulation efficacy but are not intended to have therapeutic effects (e.g. 
sugar, cholesterol). Despite the efficiency of advanced dosage form designs, certain 
barriers, such as cells of the airway or alveolar epithelium, and mucus, still compromise 
the absorption of drug, peptides and proteins by the lung.  
 
Figure 1.3 Example of particles interaction. Particles 2µm in diameter will deposit in bronchi. 
Particles may undergo to van der Wall interaction or particles of a certain shape can mechanically 
interlock forming a larger particle with consequent deposition in a different site. 
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1.2.2 Biological barriers  
The air we breathe is full of chemicals and harmful substances, including dust, bacteria, 
fungi, viruses and pollutants. The respiratory system is equipped with a number of 
defence barriers to clean and protect itself: bronchial and trachea epithelium, alveolar 
epithelium, macrophages and mucus 
 
Bronchial and Tracheal Epithelium  
The epithelium lining the upper airways is classified as ciliated pseudostratified columnar 
epithelium. At least eight morphologically distinct epithelial cell types are present in 
human respiratory epithelium, although based on ultrastructural, functional and 
biochemical criteria these may be classified into three: ciliated cells, secretory cells and 
basal cells (Figure 1.4). The ciliated cells (Figure 1.4) are columnar epithelial cells with 
specialized ciliary modifications. They are the predominant cell type within the 
conducting airways, accounting for over 50% of all epithelial cells (16). Up to 300 cilia/cell 
are usually present on a cell's surface and beat in a coordinated manner from the lung 
to the throat (17). Basal cells are small, nearly cuboidal cells thought to have some ability 
to differentiate into other cells types found within the epithelium (Figure 1.4) (18). Within 
the epithelium, basal cells are the only cell that are firmly attached  via hemidesmosomal 
complexes to the basement membrane and as such, play a role in the attachment of 
more superficial cells to the basement membrane (19). Secretory cells (Figure 1.4) are 
columnar epithelial cells that contain membrane-bound mucous granules and secrete 
mucus to trap foreign objects in the airway lumen (20). Production of the correct amount 
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of mucus and the viscoelasticity of mucus are important for efficient mucociliary 
clearance (MC) which is a mechanism that protects the lungs from deleterious effects of 
irritants and pathogens. The foreign matter is trapped by the mucus and moved up to 
the muoth thanks to the beating of cilia where is swallowed or coughed up. 
In normal human trachea, it is estimated that there are up to 6800 mucus-secreting 
cells/mm2 of surface epithelium, although in chronic airway inflammatory diseases such 
as chronic bronchitis and asthma, mucous cell hyperplasia (increase in the number of 
cells) and metaplasia (replacement of one differentiated cell type with another mature 
differentiated cell type) is a common pathological finding and is thought to contribute to 
the productive cough associated with these diseases (21). These cells are thought to be 
capable of self-renewal and may also differentiate into ciliated epithelial cells (19). 
Secretory cells have been further divided into subtypes based on their microscopic 
appearance, Club, goblet, and serous cells which are three types of non-ciliated epithelial 
cells.   
Figure 1.4 Airway Epithelium. Micrograph depicting the main components of the 
tracheobronchial epithelium, ciliated and goblet cells. The nuclei of basal cells are present also. 
Taken from Junqueira and Carneiro, Basic Histology, a text and atlas, p. 350, Figure 17-2. 
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• Goblet cells, so named because of their ‘wine goblet’ shape, are the predominant 
secretory cell of adult human tracheobronchial surface epithelium, are glandular 
simple columnar epithelial cells whose function is to secrete mucin. In the 
respiratory tract they are found inside the trachea, bronchus, and larger 
bronchioles. The nuclei tend to be displaced toward the basal end of the cell 
body, leading to intense basophilic staining. Goblet cells are the secretory cell 
generated in larger numbers in response to infection (22) and chronic irritation (23) 
of the airways.   
• Club cells are the predominant secretory cell is the in the bronchioles, are smaller 
and less numerous of the other secretory cells and with an irregular shape. Club 
cells (formerly known as Clara cells) are dome-shaped cells with short microvilli 
and are found in the bronchioles. They can be distinguished from goblet and 
serous cells by low cuboidal shape. Moreover, they act as a stem cell being 
progenitor cells of goblet and ciliated cells (24). Secreting a small variety of 
products, such as Club Cell Secretory Protein (CCSP) and 10 a solution similar to 
the lung surfactant, Club cells protect the bronchiolar epithelium.    
• Serous cells, with goblet cells, are considered to be progenitors of the secretory 
cells of the trachea. They are present in the tracheobronchial tree. Serous cells 
exist in the human epithelium before birth but not after (25). After birth it is 
possible to find serous cells only at submucosal glands. They protect the airway 
surface from the destructive effects of bacterial producing one or more protease 
inhibitors (26). For this reason, serous cell resembles an immobilized neutrophil.  
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        The Alveolar Epithelium 
There are three major cell types in the alveolar wall: Type I pneumocytes (squamous 
alveolar) cells that form the structure of an alveolar wall. These cells that make up 90% 
of the alveolar surfaces area (27). They are specialized in gas exchanges, in fact serve as 
very thin (often only 25 nm deep) gas-permeable components of the blood-air barrier. 
Type II pneumocyte (great alveolar) constitute 15% of the lung and 10% of the total 
alveolar cells (27). They are interspersed among the type I cells, to which they attach by 
desmosomes and occluding junctions. Type II cells pneumocytes are secretory cells. Their 
secretory product, pulmonary surfactant, is assembled and stored in the lamellar bodies. 
Surfactant is continuously released by exocytosis. Alveolar macrophages, known also as 
dust cells, destroy foreign material that escapes the mucus and cilia in the conducting 
portion of the system. Alveolar macrophages are important regulators of immune 
system activity through secretion of pro/anti-inflammatory cytokines (IL-1, IL-6, IL-8, 
TGF-β), but are also involved in the phagocytosis of cells in the normal lung that have 
undergone cell-death (apoptotic or necrotic cells) for cell turnover, repair of injured 
epithelium (28). 
 
Lung surface lining (mucus and surfactant)  
Mucus is a complex aqueous mixture of water (95%) and solids glycoproteins (mucins) 
(1-5%), mineral salts (0.5%), lipids (0.5-1%), free proteins (1%) and cellular debris (29). The 
higher levels of the respiratory tract, trachea and bronchi, are covered by a mucus gel 
layer, which in the case of the mammalian trachea and large bronchi was observed to 
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average 1-10 μm in thickness and is situated at the level of the tip of the cilia. Specialized 
epithelial cells called secretory cells secrete mucus, which adheres to the epithelial 
surface and forms a protective diffusion barrier between the lumen and the cell surface. 
The respiratory mucus gel performs a number of essential functions that collectively lead 
to the protection of the airways. Mucus secretions have important protective and 
lubricative properties, primarily owing to their ability to form a gel layer adherent to the 
underlying epithelium. In the airway, the major functional role of mucus is to entrap 
foreign particles and pathogens facilitating their clearance from the lung by means of 
ciliary transport or cough (30). In fact, mucus is adhesive and this helps to trap dust 
particles, bacteria and other inhaled debris. Thus, mucus is not only vital for human 
health, but it also significantly limits the potential for localized and sustained drug and 
gene delivery to mucosal surfaces (31).  
 
While the mucus blanket covering the airways is a hydrogel formed by glycoproteins 
(mucins), the alveolar epithelium is covered by a thin lining fluid, the so-called surfactant 
secreted by type II pneumocytes. Its major function is to facilitate the “wetting” of the 
alveolar epithelium by the respiratory gases. It is a very thin layer of fluid that averages 
about 50-80 nm, but may be several microns thick in pooled areas and as thin as 15-20 
nm in others (32). Pulmonary surfactant lowers the surface tension of water and allows 
the membrane to separate, therefore increasing its capability to exchange gases. It forms 
an underlying aqueous protein-containing hypophase and an overlying phospholipid film 
composed primarily of dipalmitoyl phosphatidylcholine.  
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1.3 Lung models for the investigation of lung permeability (in vivo, in vitro and ex 
vivo) 
Experimental protocols for the conduct of in-vivo drug absorption studies have been 
developed in early 1970s by Schanker and co-workers (33)  (34) (35) who primarily used small 
rodents as experimental species for in vivo studies of drug molecules administered by 
intra-tracheal instillation or by aerosol. In vivo approaches in laboratory rats continue to 
be the most important improvements have been made with the use of more 
sophisticated lung-dosing methods (such as forced instillation, nebulization and aerosol 
puff) which afford reproducible dosing and control of lung-regional distribution. Whole 
body pharmacokinetic and dispositional processes complicate greatly the interpretation 
of in vivo data and this is a major drawback of in vivo lung PK studies.  
 
A variety of in vitro lung epithelial cell lines and primary cultured lung epithelial cell 
monolayers offer opportunity to investigate the more detailed kinetics and mechanisms 
of transepithelial drug transport. Cell culture models include primary cell model from 
human or rodent or cell lines derived from malignant tissue or, alternatively, normal cells 
transformed by viruses e.g. SV40. While primary cells are relatively expensive (NHBE 
cells) and / or time-consuming (primary rat epithelia), continuous cell lines (A549, Calu-
3, 16HBE14o-) can be maintained and propagated following standard media and 
protocols to give reproducible results.  
 
The high permeability of the A549 human alveolar cell line make them unsuitable for use 
in drug permeability experiments. NHBE cells, differentiated normal human bronchial 
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epithelial cells, are considered a good system to mimic the bronchial epithelium thanks 
to mucociliary differentiation when grown at air lift interface (36) and the expression of 
multiple integrin subunits that binding to collagen and laminin and mediate adhesion to 
fibronectin which closely mimics by bronchial epithelial cells in vivo (37). However, this 
cell system is difficult to culture, requires specialist defined media that has a short shelf-
life, expensive and time and labour-intensive. There is also significant batch-to-batch and 
inter-donor variability. An alternate approach for a suitable airway epithelium model is 
to use cancerous lung epithelial cell lines e.g. Calu-3. 
 
Calu-3 cells, derive from a human bronchial adenocarcinoma and are widely used 
because of their lower cost, reproducibility and ease of use. Calu-3 are cuboidal cells and 
subapical granules that resembled goblet cell of NHBE cells have been identified by 
electron microscopic analysis (38). They express desmosomes but mucus production and 
ciliogenesis is reduced under submerged culture conditions (39). They are well established 
system for conducting broncho-epithelial permeability studies in vitro (40) (41) expressing 
the cystic fibrosis transmembrane conductance regulator (CFTR) protein (42) (43) and form 
a restrictive monolayers resembling well the in vivo lung epithelial barrier (44) (45) thanks 
to the formation of tight junction in vitro. Thanks to this, Calu-3 cells display low 
paracellular permeability and high electrical resistance. Nevertheless, the using a cell 
culture model to represent the complex disposition of intact lung may still be debatable. 
The deficiencies of in vivo and in vitro models appeared to be resolved with the use of 
the isolated perfused lung (IPL) as an ex vivo model. Despite this ex vivo model showed 
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limitations concerning short viable periods (2-3h), resulted to be kinetically predictive of 
in-vivo. 
 
1.3.1 Permeability principles 
Studies on the disappearance of radiolabelled molecules from the lungs of animals, 
shown that the pulmonary bioavailability of many small molecules is about 100% (33) (34), 
probably due to the rapid, extensive absorption and low concentration of enzymes in the 
lung compared the oral route (6). The absorption half-life can be roughly estimated using 
a log octanol–water partition coefficients (Log Po/w). Small hydrophobic inhaled 
molecules  with Log p >1 appear to be absorbed very rapidly (seconds-minutes) from the 
lung epithelium, such as nicotine (46), morphine (47). Neutral or negatively charged 
hydrophilic small molecules can be absorbed rapidly (minutes)  (34) and have a half-life of 
about 60 minutes (48). 
 
Although the rapid absorption may have many medical uses, there are situations where 
is necessary to slow the absorption of an inhaled particles, to regulate its absorption into 
the body or keep it acting over enough time locally in the lung. There are at least two 
instances in which small molecules are much more slowly absorbed: high hydrophobicity 
or positively charged molecules. Molecules with very high hydrophobicity may become 
too insoluble for rapid absorption and can persist in the lungs for hours, days (48), such as 
amphotericin B (49) and all-trans retinoic acid (50). Specific interactions (e.g., hydrogen 
bonds) caused by electron density distribution may also help the mechanism of retention 
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(e.g., amphotericin B with endogenous sterols).  Strongly cationic drugs such as 
pentamidine and tobramycin are absorbed over a period of hours following inhalation in 
humans. The long retention has been attributed to the positive charges on the molecules 
(51) (52) which may bind to the ubiquitous negative charges of the mucin glycoprotein on 
the epithelia (53).  
 
1.3.2 Transport pathways across the pulmonary epithelium 
In the context of our understanding of the molecular basis of transepithelial transport it 
appears that lipophilic molecules are rapidly absorbed presumably because they can 
integrate into the lipid bilayer surrounding the cells. This translocation constitutes the 
“transcellular pathway” in which molecules pass by a cell through a cell by diffusing 
through the cellular membrane, whereas hydrophilic molecules can be absorbed by the 
epithelium via a “paracellular route” passing through aqueous pores in the intercellular 
tight junctions (54) (Figure 1.5). Tight junctions are complexes of proteins that act as a 
barrier to fluid flow, important for ion selectivity and conductance controlling the 
passage of ions and neutral species through the intercellular. It has been noticed that 
the degree of solute ionization correlates inversely with absorption rate. This is thought 
to be due to interactions with the proteins (occludin, claudin family, junctional adhesion 
molecule) and lipids within lipid bilayers that line the pore.  Macromolecular drug 
absorption from the lungs can be regulated by vesicular transport where a membrane 
protein regulates/facilitates  the molecular movement (55).  
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Another mechanism of transportation of small molecule through the epithelium is the 
“active transport” where molecules are transported into the cell (carriers) or out the cell 
(efllux) by binding to specific carrier proteins on the cell surface and using energy 
exchange to drive against a concentration gradient. The active transporters in the lung 
are can influence the residence time of drug in the lung and affect the drug absorption 
profile. The current knowledge of expression, localization, functionality of drug 
transporters in the lung is poorly understood. 
The transporters most likely to affect the disposition of inhaled compounds are; 
• The ATP-binding cassette (ABC) superfamily. ABC transporter area family of 
transmembrane protein which function as ATP-dependent efflux pumps for wide 
range of structurally diverse molecules from the cell cytoplasm to external 
environment to which belong P-glycoprotein (P-gp), the multidrug resistance 
protein (MRPs), breast cancer resistance protein (BCRP).  
• The solute-linked carrier (SLC and SLCO) superfamily which includes the peptide 
transporters (PEPT1/PEPT2), the family of organic cation transporters (OCTs) and 
organic cation/carnitine transporters (OCTNs), organic anion transporters (OATs) 
and organic anion polypeptides transporters (OATPs).  
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P-glycoprotein  
P-gp is 170 kDa transporter encoded by the multi drug resistance (MDR1) gene in humans 
and contains electronegative groups and weak positive charge. Probably due to the 
polyspecific nature of the P-gp binding pocket, the substrate specificity of this efflux 
transporter comprises a broad range of chemically diverse molecules. As a result, 
lipophilic and amphiphilic molecules can both serve as substrates for P-gp (56) (57).  
Expression of P-gp was observed in human lung (58), on the apical of bronchial epithelial 
cells (59) (60). 
 
 
 
Figure 1.5 Conventional epithelia transport paradigm. Passive transcellular; transportation of 
solutes by a cell through a cell. Passive paracellular; diffusion between cell junctions. Carrier; 
molecules movement occurs via special transport proteins. Vesicular; molecular movement is 
regulates or facilitates by membrane protein. Efflux; molecules are moved out the cell via 
transporters. 
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Organic cation transporters (OCTs) and organic cation/carnitine transporters (OCTNs). 
OCTs transporter have the capacity to translocate neutral and positively charged 
endogenous and exogenous molecules across the plasma membrane in both directions.  
The majority of OCT/OCTN substrates are positively charged at physiological pH and 
include hormones, neurotransmitters, and drugs (61).  The expression of OCTs and OCTNs 
in the lung has been poorly studied but evidence of the expression on the human airway 
epithelia cells are available for both OCTs (62) (63) and OCTNs (64).  Lips, Volk (63) reported 
the expression of OCT1-3 on the luminal membrane in ciliated epithelial cells with also 
evidence of OCT3 in basal cells. OCTN1 have been observed in the apical side of airway 
epithelial cells, whereas there are observations of OCTN2 on both lung epithelium and 
alveolar type I epithelium (65).  
 
Organic anion transporters (OATs) and organic anion polypeptides transporters (OATPs) 
OATs are members of the solute carrier family 22 (SLC22), and OATPs belong to the 
solute carrier family SLC21/SLC0 and mediate the absorption and elimination of 
endogenous and exogenous organic anions. For these transporter there is a lack of 
expression within the lung tissue. 
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1.4 Mucus layer  
Mucus is a slippery secretion containing DNA, lipids, immunoglobulins, inorganic salts, 
antimicrobial enzymes (such as lysozyme), proteins (such as lactoferrin) (66), and 
glycoproteins (mucins) that are produced by goblet cells in the mucous membranes and 
submucosal glands. The thickness of this mucus layer varies on different mucosal 
surfaces, from 50 to 450 μm in the stomach (67), to less than 1 μm in the oral cavity. 
Mucus is a gel with properties of both a soft (deformable), elastic solid and a viscous fluid 
(68) (69) that has evolved into a dynamic semi-permeable barrier, impermeable to most 
pathogens and nanoparticles (NP) while enable exchange of water, hormones, nutrients. 
It the lung is conveyed upwards by epithelial cilia, an essential clearance mechanism that 
removes foreign material from the tracheobronchial tree, and as well, maintains the 
patency of small bronchi and bronchioles.   
 
The lung mucus blanket is not a continuous sheet but comprises two layers of differing 
physical properties: an upper gel layer consisting of mucus with a high viscosity that traps 
inhaled particles and facilitates their transport and a lower layer called periciliary liquid 
layer (PCL) that contacts surface epithelial cells where cilia beat and cell-surface is 
lubricated. This lower PCL layer was thought to be thin and watery with a low viscosity 
(30) (Figure 1.6) and formed the basis for the gel-on liquid model (Figure 1.6 A) of lung 
mucus. However, this model did not explain why components of the upper gel layer do 
not penetrate into the lower layer. Recently, Button at al proposed a gel-on-brush model 
(Figure 1.6 B) in which the watery layer (PCL) of the airway epithelial surface, contains 
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tethered macromolecules, such as membrane-bound mucins, forming a brush-like 
structure of the PCL that stabilizes the two layers and prevents the penetration of 
MUC5AC and MUC5B mucins in the mucus layer and inhaled particles into the interciliary 
space (70). 
 
 
Mucins, the principal “non-water” component of mucus, are long flexible strings coated 
with glycans, most of which show a negative charge (surfate and carboxy group) and can 
be defined as a glycoproteins of high molecular weight produced by epithelial tissues.  
 
The MUC gene family 
The human MUC gene family codes up to 20 known proteins and it is possible to 
distinguish two main forms of mucin; soluble secretory mucin and membrane bound-
mucin (71). Bound mucins differ from the secretory mucin most sharply by the presence 
of a hydrophobic domain anchoring the molecules in the membrane and lack 
Figure 1.6 Representation of “gel-on-liquid” model (A) and “gel-on-brush” model (B). A Mucus 
layer comprised of MUC5AC and MUC5B and the PCL. B Mucus layer comprised of MUC5AC and 
MUC5B and a brush-like structure of the PCL with tethered mucins (70). 
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intermolecular interaction through disulﬁde bridges. Mucins are composed of 
approximately 75% carbohydrate and 25% amino acids linked via O-glycosidic bonds 
between N-acetylgalactosamine (72). These macromolecules result to be polydisperse in 
terms of oligosaccharide composition, chain length and even when isolated from the 
same organ show an heterogeneous molecular weight (73). The carbohydrate chains can 
have branched structures and every carbohydrate chains can have 2-15 sugars in length 
and the most commune sugar residue found in mucin are; fucose, N-
acetylgalactosamine, N-acetylglucosamine, galactose and sialic acid (74). These 
glycosylated and highly hydrophilic regions are separated by “naked” central region 
formed by serine, threonine-rich tandem repeat domains and low amount of aromatic 
amino acid (75). All mucins contain a flexible domains made of proline, threonine and 
serine named “PTS domain” highly glycosylated with glycan O-linked to serine and 
threonine. 
Figure 1.7 Mucin structure. Mature mucins are composed of two distinct regions: The amino- 
and carboxy-terminal regions are very lightly glycosylated, but rich in cysteines.  A large central 
region formed of multiple tandem repeats of 10 to 80 residue sequences (76). 
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The N- and C-terminal regions of secretory mucin are rich in cysteines which establish 
disulfide linkages within and among mucin monomers (76) (Figure 1.7). 
 
In past decades mucins have been challenging to study because of their large size and 
enrichment in glycosidic modification which masks a large portion of the central protein 
core. Thanks to a number of MUC-specific antibodies, investigators have identified and 
localised the mucin glycoproteins in a number of human epithelial tissues (Table 1.1) (77). 
Tethered or membrane-bind mucin includes; MUC1, MUC3A/B, MUC4, MUC12, MUC13, 
MUC15, MUC16, MUC17, MUC20. The role of these non-gel forming mucin includes the 
activation of intracellular signal transduction pathways, cell differentiation, proliferation 
and regulation of the immune response (78). Secreted mucin can be divided in two groups; 
gel-forming mucin cysteine rich including MUC2, MUC5AC, MUC5B, MUC6, MUC19 and 
non-cysteine rich including MUC7, MUC8, MUC9 (79) (Figure 1.8). 
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Mucin Tissue expression   
  Reference 
Secreted mucins    
 Gel forming   
MUC2 Jejunum, ileum, colon, endometrium, tear fluid 
 
(80) 
MUC5AC Trachea, bronchi, stomach, conjunctiva, endocervix, 
endometrium 
(81, 82) 
MUC5B Trachea, bronchi, submandibular glands, endocervix (81, 82) 
MUC6 Stomach, ileum, endocervix, endometrium 
 
(81, 83) 
MUC19 Lacrimal gland, ocular surface, trachea, middle ear, 
salivary gland 
(84-87) 
Secreted mucins   
Non-gel forming   
MUC7 Sublingual, submandibular glands, bronchi,                                                 (88) 
lacrimal gland, conjunctiva                                                                               (89) 
MUC8 
 
Nasal epithelial, uterus, endocervix, endometrium (90, 91) 
MUC9 Fallopian tubes, lacrimal gland, conjunctiva (92, 93) 
Membrane-associated   
MUC1 Trachea, bronchi, breast, pancreas, duodenum, ileum 
colon, cornea, conjunctiva, fallopian tubes uterus, 
endometrium, endocervix, ectocervix, vagina 
(81, 94) 
(95) 
MUC3A/B  Small intestine, colon 
 
(96) 
MUC4 Bronchi, breast, respiratory tract, small intestine, colon, 
conjunctiva, cornea, endocervix, ectocervix, vagina, 
endometrium 
(81, 97) 
(98) 
 
MUC12 Colon, stomach 
 
(99) 
MUC13 Colon, trachea, kidney, small intestine, conjunctiva 
 
(99, 100) 
MUC15 Colon, small intestine, prostate, conjunctiva (99, 101) 
MUC16 Ovary, cornea, conjunctiva, trachea, endometrium 
 
(99, 102) 
MUC17 Stomach, duodenum, colon, conjunctiva (99, 100) 
MUC20 Colon, kidney, liver, lung, prostate, endometrial (103, 104) 
 
   
Table 1.1 Type and tissue expression of human mucins. 
Adapted from (77). 
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MUC1 and MUC4 are the major membrane-associated mucins of the airway that may 
function as cellular receptors and are present at the apical surface of ciliated cells. While 
MUC1 is more enriched in cells that express microvilli , MUC4 appears more strongly 
associated with cilia (105). The secreted non-gel forming mucin, MUC7 (88) is expressed in 
serous cells of the submucosal glands, while the main secreted gel-forming mucin 
expressed in the airways are MUC5AC and MUC5B. These are the most important 
structure-forming component of the mucus gel, resulting in its characteristic gel-like, 
cohesive and adhesive properties. MUC5AC is mainly produced and secreted by goblet 
cells instead MUC5B is secreted by submucosal glands (106).  
 
Once the N-glycosylated polypeptide chain of mucin has been synthesized and 
translocated into the endoplasmic reticulum, dimers are formed by disulfide-bonded 
through its COOH-terminal and cystine knot (CK) -domains. The dimers are then 
transported to the Golgi apparatus where glycan chains are added to the protein through 
successive addition of simple sugars by glycosyltransferase and assembled into disulfide-
bonded multimers. Once mucins glycoproteins are produced they are packaged into 
secretory granules and expulsed to protect the surface epithelium (107). This secretion 
occurs by conventional exocytosis with fusion of a mucous granule membrane and the 
apical plasma membrane (108). 
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1.4.1 Airway of patients with respiratory diseases 
Although mucus provides a physical and biological barrier to airway surface, impaired 
clearance or excessive mucus contributes to the pathogenesis of all the common airway 
diseases (109). Mucus hypersecretion plays a significant role in severe/terminal COPD and 
may contribute to chronic airway infection and obstruction, lung failure and death in 
patients with CF (110). In asthma, smooth muscle hyperplasia cause airway thickening and 
narrowing (111) which causes breathing difficulty and can be worsened by airway 
obstruction that results from mucus hypersecretion (112).  
 
Following the exposure of the airway epithelium to environmental irritants (allergens, 
infectious pathogens or toxins), inflammatory or immune response mediators are 
activated with the generation of a secretory cascade of mucin glycoprotein from the 
goblet cells granules or submucosal glands onto the epithelium. Moreover 
Figure 1.8. Secreted and membrane bound mucin. A Secreted mucin can be divided in gel-
forming and non-gel forming mucin. Mucin with cysteine and C and N-terminal, form disulphide 
bridge with other mucin (gel forming mucin). B membrane-bound mucins are attached to the 
epithelium by hydrophobic domain. 
A 
B 
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inﬂammatory/immune response mediators upregulate MUC genes to replenish the 
secretory granules due to mucin hypersecretion (69) (113) with a consequent increase in 
production and secretion of stored mucin. In chronic inflammatory airway diseases, 
MUC2, MUC5AC and MUC5B expression appear increased (113) (88) (114) compared with 
non-diseased airways. In CF lung disease the host is unable to clear the initial colonization 
and infection of the airways. This is followed by an influx of neutrophils, macrophages 
that initiate and coordinate the innate defence system with release of proteases, 
oxidants, and α-defensins that contribute to tissue destruction and consequent release 
of extracellular DNA from lysed neutrophils, epithelial cells, and bacteria which can make 
mucus more thick and vulnerable to infection and inflammation (Figure 1.9) (115). 
 
 
As a consequence of bacterial infection Th2 lymphocytes produce anti-inflammatory 
cytokines, including IL-4, IL-5, IL-9 and IL-13. In fact, the complex network of cytokines 
balances pro-inflammatory and anti-inflammatory effects. Although each of these 
Figure 1.9. Airway in CF. The thick mucus secreted by goblet cells obstructs airways and allows 
bacterial infection and inflammation to occur. DNA left from neutrophil after fight bacteria lead 
to increased adhesive characteristic of mucus. 
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cytokines are implicated respiratory diseases, IL-13 is thought to be critical. IL-13 induces 
many features of allergic lung disease, including airway goblet cell metaplasia (116) (Figure 
1.10) and mucin (mainly MUC5AC) hypersecretion, which all contribute to airway 
obstruction. IL-4 contributes to these physiologic changes, but is less important than IL-
13 which induces secretion of chemokines that are required for recruitment of allergic 
effector cells to the lung (117). 
 
 
 
1.4.2 Mucus as a barrier for drug delivery 
Once secreted, mucus forms a barrier to protect against infection and injury but it can 
potentially trap and affect the absorption or action of orally inhaled drugs. The influence 
of mucus layer on drug absorption has been widely investigated in intestinal perfusion 
studies (118) and diffusion studies which confirmed that gastrointestinal mucus is a barrier 
Figure 1.10. Effect of IL-13 on Goblet cells density (GCD) 
Treatment of human bronchial epithelial cells (HBEs) 
with IL-13 (1ng/ml) induced an increase in GCD as 
assessed by manual counting of Alcian blue-stained cells 
(116). 
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to absorption and diffusion of drug molecules (119). Furthermore, in vitro studies have 
suggested that intestinal mucus layer produced by HT29-H goblet cells is a significant 
barrier for the absorption of high hydrophobic drugs such as testosterone but not to 
hydrophilic molecules such as mannitol (120)  (121) (119). This was also confirmed later by 
Behrens, Stenberg (122) who analysed six molecules having 128-288 g/ml and Log P in the 
range of -1.4 to 3.3 and noticed a significant decrease in the rate of drug diffusion for 
molecules with a Log P >1. 
 
The ability of a drug or drug delivery system to diffuse through the mucus depends on 
the mesh spacing of the mucus and the relative size of the drug molecule. Furthermore, 
the physiochemical properties of the drug and mucins can influence the barrier function 
of mucus (123). In fact, it is thought that particles and solutes may be stopped from their 
diffusion through mucus gel by two main mechanisms: size filtering and interaction 
filtering (Figure 1.11) (124). In the size filtering mechanism drug molecules smaller than 
the cut-off size of the mesh will pass through the mucus gel, whereas larger molecules 
will be hindered by mucin fibres or other mucus components. In the interaction filtering 
mechanism physicochemical properties such as electrostatic, hydrophobic forces, 
hydrogen bonds or specific binding interaction are involved. Particles can strongly 
interact with the polymer matrix of the hydrogel and be trapped by the mucus. Opposite 
to this, same molecules can show only weak interactions and be allowed to pass. 
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Physical characteristic of lung mucus. 
The mucins in airways mucus consisted is a heterogeneous mixture of extremely large 
glycoproteins. The molecular weight has been estimated to be in the range of 2-50 MDa 
measured by light-scattering (125, 126). Monomers or subunits of mucin are linearly 
assembled and held together by disulfide bonds and the estimate length appears 
polydisperse, from 0.5 to 10 μm in length.  Whole mucins purified from healthy human 
tracheobronchial secretion in 4-6 M-guanidinium chloride was studied with electron 
microscopy and showed length of 0.5-1 μm (125, 126). The mesh pores of mucus isolated 
from NHBE was studied by Matsui, Verghese (127) from the images acquired with confocal 
microscopy and pores were estimated to be 1-8 μm. Kirch, Schneider (128) using a cryo-
scanning electron microscope (SEM) showed that the mesh size of native respiratory 
mucus is 100 nm to 10 μm in diameter and a thickness of ~500 nm. Moreover, the mesh 
spacing of PCL in sample of respiratory mucus from NHBE cells reported by Button, Cai 
Figure 1.11. Mechanisms that may stop particles from readily diffusing through mucus gel. (A) 
Size filtering mechanism allows particles that are smaller than the mesh of the mucus to pass. 
(B) In the interaction filtering mechanism, particles are distinguished according to their surface 
properties: same particles (orange) can interact strongly with mucus components and are 
trapped, whereas other particles (green) show only weak interactions and are not hindered to 
pass. Taken from (124). 
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(70) was on the order of ~20- 40µm estimated using rapid freezing techniques coupled 
with electron microscopy. 
 
Mucus-penetrating particles 
Nanoparticles are defined as particles with sizes between 1 and 100 nm. Mucus 
penetrating particles can potentially improve drug delivery by shielding the drug 
molecules and overcoming the MC mechanism. Several types of nanoparticles have been 
developed for mucus penetration by most of them are efficiently trapped in and rapidly 
removed by mucus, making controlled release difficult. Mucus penetrating particles can 
potentially improve drug delivery by shielding the drug molecules and overcoming the 
MC mechanism. A promising approach for improved mucus penetration has been 
described in several papers from Hanes and co-workers. They have demonstrated that 
controlled coating of nanoparticles (up to 200 nm) with the hydrophilic and uncharged 
polymer, polyethylene glycol (PEG), were able to rapidly penetrate fresh, undiluted 
human mucus (129). This possibility to reduce particles affinity to mucus may be promising 
in improving drug delivery to mucosal tissues. The challenge remains to develop a mucus-
penetrating nanoparticle that can efficiently deliver its loaded drug cargo to the 
epithelial surface before triggered drug release. 
 
1.4.3 Serum protein binding and its effect on drug disposition 
Serum proteins and plasma proteins serve many different functions, including transport 
of hormones, lipids, vitamins in the circulatory system. The ability of plasma proteins to 
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interact with drugs is well established and the plasma protein binding (PPB) of drugs may 
have a significant effect on pharmacokinetics and pharmacodynamics (130) (131) (132). 
Binding experiments of PPB-drug interaction are widely used in drug discovery to guide 
the design of new drug model and optimize in vivo efficacy. 
 
Although the plasma contains many other proteins, serum albumin (55%) is the most 
abundant protein in plasma and with α1-acid glycoprotein (AGP) can play a dominant 
role in drug disposition and efficacy. Serum albumin has multiple hydrophobic binding 
sites and has been shown to bind to a wide set of aromatic ligands such as thyroxine (133)  
and a wide range of drugs e.g. warfarin, diazepam, ibuprofen(134). In the context of 
inhaled drugs the inhaled corticosteroid, ciclesonide displays extensive PPB of 98% in 
human serum (135).  Serum Albumin binding is capable of altering drug pharmacokinetics. 
It has a central role in drug distribution as most drug reach the target tissue bound to 
serum albumin and its prevents drug from being metabolized with consequent increases 
their biological lifetime. Moreover, serum protein helps hydrophobic compounds 
solubilisation and drug distribution through the body (136) (137).  
 
Kratochwil, Huber (138) suggested that the interaction of drugs with plasma protein is not 
only based on hydrophobic interaction but different forces are involved, such as charge 
interactions, hydrogen bonds, and space-filling of binding pockets. It is assumed that in 
plasma, acidic drugs manly bound to human serum albumin whereas AGP has the ability 
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to bind manly basic drugs like such as propanolol (139) but AGP interaction to acidic drugs 
has also been demonstrated, such as phenobarbital (140) and endogenous steroids (141).  
 
The administration of therapeutics by pulmonary route represents a significant 
opportunity for several classes of drugs (small molecules/macromolecules). PPB is an 
important factor and a subject of concern for the systemic delivery of various drugs 
through aerosol administration and with evidence of drug-mucus binding for a number 
of drugs it is key that more is learned about the extent and nature of these interactions 
and whether they can affect the PK/PD of inhaled drugs. 
 
1.4.4 Mucus models to evaluate drug diffusion 
Various mucus models are described in the literature, including in vivo, ex vivo and in 
vitro models, from the crude (natural) to the simplest methods only represented by 
mucin solution. Natural mucus from airway is probably the most ideal to study drug 
diffusion through lung but has some drawback; in a healthy person the mucus layer is 
very thin, strongly attached to the epithelium and difficult to access. Cervical mucus may 
be used as a more voluminous mucus model (142) and a relatively larger amount of mucus 
can be obtained from porcine gastrointestinal mucus (143) (144) but in vivo and ex vivo 
assays may be time consuming and a number of animals are required. Pig and human 
mucus, as showed by Kararli (145), displayed similarity in structure and molecular weight 
but for both human and pig mucus the physical-chemical properties and composition are 
subjected to inter-individual variability (146) (147) so that mucus properties may vary 
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between batches. To overcome this problem mucus from different batches can be 
pooled together  and frozen at -20 °C until needed without significant effect on 
viscoelasticity (146) and the diffusion coefficient of drugs (143). 
 
PGM has a more stable composition and has been used to prepare mucin solution or to 
reproduce a mucus “substitute” by adding buffer, bovine serum albumin (BSA) and 
dipalmitoylphosphatidylcholine (DPPC) (148) or buffer, BSA, lecithin (149), but as showed by 
McGill and Smyth (150) the heterogeneity observed for natural mucus was not overcome 
with the mucus “substitute” used for in vitro assays. 
 
1.4.5 Method to study drug binding to biomacromolecules  
The classical ligand protein interaction depends on the following assumptions: 
• The interaction is reversible 
• All the receptor molecules are equivalent and independent 
• The biological response depends on the number of occupied receptor sites 
• The interaction and response are measured at equilibrium. 
At equilibrium ligand (L) binding to a protein (P) gives a stabilized complex (PL) 
represented as follows: 
L + P ↔LP 
 The equilibrium constant for association Ka for this reaction is given by: 
Ka =
[]
[][]
 
The equilibrium constant for dissociation Kd is: 
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Kd =
[][]
[]
 
Plotting  
[]
[]
  versus [L] the graph in Figure 1.12 will be obtained. Increasing the ligand 
concentration, the PL increases until binding sites are saturated. For the total amount of 
protein [Pt] the maximum fraction PL is 1. Kd is L concentration at which half P is half 
saturated. 
 
The methods used for the investigation of drug binding to macromolecules can be 
broadly divided into spectroscopic and non-spectroscopy techniques. 
 
• Non-spectroscopic techniques 
Non-spectroscopic techniques (Figure 1.13) involve the separation of the free drug from 
the complex drug-macromolecule and allow the monitoring of the free drug levels.  
The most widely used methods are equilibrium dialysis and ultrafiltration (151) (152) as 
these methods can be applied to measure solutions with high protein concentrations. 
Figure 1.12 Protein-Ligand classic hyperbolic binding curve.  As L concentration increases the 
PL increases reaching a plateau.  Kd is the L concentration at 


 =0.5  
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Equilibrium Dialysis 
Equilibrium dialysis is considered the reference method although the long test period 
(hours or days) is inconvenient for routine testing. The development of rapid equilibrium 
dialysis offers the advantages of miniaturisation and a greatly reduced experimental 
duration (1-2 h) (153). Drawbacks of the equilibrium dialysis approach include the 
potential for non-specific drug binding to the dialysis membrane. Moreover, analyte 
instability may compromise studies using conventional equilibrium dialysis techniques 
(151) (152). 
 
Ultrafiltration binding  
Compared to equilibrium dialysis, ultrafiltration binding experiments are less labour-
intensive, rapid, and able to accommodate the simultaneous testing of many drug and 
Figure 1.13 Separation of bound and free compound by non-spectroscopy technique.  A semi-
permeable membrane allows the passage of free compound retaining the compound bound to 
the macromolecules. 
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protein mixtures on when presented in the multiwell plate format. The ultrafiltration 
assay combines the centrifugation speed with the separation of bound and unbound 
ligand by a membrane. Yet, ultrafiltration can be used for sample with small amount of 
protein to overcome the problem of oncotic pressure. The major difficulty for 
ultrafiltration is related to the membrane devices, which may induce additional binding 
effects (151) (154) and membrane pores has to be chosen accurately to avoid the “sieve 
effect”. In fact, one drawback of ultrafiltration binding assay is the Non-specific binding 
(NSB) effect which refers to the binding of the ligand to something other than its 
“receptor” which seems correlated to the lipophilic character of molecules (155). Another 
concern regarding the 96-well ultrafiltration plates is the “edge effect” which refers to 
the variation in filtrate volumes observed across the plate and has been considered is a 
major concern regarding the determination of free drug in PPB (156). In short, more 
methods need to be developed and ideally the best method has to have a more 
convenient approaches for the analysis of the interacting amount of drug and be faster.  
 
Chromatographic techniques 
An alternative to dialysis and ultrafiltration is the use of chromatographic methods 
where is possible to distinguish two different approaches. 
In the first approach both drug and protein may be mixed in the mobile phase. The 
mixture drug and protein can be injected through the column of the liquid 
chromatography which may be able to separate the free ligand from the complex ligand-
macromolecule. The application of this system depends on the interaction kinetics, as it 
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requires no or little dissociation of the complex drug-protein (157). Another approach 
using chromatography technique is the affinity chromatography, where one of the 
interacting species (macromolecules, drug) can be used as immobilised ligand (157). This 
technique is usually applied for studying weak reversible equilibria typical of drug-
protein interaction and relies on the chemical equilibrium between the molecules 
immobilized and those in solution. Thanks to Larsson (158) this method assembled with 
HPLC has gained in precision and speed and the development of affinity chromatography 
with commercial serum albumin columns to evaluate PPB has widespread for drug 
screening in industry (159). 
 
Diffusion cells 
Another method used to separate the free drug from the bounded form is the Franz-cell 
diffusion chamber. This system is commonly employed for the measurement of 
permeation kinetics of drugs across skin, synthetic (cellulose) membrane or biological 
membranes / tissues (160). It was also used for studying drug diffusion through polymers 
(161). The system consists of two chambers, the donor and receiver chamber separated 
by a membrane impermeable to the system of interest. For the study of mucus 
permeation the mucus and drug are added onto the support membrane (or mucus layer) 
in the donor chamber and drug transport into the receiver chamber is determined by 
serial sampling from the receiver chamber. Franz-cell system is widely used for studying 
formulation but its open donor compartment design does not permit the use of any 
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stirring setup, as in the receptor compartment, so it is not suitable for the evaluation of 
solution or suspension-formulations or volatile drugs.  
 
• Spectroscopic technique 
Spectroscopic techniques are able to identify and characterize the drug-macromolecule 
binding by monitoring either the ligand or the target protein. Techniques include 
ultraviolet, fluorescent and visible spectroscopy, circular dichroism, Nuclear magnetic 
resonance (NMR) spectroscopies. To date each of these techniques has been used to 
study drug-mucin interactions. 
 
UV–vis absorption is probably the simplest and most commonly employed instrumental 
technique for studying drug-macromolecules interactions by monitoring the changes in 
the absorption properties of the drug or macromolecule.  
This technique relies on the fact that the small molecule shows an absorbing band in the 
UV/visible region.  As attenuation of the beam increases, the absorbance of a solution 
increases and is directly proportional to the path length and the concentration of the 
matter.  
Comparing the absorbing band when the ligand is free in solution to when is mixed with 
a macromolecule, the shifting of the position of the maximum value is an easy way to 
determine whether there is any interaction of the drug with other molecules. The 
strength of the interaction may be interpreted from the magnitude of this peak shifting 
or absorbance intensity increases (162) (163) (164). The disadvantage of this technique is that 
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weak interactions cause minor changes in spectral profiles that may not be easily 
identifiable (165). Moreover, the technique relies on the presence of an appropriate 
chromophore that does not significantly overlap with hat of the macromolecule.  
 
Fluorescence spectroscopy is electromagnetic spectroscopy used to analyse the 
fluorescence from a sample.  It is a simple and fast method to determine the 
concentration of an analyte in solution based on its fluorescent properties. It is one of 
the techniques most commonly used to study interactions between small ligand 
molecules and macromolecules thanks to its high sensitivity, large linear concentration 
range and selectivity. Fluorescence emission may be very sensitive to the environment 
and the binding may cause spectral shifts in the excitation and emission spectra of drugs 
(166). The interaction of a ligand to a molecule may lead to a significant enhancement or 
a reduction of the fluorescence intensity. For instance, the rotation of free molecules 
favours the radiation deactivation of the excited states, but when a drug molecule 
intercalates with a macromolecule, the small molecules are well protected from the 
aqueous solvent leading to a significant increasing in the fluorescence emission (167). In 
contrast, in case of electrostatic, hydrogen bonding or hydrophobic interactions are 
involved and the molecules may not be protected from water-bound anionic 
fluorescence quenchers and is possible to observe a decrease in the fluorescence 
intensity (167).  
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1.5 Cystic fibrosis  
Cystic fibrosis (CF) is a recessive autosomal genetic disease caused by mutations in the 
gene encoding cystic fibrosis transmembrane conductance regulator (CFTR). The CFTR 
protein is responsible for chloride and bicarbonate transportation across epithelial cell 
membranes. The most common mutation is a deletion of three nucleotides with a loss 
of a single phenylalanine amino acid at the 508th position on the protein, (ΔF508). This 
mutation accounts for 70% of CF cases (168) although over 1000 known mutations have 
been associated with CF. The CFTR protein is an ATP-binding cassette transporter and is 
made up of five domains: two transmembrane domains (TMD1/TMD2), two cytoplasmic 
nucleotide binding domains (NBD1 and NBD2) and a regulatory (RD) domain (169) (170) 
(Figure 1.14). The process of channel opening and closing is called “gating” and each 
domain is important for the correct function of the gating and for chloride transportation 
through the cell membrane. Channel opening is regulated by phosphorylation of the R 
domain by protein kinase A and recruitment of ATP to NBD1 and NBD2. To open the 
channel pore these domains dimerise (NBD1:NBD2) and dissociate to close the channel 
following ATP hydrolysis (169) (171) (Figure 1.14). 
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Five functional classes of CF mutations can be identified according to the nature of the 
gene mutation and its functional consequence on CFTR function (172) (173) (Figure  1.15): 
 
o Class 1. Mutations produce few or no functioning CFTR chloride channels 
due to premature termination of CFTR protein production. 
o Class 2. Defective trafficking. CFTR does not reach the apical surface 
membrane. This includes ΔF508. 
o Class3. Limited channel gating. This includes G551D. 
o Class 4. CFTR reaches the apical surface and able to open and close but 
conduction (passage of chloride ions through the channel) is defective. 
o Class 5. Limited transcription regulation Reduced synthesis of functional 
CFTR  
Figure 1.14 CFTR structure and gating conformation. CFTR is composed of two transmembrane 
domain MSD1-2 and three cytoplasmic domains; NBD1-2 and RD. CFTR channel closed (left) 
and open (right). Phosphorylation of the R Domain by the cAMP-dependent protein kinase (PKA) 
leads to the dimerization of NBD1 and NBD2 and consequent release of Cl-. Taken from (170). 
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CFTR has a diffuse epithelial distribution in lung, pancreas, liver, kidneys and intestine 
(174). As a consequence, CF patients experience a multiorgan disease involvement with 
variable degrees of severity. The inactive or inefficient function of CFTR leads to impaired 
Cl- transport and the main signs of CF is a characteristically salty sweat. The Cl- imbalance 
on internal organs leads to a build-up a dehydrated mucus in ducts of the pancreas, in 
male sex ducts and in lungs with consequent poor weight gain, infertility, shortness of 
breath, accumulation of thick and dehydrated mucus.  The dehydrated mucus is due to 
the increased salt absorption which is believed to result by the involvement of another 
salt regulator functionally coupled with CFTR. The epithelial sodium channel (ENaC) with 
CFTR, is a major regulator of salt and water reabsorption in a number of epithelial tissues 
Figure 1.15 CFTR gene mutations are categorised into five classes. Class I mutations results from 
nonsense and frame-shift mutations or mRNA splicing defects. Class II mutations, results in folding 
or maturation defects, which consequent premature CFTR degradation. Class III mutations result 
in defective regulation (opening and closing). Class IV conductance defect of Cl-. Class V 
reduced quantity of the protein. Taken from (173). 
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(colon, the salivary duct, the cortical collecting duct of the kidney, lung) (175) and is 
functionally related and influenced by intact CFTR (176).  
 
In a normal airway (Figure 1.16 A) CFTR regulates the movement of Cl- across epithelial 
cell membranes which downregulate  ENaC inhibiting an excessive absorption of Na+ and 
water, although the mechanism by which CFTR modulates the function of ENaC proteins 
is still not clear (177) (178). A defective inhibitory regulation of ENaC in CF (Figure 1.16 B) 
leads to enhanced Na+ absorption and, consequently, an increase of water volume 
absorbed across the CF airway epithelial cells (179) (180). Therefore, the water absorbed 
leads to a reduction in airway surface liquid and increased mucus viscosity that slows 
MC. Defective MC can predispose airways to bacterial infection leading to lung infections 
and pulmonary complication which is the primary cause of mortality in CF. 
 
Figure 1.16 Model depicting ion transport mechanisms regulating ASL volume in normal (A) 
and CF airway epithelia (B). (A) CFTR pumps Cl- in the cell which inhibits Na absorption from 
ENaC. (B) Defective CFTR leads to decrement of Cl- with enhanced Na+ absorption through 
ENaC leading to a thicker mucus layer favorable to bacterial infection.  
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No cure for cystic fibrosis is known. Nowadays the life expectancy is 42-50 years and 
failed lung compliance is responsible for about 80% of death (181). This improvement is 
due to the rationalisation of antibiotic therapy. Correction of the CF disease by gene 
therapy has been explored as a potential cure for CF has been widely tried. Several 
approaches have been tested to successfully deliver genetic material encoding for CFTR 
to the lung epithelium using liposomes (182), recombinant viruses (183), PEG-coated DNA 
nanoparticle (184). Non-viral delivery systems penetrate the mucus layer inefficiently and 
immunogenicity, safety concerns have precluded successful viral approaches reaching 
the clinic to date (185). 
 
Novel oral therapeutics for CF are ataluren, lumacafton and ivacaftor.  In particular, 
ataluren allows the ribosome to overcome premature stop mutations of CTFR. For 
mutation ΔF508 a novel therapy consists in the use of lumacafton. In this class of 
mutation, the CFTR is only partially glycosylated and subject to degradation.  Lumacaftor 
restores the post-translational modification at the endoplasmic reticulum avoiding 
degradation (186). Improvement for gating mutations due to G551D mutation or other 
gating mutations have been made with ivacaftor with works as a CFTR potentiator (186) 
(187). Although the improvement led from these novel therapeutics, antibiotics and 
bronchodilators is still administrated alonside and are essential in CF patience. 
 
The development of new therapeutic option is essential for increasing survival. Therapies 
that increase the volume of airway surface liquid (ASL), and hence MC, should improve 
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life-quality of CF patients. Inhaled hypertonic saline has been shown to stimulate of MC 
(188) but the effects were transient and, therefore, with limited therapeutic benefit (189). 
ENaC inhibitors may be used in blocking the hyper absorption of sodium ions and water 
absorption across airway epithelia, so that the hydration of the ASL is likely to be reduced 
and MC enhanced.  
 
1.5.1 ENaC blockers 
The ENaC channel is a heteromeric membrane protein consisting of at least three similar 
subunits in α, β, and γ subunits with two transmembrane domains each (190, 191) (Figure 
1.17).  All these subunits are essential to form a functional and highly Na+ selective 
channel (191) (192).  
ENaC is involved in the transepithelial Na+-ion transport, which it accomplishes together 
with the Na+/K+-ATPase and is typically located at the apical membrane of epithelial 
tissues throughout the body. This indicates that ENaC functions as a regulator of 
osmolarity. Its presence has also been demonstrated on arterial endothelial cells where 
may act as a vascular mechanosensor (193) (194). 
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ENaCs are also known as amiloride-sensitive sodium channel as are characterized by 
their high affinity to the diuretic blocker amiloride (195) (196).  Amiloride (Figure 1.18) is a 
selective ENaC blocker (192) that was developed by Cragoe and his colleagues at Merck 
Pharmaceuticals in the early 1960s. It was initially designed to be delivered orally and act 
primarily as a “potassium-sparing diuretic“ (197) by directly blocking the ENaC thereby 
inhibiting sodium reabsorption at the lumen of distal cortical collecting duct in the 
kidneys  (198) and has been widely used for treating hypertension and congestive heart 
failure (199).  
Figure 1.17. The epithelial sodium channel. ENaC consists of three related subunits, termed α, 
β, and γ. Each subunit (M) consists of two transmembrane helices, a cytoplasmic C-terminal and 
an N-terminal domain and a large extracellular loop.  
Picture taken from jasn.asnjournals.org/content/19/10/1845  
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Decades later the effects of nebulized amiloride on pulmonary function were studied (200) 
(197). Studies showed that aerosol administration of amiloride to patients with COPD, 
cystic fibrosis, blocked entry of sodium into respiratory epithelial cells, thus reducing the 
potential difference of the airway epithelium (201) and improved the rheological 
properties of mucus (202). Although there are in vitro data to support short-term 
improvements in MC and lung function following amiloride therapy (200, 202, 203), early 
clinical trials (using a delivery dose of 0.2mg/ml) failed to demonstrate any clinically 
significant changes in both thickness and volume of ASL and pulmonary function of cystic 
fibrosis patients was not improved with amiloride (204). The lack of therapeutic benefit 
was attributed to its low potency, and its short half-life (about 20 minutes) on airway 
surfaces (205) (206) due to rapid absorption by the airway epithelium (207) (205, 208). 
Amiloride’s limitations in enhancing MC for long periods can be due to a weak affinity of 
the ENaC blocker to its receptor so that complete block is not achieved (206) (204) or its 
limited solubility may restrict the mass that could be delivered (209). The clinical utility of 
amiloride is also limited by its rapid reversal form of ENaC block (208). These limitations 
Figure 1.18 Amiloride structure 
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led to the development of more potent, long-acting amiloride analogues as alternatives 
to amiloride for CF pharmacotherapy (206) (210) (211).  
 
A chemical modification of ENaC blocker amiloride may result in the development of 
more efficiently ENaC inhibitor that may achieve more favorable pharmacodynamic 
properties than amiloride. Cragoe demonstrated that the 3,5-diamino-6-chloro-
pyrazinoyl guanidine is a privileged structure for ENaC blockade and the most potent 
ENaC blockers must contain the same pyrazinoyl guanidine chemotype of amiloride (212, 
213). Benzamil (Figure 1.19 A) and phenamil (Figure 1.19 B) are two second generation 
amiloride analogues with benzyl and phenyl substitutions onto the guanidinium.  
 
The guanidine moiety in amiloride imparts a cationic charge at physiologic pH (pKa 8.8 
in H2O).  It exists primarily as a monovalent cation and interacts with sodium channel  in 
its protonated form (214). The pKa values reported for its analogues are 8.1 for benzamil 
Figure 1.19 Benzamil (A) and phenamil (B) structure. 
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and 7.8 for phenamil (209). These results indicate that benzamil and phenamil are less 
protonated and more lipophilic than amiloride leading to an increased affinity to the 
ENaC (209). The observation of increase ENaC affinity and potency for hydrophobic 
analogues supported the hypothesis that the binding site in ENaC has a hydrophobic 
binding pocket (215) (216) and (217). Although benzamil and phenamil are more potent than 
amiloride, they are predicted to be absorbed more rapidly and this could potentially 
increase their systemic absorption and toxicity. The whole body toxicity results from a 
reduction in Na+ absorption which alters the Na+/K+-ATPase with consequent 
hyperkalemia (206). 
To identify a selective blocker of airway ENaC a series of novel analogues were tested for 
potency, reversibility of ENaC block, epithelial absorption and biotransformation. Parion 
compounds 552-02 (Figure 1.20) and and GS9411 (undisclosed structure) have been 
specifically designed for aerosol delivery to the pulmonary system and selected as 
potential lead compounds for CF (218) . 
Both in vitro and in vivo testing showed that 552-02 crossed the epithelium more slowly, 
was 100-fold more potent and 5-fold less reversible than amiloride and displayed the 
Figure 1.20 Compound 552-02 structure. 
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lowest IC50 value (7 nM) ever reported for an ENaC blocker (218).  Preclinical data support 
the clinical utility of 552-02 to promote an expansion in ASL volume, with or without 
hypertonic saline for lung disease and completed Phase II trials as a nebulized therapy 
for CF (219) but when O'Riordan, Donn (220)  reported GS9411-induced hyperkalemia the 
development of these compounds was halted.  In contrast to most of the earlier 
investigations, Russ, Ried (221) showed that a guanidine or amidine side chain in the 2-
position of amiloride is not necessarily required to have a diuretic and natiuretic effect. 
The substitution of guanidine or amidine side with an amino group of similar basicity 
(Figure 1.21), protonated at physiological pH, was showed to retain diuretic, natiuretic 
and anti-kaliuretic effects and displayed an increase of potency up to 40 folds when 
compared to amiloride (222). 
 
 
Further, Novartis has reported the synthesis and biological evaluation of a novel series 
of human ENaC blockers that are structurally distinct from the pyrazinoyl guanidine 
chemotype found in amiloride analogues previously cited.  As an amine should be 
significantly basic at physiological pH although less protonated than an acylguanidine, 
Hunt at al explored the use of amines as bioisosteres for the acyl guanidine present in 
Figure 1.21 Example of non-pyrazinoyl guanidine ENaC blocker 
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amiloride. These novel ENaC blocker, characterized by a permanent cation via 
quaternization of the amine (Figure 1.22 A) improves ENaC potency and increase 
solubility. Quaternary amines deliver compounds equipotent with compound 552-02 (223) 
which was hitherto the best examples of a promising new class of human ENaC blockers 
that showed improved potency at ENaC in HBEC cells, efficacy and duration of action in 
a sheep model when compared to amiloride (219). Following the hypothesis that a 
hydrophobic tail group is able to increase potency, a series of novel α-branched 
pyrazinoyl quaternary, exemplified by Figure 1.22 B were synthesised and it was 
demonstrated that these analogues provide up to a 20-fold improvement in potency (223). 
 
 
A new ENaC inhibitor with molecular weight > 600 Da and decreased hyperkalaemic 
effect has been recently disclosed from Novartis. NVP-QBE-170 (Figure 1.23) is a dimeric 
amiloride-derivate which professed to improve mucus hydration and enhance 
Figure 1.22 Example of quaternary amines (A) and α-branched quaternary amines ENaC 
Blockers (B) 
B 
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mucociliary clearance in CF people. The intra-tracheal installation of NVPQBE-170 in 
guinea pig airway showed the higher potency of this compound to inhibit ENaC and 
superior duration of action in vitro (NHBE cells) compared to amiloride. In particular, the 
recovery of short-circuit current (Isc) was of around 100% for amiloride and 14% for 
NVPQBE-170 after 300 s. 
 
NVP-QBE-170 also showed an improvement of MC in sheep airway after inhalation with 
a duration of action superior to hypertonic saline but long-term safety studies showed a 
hyperkalaemia effect after 28-days inhalation and studies have been halted. The 
development of a new class of inhaled ENaC blockers may represent a promising target 
for the improvement of MC in diseases such as cystic fibrosis. 
 
 
The literature reported the interaction of mucin to inhaled drugs molecules and in this 
work we sought to determine if secreted mucin may represent a barrier for the 
disposition of ENaC blockers. 
Figure 1.23 NVP-QBE-170 structure 
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1.6 Thesis Aims and objectives 
The overall aim of this thesis was to evaluate whether mucin may represent a 
dispositional barrier for the absorption of ENaC blockers after inhalation. General 
information of the source of material, sample preparation procedures and 
methodologies used throughout this PhD project are presented in Chapter 2 and the 
experimental work for this thesis is presented in three separate chapters (Chapters 3-5). 
 
The work in chapter 3 was focused on the establishment and validation of mucin gel 
model for studying drug transportation through a 3D mucus model. Towards this aim, 
different sources of mucus were considered; human mucus from in vitro culture of 
human epithelial cells (NHBE cells), ex-vivo mucus from porcine lung and a commercial 
available porcine gastric mucin (PGM). PGM was chosen as mucus model to study the 
diffusion of FITC dextran probes at different molecular weight using the Franz-cell 
system. The diffusion studies where then extended on two ENaC blockers (amiloride and 
benzamil). 
 
In Chapter 4, the amiloride and benzamil interaction to mucin was firstly studied using 
fluorescence and UV-spectroscopy techniques. The absence of a standard method for 
specifically study drug-mucin interactions lead us to the development of 96-well 
ultrafiltration assay which was used to screen a range of 12 ENaC blockers and correlate 
the extend of binding with the physical properties of the drug molecules. The 96-well 
ultrafiltration assay was also applied to study the extent of binding of drug molecules to 
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other two macromolecules found in CF mucus, DNA and alginate. Chapter 4 ends with 
studies on the permeability characteristic of Calu-3 monolayer to predict amiloride and 
analogues absorption in lung. 
 
The aim of Chapter 5 was to gain molecular level information of the drug-mucin 
interaction using the Saturation Transfer Difference-NMR spectroscopy (STD-NMR). In 
the same chapter, the purification and biochemical analysis of jejunal porcine mucin 
(PJM) is described. Early STD-NMR studies were focused on the interaction of salbutamol 
and tobramycin to PGM. STD-NMR was then used to identify “interacting” and “non-
interacting” domains within two ENaC blockers, 552-02 and OF-80-NS22, and results 
obtained using PGM and PJM were comparable and confirmed the ultrafiltration binding 
assay results. 
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This project was focussed on increased understanding of whether mucin, a heavily 
glycosylated protein contained in the mucus, may limit the access of ENaC molecules 
to their site of action. Moreover, the project aimed to increase the understanding of 
the relationship between ENaC blocker physico-chemical properties and mucin 
binding. Different sources of mucus and mucin have been used but the larger part of 
experiments were carried out using a commercial partially purified gastric mucin, and 
later in the project, porcine gut mucin has been purified and used.  
An ultrafiltration binding assay has been developed, Calu-3 cells have been used for 
absorption studies of ENaC blockers, and a very powerful NMR technique, the 
Saturation Transfer Difference NMR, was applied as mechanistic method for studying 
mucin-drug interactions.   
 
This chapter is intended to present general information of the source of material, 
sample preparation procedures and methodologies used throughout this PhD project. 
 
2.1  Normal Human Bronchial Epithelial 
Normal human bronchial epithelial (NHBE) cells were cultured at an air-liquid 
interface in order to produce an in vitro model of the respiratory epithelium for the 
production of human mucus and for the study of transportation assay using small 
drug molecules.  
 
2.1.1  NHBE cells culture reagents and media preparation 
B-ALI TM growth medium, B-ALI TM differentiation medium, Human Bronchial 
Epithelial cells, trypsin EDTA, bronchial epithelial cell growth medium supplemented 
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were purchased from Lonza (Walkerville, USA), Alexaflour-633 labelled WGA and 
goat anti-rabbit AlexaFluor 488 antibodywere purchased from Life Technologies 
(Paisley. UK), anti-mucin 5AC purchased from Santa Cruz (Texas, USA from life 
technologies, Paisley, UK). Dulbecco's modified Eagle's medium, gentamicin was 
bought from Gibco (Carlsbad, California). Recombinant Human IL-13 (PetroTech, 
USA). DAPI, trans- retinoic acid purchased from Sigma (Poole, UK), Leica TCS-SP1 
Laser scanning confocal microscope (Leica Microsystems, Wetzlar, Germany), Image-
Pro Plus 7.0 software (Media Cyberntics INC., Silver Spring, MD). Olympus BX60 
epifluorescent microscope (Olympus, Japan) and images captured by a ProgRes 
c10Plus digital camera (Janoptik, Schwenningen, ermany). Epithelial voltohmmeter 
Millicell-ERS was from Millipore (Bedford, MA, USA). 
 
2.1.2 NHBE Cell Culture  
Cells were seeded into plastic T-75 flasks and grown in bronchial epithelial cell growth 
medium supplemented with bovine pituitary extract (52 μg/ml), hydrocortisone (0.5 
μg/ml), recombinant human EGF (0.5 ng/ml), epinephrine (0.5 μg/ml), transferrin (10 
μg/ml), insulin (5 μg/ml), retinoic acid (0.1 μg/ml), triiodothyronine (6.5 ng/ml), 
gentamicin sulphate (50 μg/ml) and amphotericin-B (50 μg/ml). Medium was 
changed every 48 h until cells were ~80% confluent. Cells were then seeded at 24.3 
× 104 cells/insert onto 6.5-mm-diameter polyester Corning Costar Transwell-Clear 
inserts with 0.4 μm pores. Cells were submerged in differentiation medium 
containing a 1:1 mixture of Dulbecco's modified Eagle's medium and bronchial 
epithelial cell growth medium (DMEM:BEBM) with the same supplements as above, 
except that triiodothyronine and retinoic acid were omitted, and replaced with all-
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trans retinoic acid at a final concentration of 50 nM. Cells were submerged for the 
first 7 days in culture, after which time the apical medium was removed and cells 
were exposed to an air–liquid interface that was maintained for the remainder of the 
culture period (Figure 2.1). Medium was exchanged three times weekly: Monday, 
Wednesday, and Friday. The apical surface of the cells was rinsed with 100μl of warm 
PBS twice weekly to remove debris. Cells were maintained at 37°C in 5% CO2 in a 
humidified incubator.  
 
 
2.1.3  Cell counting and viability  
When passaging cells, the cell suspension was diluted 1:1 with 0.4% trypan blue 
solution. 10 μl of the solution was added onto the haemocytometer allowing the cell 
suspension to be drawn out by capillary action and visualised with a light microscope 
with a 10X objective. Trypan blue dye was used to calculate the cell viability. Live, 
unstained cells were counted in one set of 16 squares. The trypan blue dye is able to 
penetrate the cells in which the membrane is not intact and therefore dead cells 
stained are non-viable.  
Figure 2.1 NHBE cells ALI culture. Cells grown into plastic T-75 flasks in Growth media. Once the cells 
are 80% confluent are transferred onto inserts (24.3×104 cells/insert) submerged in differentiation 
media for 1 week. Media is then removed from the apical side and cells grown at ALI. 
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2.1.4 Cytokine Treatment 
Lyophilized recombinant human IL-13 was prepared as 1000X stock solution in PBS 
+0.1% BSA then stored at -20°C. IL-13 was added to the differentiation medium to 
increase mucus production for all the duration of ALI cultures at a final concentration 
of 1ng/ml (1). 
 
2.1.5 Electrical Measurements  
The Millicell-ERS (Electrical Resistance System) measures membrane potential and 
the Trans Epithelial Resistance (TER). An increase in TER detected with the electronic 
circuit electrode is an indication of cell monolayer confluency and integrity. A 
silver/silver chloride (Ag/AgCl) pellet (4mm wide and 1mm thick) on each electrode 
tip measures voltage. 
 
Once cells were 100% confluent, the TER (Ω·cm2) was measured every Monday, 
Wednesday and Friday before the media was refreshed. TER was measured across 
the cell layers using an epithelial voltohmmeter and silver chloride ‘chopstick’ 
electrodes. For ALI cultures measurements were made at 37°C after a 15 min 
equilibration period with 100μl of warmed PBS (10 Na2HPO4, 2 KH2PO4, 2.7 KCl, 137 
NaCl mmol/L) in the apical chamber and 500μl of media in the basolateral chamber. 
The resistance across a cell-free culture support was subtracted from the resistance 
measured across each cell layer to yield the TER of the epithelial cells:  
(Ω·cm2) epithelia cells= (Ω·cm2) Cell culture- (Ω·cm2) Cell-free culture 
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2.1.6 Immunochemistry assay for MUC5AC identification 
After 15 post-seeding, NHBE cells and cells cultured with IL-13 were fixed adding onto 
the apical side of each inserts 100μl of ice-cold acetone and methanol (1:1) for 5 
minutes. Nonspecific binding was blocked by the addition of 5% bovine serum 
albumin (BSA) in PBS with 0.05% Tween 20 and incubated for 30 minutes. The inserts 
were subsequently rinsed with PBS. Cells were then incubated for 2h with anti-
MUC5AC antibody at 0.4μg/ml in 1% BSA. After rinsed with PBS cells were incubated 
for 1h with anti-rabbit Alexaflour-488 secondary antibody at 0.4μg/ml in PBS. The 
cultures were stained with Alexaflour-633 labelled WGA to visualise all glycoproteins 
and incubate for another hour. Cell nuclei were counterstained with 300 nM 4,6-
diamidino-2-phenylindole (DAPI) for 10 min after washing twice with PBS-Tween 20 
and once with PBS. After DAPI staining, cells were washed once with PBS for 5 
minutes. The Transwell membranes were removed by scalpel, placed (apical side on 
the top) on a microscope slide with a drop of Fluoroshield for preserving fluorescence. 
The slides were examined using an Olympus BX-60 epifluorescent microscope and 
images captured by a ProgRes c10 Plus digital camera. Analysis was conducted using 
a Leica SP1 confocal microscope with assistance from Balazs Bajka (Institute of Food 
research). 
 
2.1.7 Human mucus harvesting from NHBE cells 
To detach the slimy mucus from the NHBE monolayer 100 µl were added to each 
insert (+/- IL13) and left into the incubator for 10 min at 37°C. The mucus was then 
collected and frozen at 4°C for future use. 
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2.1.8 Identification of mucin structure by AFM 
During sample preparation for immunohistochemistry it was observed that 
significant amounts of mucus were removed from the apical membrane. The PBS 
washes containing the secreted mucus was centrifuged (5,000 g at 4°C for 30 
minutes). The supernatant was aspirated and the pellet was diluted 10-fold in 
ultrapure water. Four microliters of the diluted sample were spotted onto freshly 
cleaved mica, then incubated for 1 min to allow glycoprotein adsorption to take place. 
The sample was blown dry using dry nitrogen gas. Patrick Gunning from the Institute 
of Food Research analysed the sample with an MFP-3D BIO atomic force microscope. 
The cantilevers were Olympus AC160TS (Olympus, Tokyo, Japan) with a nominal 
spring constant of ∼42 N/m, oscillated at a frequency 10% below resonance (typically 
around 320 kHz). The damping set point for imaging was kept to the minimum value 
that allowed stable tracking of the sample surface to minimize any sample 
deformation. Images were acquired at a scan rate of 1 Hz. 
 
2.2 Ex vivo system using porcine respiratory tract mucus 
NHBE cell culture is expensive and it takes a long time to obtain a small amount of 
mucus. An ex vivo system using porcine respiratory mucus was investigated as a 
source of fresh porcine mucus.  
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2.2.1 Materials for porcine lung mucus extraction 
Porcine lungs were donated by H G Blake, Ltd. Bull Farm Abattoir (Norwich, UK). 
Nitrocellulose transfer membrane 0.45um RPMI 1640, Antibiotic-antimycotic mixture 
(100x) was bought from Gibco (Carlsbad, California), NaCl and gentamicin solution 
50mg/ml were bought from Sigma. 
 
2.2.2 Tracheal and lung dissection and mucus harvest 
Dissection was performed on fresh porcine lungs. Each trachea was removed intact 
by sectioning below the larynx and above the first bronchial branch (15-18cm long). 
Primary and secondary bronchi (60-80mm long) were dissected intact from lung 
tissue (Figure 2.2). Sterile saline solution (NaCl 0.150 M) was used to rinse off blood 
contamination. After several washes with NaCl, dissected tissue was rinsed and rolled 
with a tube roller (Stuart®) for 30 minutes in 5 ml of RPMI 1640 supplemented with 
a mix of antibiotics: penicillin (100 or 300Units/ml), streptomycin (100 or 300μg/ml), 
fungizone (25 or 75μg/ml) and gentamicin (5 or 15μg/ml). Tracheal and bronchial 
explants were then incubated at room temperature, 4°C and 37°C for 24 and 48 hours 
with 5ml of fresh RPMI, supplemented with antibiotics as above (Figure 2.2). After 
incubation, the trachea and bronchi were cut open longitudinally and porcine lung 
mucus (PLM) was collected by scraping gently with a cell scraper and frozen at -20°C 
until required. The same was followed after 48 hours of incubation.  
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2.2.3 Alcian Blue Staining 
Alcian blue (AB) is a dye containing a group of water soluble polyvalent basic dyes. 
The blue colour is due to the presence of copper in the molecule. When used in an 
aqueous solution Alcian blue can react with anionic groups (mucin, mucosubstances, 
and DNA). It is believed that AB forms salt linkages with the acid groups of acid 
mucopolysaccharides that act as the binding force.  
Figure 2.2 Porcine lung dissection.  Trachea and bronchi were cut out from the porcine lung 
and washed with 0.9% NaCl before be keep at different temperature (RT, 4 and 37 C). Tissue 
fraction were cut and mucus was collected. 
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To stain mucus with AB a piece of nitrocellulose membrane (7cm x 4cm) were washed 
in distilled water for 5 min. 2μl of mucus isolated from NHBE cell cultures (± IL-13), 
and fraction of mucus isolated from porcine lungs/ileum, were dropped onto the 
membrane and air-dried. As a control, 2μl of water were used. The membrane was 
stained by immersion in a solution of 1% Alcian blue (AB) stain dissolved in 3% acetic 
acid pH 2.5 for ~30 minutes. The membrane was rinsed three times with distilled 
water, soaked for 10 minutes in distilled water and left to air dry.  
 
2.2.4 Determination percentage dry weight of sample harvest from porcine   
trachea and bronchi and purified gut porcine mucin 
The dry weight of harvested mucus (Wdry) was determined by placing 4 sample 
aliquots of mucus (180-200 mg for respiratory mucus and porcine jejunal mucus) in 
pre-weighed eppendorfs tube (Wep) and freeze-dried for 4 days. Every day the weight 
of each tube was recorded and the freeze -dry was stopped when the weights of the 
eppendorfs were stable (Table 2.1). The dry weight of the mucus is: 
    Wdry = Wep +dry – Wep 
 
Where Wep +dry is the weight of the eppendorf with dry mucus after freeze-dry 
The percentage of dry mucus (dry) was given by 
  
%ry = 	
 100 Where W wet (liquid weight mucus) is 
     W wet = Wep +wet – Wep 
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2.3 Solute transport assays using purified PGM 
Transport assays were carried out for the establishment and validation of mucin gel 
model for studying the ability of probes and drug molecules to penetrate mucin gels.  
 
2.3.1 Franz-cell chamber  
The Franz cell system (Figure 2.3) consists of two chambers, the donor and receiver 
chamber separated by a membrane impermeable to mucus. The mucus and drug are 
added onto the membrane (or mucus layer) in the donor chamber and drug transport 
into the basal chamber determined by sampling the receiver chamber. The maximum 
capacity of the receptor chamber in this thesis was 5 ml and is kept under stirring 
throughout the experiment using a small magnetic stirrer bar.   
 
 
 
Figure 2.3 Franz-cell system 
The donator and receptor chambers are separated by a membrane. The test product is 
applied to the membrane via the top chamber. The bottom chamber contains fluid from 
which samples are taken at regular intervals for analysis. Taken from, pharma science and 
monitor, vol-1, Figure 1, Issue-2, 2010. Shah at al. 
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2.3.2 High-performance liquid chromatography (HPLC) 
HPLC is an analytical technique (Figure 2.4) used to separate and quantify one or 
more components in a mixture (2). All forms of chromatography work on the same 
principle. The mobile phase is forced through the stationary phase by high pressure 
pumps. Pressure may reach 60 MPa, or about 600 atmospheres. The separation of 
singles component of a mixture depends on the equilibrium affinity between the 
stationary phase (solid or liquid) packed inside the column and a mobile phase (liquid 
or gas) that flows through it. Column dimensions are typically 30–250 mm length and 
2.1–4.6 mm diameter. The particle size in the columns are made with sorbent 
particles of about 2–50 µm. The most used stationary phase is silica but some column 
may be packed with alumina. The silica spheres efficiency is controlled by the size of 
the; the smaller the particle size distribution, the more efficient and robust the 
packing material.  Modern HPLC systems (such as Ultra High Performance Liquid 
Chromatography) have been improved to work at much higher pressures, up to 120 
MPa, and are therefore able to use much smaller particle sizes in the columns (<2 μm) 
which gives a much greater surface area for interactions between the stationary 
phase and the analytes flowing through it leading to improved separation of all 
components of the mixture.  
 
After the sample has been injected, the analyte first encounters a guard column 
which is responsible for removing contaminants from solvents or samples that would 
bind to and damage the expensive analytical column. The composition of the guard 
column packing should match that of the column to which it is connected, although 
particle size is usually larger. The time that any component takes to elute the column 
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and move to the detector is known as retention time and can be used to identify the 
different compound of a mixture. How fast each component of a mixture moves 
through a column depends from their relative affinity for the mobile phase and 
stationary phase; an analyte with stronger interaction with the stationary phase will 
take a longer time to move through the column compare to a molecule with weaker 
interaction with the stationary phase and stronger interaction with the mobile phase. 
The solvent emerging from the column and carried the separated components of the 
mixture pass in the detector. A wide range of detectors can be used and the most 
used one is a UV-Vis absorbance detector. The fluorescence detection offers greater 
sensitivity than a UV-VIS detector but in comparison to light absorbing compounds 
the number of naturally fluorescent compounds is smaller. Another detector type 
used in HPLC systems is mass spectrometer which offers very high sensitivity and 
selectivity and can be combined with UV-Vis detector (LCMS). 
  
  
 
Depending on whether the stationary phase and mobile phase are polar or non-polar 
is possible to distinguish between Normal phase HPLC and Reverse phase HPLC. 
Figure 2.4 HPLC system. The pumps move the solvents and the sample injected through the 
column. The analyte with weaker interaction with the stationary phase will be eluted and 
detected first.  
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Normal phase HPLC 
The solvent is non-polar (hexane) and the column is filled with tiny silica particles, 
and uses a non-polar, non-aqueous mobile phase (e.g. chloroform). 
Therefore, a polar analyte will have a stronger interaction to the polar silica than a 
non-polar one. The non-polar compound will have a shorter retention time as will 
move quickly through the column. 
 
Reversed phase HPLC 
It is the most used form of HPLC. The stationary phase is made of silica which is 
modified to make it non-polar by attaching hydrocarbon chains (8-18 carbon atoms) 
to its surface. The mobile phase used is polar with can be a mixture of water and less-
polar but water miscible organic solvents e.g. alcohols. Polar compounds will stronger 
interact with the polar solvent and passed through the column rapidly. Non-polar 
compounds will therefore more retained to the hydrocarbon chain.  Depending on 
whether the ratio of solvent used is changed during the elution, we can distinguish 
between two methods: isocratic system and gradient system.  
 
An isocratic elution involves a single solvent or solvent mixture but the composition 
remains constant all the time. In this way the system and column are equilibrated 
throughout the elution. A gradient elution involves two or more solvent with different 
polarity (such as water and acetonitrile) are employed. The ratio of the solvents is 
varied in a programmed way after sample injection. Compared to the isocratic system 
separation efficiency is greatly enhanced in gradient elution. 
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2.3.3 Materials  
Purified mucin powder from porcine stomach (type III) containing ~0.5-1.5% of bound 
sialic acid, partially purified powder, sodium fluorescein, fluorescein isothiocyanate-
conjugated dextran probes (4, 10, 40, 70 kDa), amiloride hydrochloride hydrate and 
benzamil hydrochloride were purchased from Sigma Aldrich (Gillingham, UK). 
Cellulose Ester Dialysis membrane 100 kDa cut-off were purchased from 
Spectra/Por® Biotech, Corning® NBS™ 96 well plates were purchased from Fisher 
Scientific (Loughborough, UK). Glass screw thread vial, plastic vials target PP 
polyspring insert and Acetonitrile were purchased (Thermo Fisher Scientific). 
 
2.3.4 Descriptions of samples preparations 
FL-Na and FITC-dex preparation  
A stock solutions of sodium fluorescein (FL-Na), and fluorescein isothiocyanate-
dextran probes (FITC-dex) at different molecular weight (4, 10, 40, 70 kDa) were 
obtained dissolving the powder into phosphate buffer (PO4) buffer 100mM Na2HPO4 
and NaH2PO4 (NaPO4) and 50mM NaCl with pH 6.8 (PBS pH 6.8) at a concentration of 
10mg/ml. The stocks were stored at -20°C until needed.  Franz cell donor solutions 
were obtained diluting the stock solution with the same PBS pH 6.8 to a final 
concentration of 200 µg/ml for FL-Na and FITC-dex 4 (FD4). A dose donor of 1mg/ml 
for FITC-dex 10, 40 and 70 (FD10, 40, 70) was needed to ensure that high molecular 
weight probes were detectable at each time point of the experiment.  
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Amiloride and Benzamil preparation 
Stock solutions (10mg/ml) of Amiloride and Benzamil were made up using DMSO and 
diluted to 200 µg/ml (dose donor) using PBS pH 6.8. 
   
  Preparation of mucin gels with Porcine Gastric Mucin 
PGM solutions (1, 3, & 5% w/v) were prepared using PGM dissolved PBS pH6.8. PGM 
solutions were rolled for 2-3 hours until mucin was completely dissolved then left 
overnight at 4°C to hydrate fully. PGM solutions were rolled for 1h at RT immediately 
before commencing Franz cell experiments. Vigorous agitation of the samples was 
avoided to avoid the introduction of bubbles in the mucin solution.  
 
2.3.5 Analysis of solute transport across PGM solutions 
Permeation studies using PGM solutions or buffer (PBS pH 6.8) were conducted using 
the Franz-cell diffusion system. The surface of the donor and receiver chambers was 
greased before adding a cellulose ester membrane (MWCO 100,000) which 
separated the two chambers. The donor (9mm diameter) and receiver chambers (5 
ml) were fixed together using a clamp. Mucin solution 1, 3 & 5%v/w (189 µl to give 3 
mm deep) were applied to the membrane via the donor chamber. The receptor 
chamber was filled with 5 ml of PBS pH 6.8 and kept at 37°C throughout the 
experiment by recirculating water bath (HAAKE SC100, Thermo Scientific). 
Continuous stirring (500rpm) was provided by a small magnetic bar in the receiver 
chamber. Dose donor (50 µl), 0.2mg/ml for FL-Na and FD4 and 1mg/ml FITC-dex 4, 
10, 40 and 70 kDa, were placed gently on the top of PGM. At regular intervals (10, 20, 
30, 60, 90, 120min) 200μl of sample was taken from the receptor chamber for 
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analysis and replace with 200μl fresh, pre-warmed buffer. Permeation assays were 
also performed using amiloride and benzamil at a dose donor of 200µg/ml in a 
volume of 50µl. Experiments were set and carried out in same way as described for 
FL-Na and FITC-dex. 
 
2.3.5.1 Quantification of FL-Na and FITC-dex probes in diffusion assay 
The amounts of FL-Na and FITC-dex probes (4, 10, 40 & 70 kDa) in receiver chamber 
samples was quantified by comparing their fluorescence to their calibration solutions 
(Table 2.1). Samples were added to black 96 well plates (Corning #3686) and the 
fluorescence measured a FLUOstar OPTIMA microplate reader (BMG Labtech) with 
excitation and emission wavelengths of 492nm and 520nm, respectively 
 
2.3.5.2 Quantification of amiloride and benzamil in diffusion assay 
Quantification of amiloride and benzamil was performed on a Perkin Elmer 
fluorescence HPLC system equipped with a Perkin Elmer LC 240 fluorescence detector 
(UK) using Phenomenex column C18 (4.6 x 250 mm 5µm) using a Security Guard 
column C18 3x4mm (Phenomenex). The isocratic elution method was composed of 
50% 10 mM phosphate buffer pH 4.2 and 50% acetonitrile (solvent A and B 
respectively) at a flow rate of 1 mL/min. Excitation and emission were set at 362 and 
417 nm for amiloride and 366 and 412 nm for benzamil. The rage of the calibration 
curve and analytical method used are showed in the Table 2.1. 
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2.3.5.3 Apparent permeability coefficients 
Apparent permeability coefficients (Papp) for mucin gels were calculated according to 
the following equation: 
                                                                Papp=   

 
   
Where 

  is the rate of appearance of probes in the receiver side (ng/s), A is the 
surface area of the filter (0.189 cm3), C0 is the initial concentration of probe in the 
donor chamber (ng/ml). 
  
Table 2.1. Summary of calibration curve range and analytical 
method used to analyse probes and drug molecules used for 
the permeation assay. 
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2.4 Biochemical Analysis of PGM, ex vivo PLM and porcine jejunal mucin 
Biochemical analysis of the harvested mucus from porcine trachea and bronchi and 
purified mucin from porcine gut were carried out to calculate the percentage of dry 
weight, determined the mucus pH, to quantify mucin and to determine the presence 
of DNA. Mucin and DNA determination were performed also for PGM. 
 
 Determination of mucin concentration  
2-cyano-acetamide was used for the determination of mucin percentage of the fresh 
porcine mucus. The assay involved the liberation of O-glycosylated glycoprotein by β-
elimination with alkali and the consequent derivation of the reducing end with 2-
cyano-acetamide. 
 
 Determination of DNA concentration 
The reaction of 3, 5-diaminobenzoic acid (DABA) with DNA was applied for the 
identification and measurement of DNA contamination in fresh porcine mucus using 
the same aliquots used for mucin determination. Acid hydrolysis of DNA in DABA 
leads to a formation of a fluorescent product which is used for DNA quantification. 
 
2.4.1 Materials details 
PGM (type III) containing ~0.5-1.5% of bound sialic acid, 2-cyanoacetamide (2-CNA), 
3, 5-diaminobenzoic acid (DABA), calf thymus DNA, tris-(2-carboxyethyl) phosphine 
(TCEP) 0.5M, borate salt, borate-HCl were purchased from Sigma Aldrich (Gillingham, 
UK). HyClone™ 0.1µm sterile filtered water was purchased from life science. 
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2.4.2 Respiratory porcine mucus pH determination 
The porcine mucus was diluted in sterile water 1:500 and 1:100 and pH was 
determined using a hydrus300 pH meter Thermo Fisher Scientific (UK) 
 
2.4.3 Determination of mucin concentration  
A fluorometric mucin assay was carried out to determine the mucin concentration. 
Eight samples of PLM and porcine jejunal mucin (PJM) was used for mucin assay. 
Aliquots of fresh PLM and PJM were diluted as shown in Table 2.2 using dH2O and 
rolled for 2h to mix. 1ml of each dilution was boiled for 1h in sealed tubes and 
samples were then spun at 5000 g per 5 min to remove insoluble material. The 
supernatant (100 µl) was added to 120 µl of alkaline 2-CNA (20% CNA 0.6 M in 150 
mM NaOH). The mixture was heated at 100°C for 30 minutes then mixed with 1ml 
borate buffer 0.6 M, pH 8 and samples left to cool to RT. Calibration solutions of PGM 
spanning 10 to 1000 µg/ml were prepared as described above. Fluorescence intensity 
measurements were performed on a Hitachi Fluorescent FL4500 using 0.5 cm quartz 
cell and 2-CNA fluorescence was measured using excitation/emission at 336/383 nm 
respectively. Mucin determination was performed also for 1,3 and 5% PGM diluted 
as showed in Table 2.2. 
 
2.4.4 Determination of DNA concentration  
All eppendorfs tubes and tips used for the DNA assay were autoclaved twice to 
eliminate any DNA/DNase contamination. Standards, DAPA and samples were made 
up using sterile filtered water. Standards were obtained using calf thymus DNA in a 
range between 2 to 10 µg. The Table 2.2 shows all dilution used for PLM, PJM and 
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PGM. Each standard and sample dilution (50 µl) were transferred into eppendorf 
tubes in a laminar flow hood, and left at 60° C overnight to dry the sample. The next 
day, 100 µl of DAPA 100mg/ml were added to each tube and left at 60°C for 45 
minutes. The fluorescence was measured in 0.5 cm quartz cell after addition of 1ml 
of HCl 1N in each tube and left to cool down. The spectrophotometer excitation and 
emission wavelengths set on the Hitachi Fluorescent FL4500 were 420 and 490 nm 
respectively.  
 
  
2.4.5 Investigation of the amiloride and benzamil interaction with mucin  
The investigation of the Amiloride and Benzamil interaction with mucin was 
investigated by fluorescence and UV–Vis spectroscopy. 
 
2.4.6 Fluorescence spectroscopy 
Fluorescent spectroscopy analyses the emission of fluorescence radiation by an 
analyte. Molecules have various electronic energy levels. By absorbing a beam of light 
they can pass from a lower to a higher energy level. The molecule’s electrons are 
excited by absorbing a photon from its low energy state to one of the various 
vibrational states.  The excited state lasts about 10-5 seconds before the molecule 
Table 2.2. Summary of dilution used for Mucin and DNA assay for different mucus/mucin 
model: ex-vivo porcine respiratory mucus, PGM 1,3,5%, purified gut mucin.  
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collides, with a consequence loose of vibrational energy and emission of light. Each 
fluorescent molecule has a characteristic maximum wavelength of absorption and 
emission and the difference between positions of the maximum wavelengths of the 
absorption and emission spectra is called Stokes shift. The ratio of photons absorbed 
to photons emitted through fluorescence is called quantum yield. Quantum yield may 
be affected by environment factors (viscosity, pH, solvent) and depends on structure 
characteristic of the fluorophore. Higher fluorescence is given from rigid, planar 
molecules due to energy dissipation after absorption of photons (3). An intensity 
change of fluorescence can be observed when the fluorophore is restricted in a 
binding site with a consequent decrement of fluorescence intensity or increment 
when the quantum yield is higher than free form.  
 
2.4.7 Ultraviolet-Visible Spectrophotometer (UV-VIS)  
In analytical chemistry UV/Visible spectroscopy is used for the quantitative 
determination of matter. The spectrophotometer operates by passing a beam of light 
(stream of photons) through a sample. The analyte will absorb the photon and the 
instrument will measure the intensity of the light reaching a detector. The Beer-
Lambert law (Eq.  1) is the base for UV and visible quantitative analysis (2). The Beer-
Lambert law states that the absorbance of a solution is directly proportional to the 
molecules concentration in the solution (C), to the molar absorptivity (with units of L 
mol-1 cm-1), also known as the extinction coefficient (ε), and to the path length ( l ). 
  Eq. 1  A = ε ⋅ c ⋅l 
To simplify the calculation of absorbance and molar absorptivity a path length of 1 
cm is usually used. The proportion of the light absorbed will depend on how many 
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molecules it interacts with and a calibration curve can be used to accurately know 
how quickly absorbance changes with concentration.  
  
2.4.8 Materials 
Mucin from porcine stomach, type III, amiloride and benzamil were purchased from 
Sigma Aldrich (Gillingham, UK). 
 
2.4.9 Sample preparation 
  Mucin from porcine stomach, type III 
As the molecular weight of the commercial mucin is not available the molecular 
weight of mucin was considered to be 1MDa. Mucin solution at 10 µM was prepared 
by dissolving 10 mg lyophilized powder in 1 ml of PBS pH 6.8 and left on the roller 
overnight. The day after the mucin was spun at 5000 rpm for 5 minutes at room 
temperature and diluted as appropriate with phosphate buffer. 
 
  Amiloride and Benzamil preparation 
Stock solutions at a concentration of 10 mM of both model drug were diluted with 
PBS pH 6.8 to have stock solution to be used for the fluorescent and UV approach. 
Stock solution for fluorescent approach; 0.1 mM and of 1mM  
Stock solution for UV approach; 100 µM and 2mM.   
 
2.4.10 Fluorescence spectroscopy  
A 2.5 mL solution containing 1 µM mucin was titrated by successive additions of 0.4 
µM of amiloride or benzamil (adding 10 µl of 0.1 mM solution) over a range of 0 – 3.2 
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µM. The mucin titration was continued by successive additions of 4 µM (adding 10 µl 
of 1mM solution) until the final concentration of drug molecule in the mucin solution 
was 15.2 µM. Fluorescence spectra using the same concentration of drug was also 
performed in PO4 buffer pH 6.8 without mucin. Fluorescence spectra were recorded 
on a Hitachi Fluorescence FL-4500 using 1cm Quartz cuvette at room temperature. 
Amiloride was detected using excitation 362 nm and Emission 417 nm. For benzamil 
the excitation and emission used where 366 and 415 nm respectively.  
 
2.4.10.1 Effect of solvent polarity on amiloride and benzamil fluorescence 
The fluorescence emission of 100 nM solutions of amiloride or benzamil where mixed 
with 0, 1, 5, 25, 50, 75 or 100% ethanol and fluorescence spectra recorded as 
described in section 2.4.10. 
   
2.4.11 UV spectroscopic approach 
A 1 ml solution containing 0.5 µM mucin was titrated by successive additions of  
5 µl of 100 µM amiloride/benzamil solution. Drug concentration was then increased 
by addition of 5, 10 and 20 µM (adding 2.5, 5 and 10 µl of 2mM stock) until the final 
concentration of drug molecule in the mucin solution was 130 µM. The UV–Vis 
absorption spectra of the mucin solution with concentration of drug between 0 and 
130 µM was measured with an Agilent technologies Cary 60 spectrophotometer in 
the range of 200–450 nm at room temperature. The same UV–Vis absorption spectra 
was carried out in a pure drug solution using the same range of drug concentration 
used for the mucin titration. 
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2.5 Development of ultrafiltration binding assay  
This work was mainly focused on the development of an analytical method that 
allows us to understand whether ENaC blockers interact with mucin. This assay has 
then extended to study drug-DNA interaction as well as drug-alginate interaction.   
 
2.5.1 96-well ultrafiltration assay 
96-well ultrafiltration plate (Figure 2.5) and assembly, for the determination of 
ligand-protein binding, includes the MultiScreen® filter assembly with Ultracel-PPB 
membrane, which is specifically optimized for in-vitro plasma protein binding assays, 
or a MultiScreen filter plate with Ultracel-10 membrane for the concentration and 
purification of biological solutions. The donor solution is added onto the membrane. 
The system operates by centrifugation for the separation of unbound from protein-
bound compound and includes a receiver plate were the free ligand is collected. 
2.5.2 Materials 
Amiloride, benzamil, rhodamine B, sodium alginate, DNA from fish sperm, DNase I, 
FL-Na and FD4 were purchased from Sigma Aldrich (Gillingham, UK). Analogues were 
Figure 2.5 Multiscreen plate. Donor solution is added onto the membrane via the up plate. 
Ultrafiltration solution is taken from the bottom plate wells. 
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donated from Novartis (Basel, CH). Glass screw Thread Vial, Plastic vials target PP 
polyspring insert and acetonitrile were purchased from Thermo Fisher Scientific (UK), 
guard column C18 4x3 mm was purchase from Phenomenex (UK), MultiScreen 
Ultracel-10 Filter Plate 10 kDa were from Millipore (UK). 
 
2.5.3 Sample preparation 
 PGM and Rhodamine B preparation 
For the binding assay a concentration of 2µM was made up dissolving the powder 
into PBS pH 6.8. 
Rhodamine B was dissolved in PBS pH 6.8 as appropriated and used as internal 
standard for FL-Na and FD4. 
 
 Stock solution and internal standard preparation for ENaC blockers 
All model drugs (Figure 2.6) were dissolved in DMSO at a concentration of 20mM and 
stored at -20°C. When needed stock solutions were diluted, as appropriate in PBS pH 
6.8. Stock solutions of internal standard were instead dissolved in DMSO to a 
concentration of 10mg/ml. The combination of analyte and internal standard was 
chosen considering their resolvability on the HPLC column (Table 2.3) and compound 
availability. Concentration of the internal standard was dependent of the analyte 
concentration into the mixture drug-mucin (or buffer solution for controls) (Table 2.4). 
Due to the low aqueous solubility of few compounds (amiloride, NVP-QBE170 and 
GD-40-QQ33) a first dilution (1 out 4) of all drug molecule was made using NaPO4 
buffer at pH 5 instead. The pH of dose donor was then verified using a hydrus300 pH 
meter Thermo Fisher Scientific (UK). 
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Figure 2.6 Structure of Amiloride and its Analogues used in this project. 
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Table 2.3. Summary of Amiloride and analogues calibration range, EM/EX, Analytical method, LOD/LOQ, analyte retention time (RT) and internal 
standard used for the development of the multiscreen binding assay. 
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2.5.4 Sample preparation for ultrafiltration assay 
Mucin solution (10 x 10-6 M) was prepared by dissolving 20 mg lyophilized PGM 
powder in 10 ml of PBS pH 6.8 and left on the roller overnight. Mucin solution (1 ml) 
was mixed with 1 mL of double-strength analyte solution to obtain different molar 
ratios; 1:1, 5:1, 10:1, 20:1, 50:1, 100:1, 200:1.  Non-specific binding controls were 
performed by mixing 1ml of PBS buffer with 1ml of double-strength analyte solution. 
 
Internal standard control (10 µl), at a known concentration, were added into each 
well of the receiver plate to allow, after filtration, the determination of the exact 
filtered volume (Vultrafiltrete). The mixture drug-mucin mixture (400 µL) was added onto 
the membrane (10 kDa cut-off) of the donor plate. The plate was left to equilibrate 
at room temperature for 1 h and then centrifuged (Beckman centrifuge) at 2000 g for 
1,5 h at 19°C. Following centrifugation, the filtrate was removed from the receiver 
plate and internal standard (10 µl) was added into each donor well to be able to 
determine the exact retentate Volume (Vretentate). A small amount of the donor 
solution was processed for measurement of initial compound concentration (Dinitial). 
Table 2.4. Concentration of drug molecules (analyte) used to study the interaction with 
mucin (1µM) and concentration of internal standard used for each analyte concentration. 
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2.5.5 Analyses of interaction between 552-02 and benzamil with reduced mucin 
Ultrafiltration binding assay was also carried out after disulphide reduction of mucin 
with 50 mM of Tris 2-Carboxyethyl Phosphine (TCEP) for both 552-02 and benzamil 
at 20 µM. 
 
2.5.6 Mucin precipitation 
For the determination of the drug retentate concentration (Dretentate) the disruption 
of drug-mucin interaction was achieved by taking 50 µl of donor solution and diluting 
it 1:5 with cold acetonitrile (-20°C) and spun at 10000 rpm for 5 min. Pre-cleared 
sample were analysed with HPLC. 
 
2.5.7 Solute analysis 
Analytes were resolved as described in section 2.3.5.2. Excitation and emission were 
set at 314 and 416 nm respectively for all compounds. The range of calibration curve, 
LOD, LOQ, Em/Ex for each molecule is show in the Table 2.3. 
 
For FL-Na and FD4 the control used was Rhodamine B and samples were quantified 
by microplate reader Polar start Optima (BMG LabTech) at an excitation and emission 
of 495 and 510 nm For FL-Na. For rhodamine B the excitation and emission were set 
at 560 and 590 nm. 
 
2.5.8 Determination of Mass Balance 
The mass balance was determined according to: 
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 Eq.2   ! = "#$%% &'()*+,'()*(-.#$%% )-(-/(*(-#$%% ,/,(,*' 0 100% 
 
Where Massultrafiltrate is the concentration of the drug in the bottom plate after 
centrifugation multiplied by the ultrafiltered volume. Mass initial is the concentration 
of the dose donor added into the top plate and multiplied by the volume added. 
Massretentate  is the concentration of drug retained on the top plate after centrifugation 
multiplied by the unfiltered volume: 
 
  ! = 12345$6745$89345$6745$8 + 2588;$89588;$827;77$497;77$4 < 100% 
 
Where; 
D= Drug concentration 
V= Volume 
    Vretentate = V initial - V ultrafiltrate 
 
The volumeretentate and the volumeultrafiltrate were obtained considering the initial and 
final concentration of the internal standard added at the top and bottom plate using; 
     C1V1 = C2V2 
C1 = original concentration of internal standard 
C2 = final concentration of the solution 
V1 = volume added to top and bottomwell plate 
V2 = final volume  
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2.5.9 Determination of % binding 
The percentage of model drug interacting with mucin was determined according to 
(4); 
Eq.3 % =>=? = "1 − [B53C&'()*+,'()*(-][B53C(E(*'] 0 100 
 
2.5.10 Determination of non-specific binding (%NSB) 
The determination of the %NSB was determined using the same formula above but 
considering the mucin-free control of each analyte. 
 
2.5.11 Isothermal binding curve  
The isothermal binding curve for each compound was obtained plotting the free 
concentration (Dultrafiltrate) of compound against the molar ratio of bound drug to 
mucin (mol/mol) using Graph Pad Prism 6. The free concentration of drug is the 
filtered drug from the mixture (drug-mucin). The molar ratio of bound drug to mucin 
(Eq.4) was calculated by difference between the free concentrations of drug and the 
molar ratio of bound drug to mucin is; 
 
Eq.4 FG GH=F FI JFK> >GK? HF LK =(NOPNOP) =
R48% S3; 53C
R48% R3T7; 7; U,/,(,*' 
The moles of bound compound was calculated as following; 
 
 Molar ratio of bound  
 drug to mucin (mol/mol)= (BVE/()E' &'()*+,'()*(-WBX,Y(&)- &'()*+,'()*(-)Z U,/,(,*'#3T7; R48% 7; U,/,(,*'  
 
Where; 
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D control ultrafiltrate is the concentration of drug in the bottom wells plate of the control 
(buffer solution). D mixture ultrafiltrate is the concentration of drug in the bottom wells 
plate considering the mixture drug-mucin. 
 
2.5.12 Ultrafiltration binding assay using DNA and Alginate  
The ultrafiltration binging assay developed to study the mucin-drug interaction was 
also applied to study the interaction of drugs molecules with DNA and alginate. The 
experiment was performed as described in section 2.5.4 however only a 
concentration of 20 µM for all compound and FL-Na and FD4 was used. Based of 
viscosity the molecular weight of DNA and alginate are expected to have a molecular 
weight range of 12-40 kDa and 50-120 kDa respectively (Sigma-Aldrich, personal 
communication). An arbitrary value of 30kDa for sodium alginate and 100 kDa for 
DNA was chosen for this project. 
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2.6 Calu-3 cell culture 
The Calu-3 cell line is derived from human bronchial submucosal glands (5) and is a 
well-differentiated under submerged culture conditions (6) and well characterized cell 
line. Although the mucus production is limited compered the in vivo phenotype, Calu-
3 cells form a restrictive monolayers reflecting in vivo physiology (7, 8)  and are finding 
increasing application in the pharmaceutical industry. For this reason, we used Calu-
3 cell to study their permeation to amiloride and analogues. 
 
2.6.1 Calu-3 cell culture reagents and media preparation  
Calu-3 were purchased from ATCC.  DMEM/F12 and DMEM/F12 phenol red-free 
(Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12) and non-essential amino 
acids were purchased from Thermo-Fisher Scientific. Penicillin/streptomycin (10,000 
U/ml and 10,000 μg/ml), 0.25% trypsin-EDTA were purchased from Invitrogen 
(Paisley, UK). Clear Transwell inserts (#3470) were from Corning. Amiloride and 
benzamil were purchased from Sigma Aldrich (Gillingham, UK) Analogues were 
donated from Novartis (Basel, CH). Glass screw Thread Vial, Plastic vials target PP 
polyspring insert and Acetonitrile were purchased (Thermo Fisher Scientific). 
 
2.6.2 Calu-3 cell culture 
The Calu-3 human bronchial epithelial cell line was grown in 75cm2 cell culture flasks 
in a humidified 5% CO2/95% atmospheric air incubator at 37 °C using Dulbecco's 
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM-F12) media supplemented 
with 10% foetal bovine serum, 1 % v/v non-essential amino acid solution (100X), and 
2 % v/v penicillin-streptomycin (full media). Medium was refreshed three times per 
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week until cells were ~80% confluent. Cells were then seeded onto the apical 
chamber of Transwell inserts (diameter 6.5 mm and a pore size of 0.4μm) at a density 
of 10× 104 cells/insert using 100 µl of full media. 500 µl medium were added in the 
basolateral chamber. The day after the media was changed in both apical and bottom 
side and washed with warm PBS to remove debris. The submerged monolayer was 
then fed three time per week. Once cells were 100% confluent TER was tested as 
described in the section 2.1.5 immediately before monolayer medium was changed. 
 
2.6.3 Sample preparation for transportation assay through Calu-3 
  Dose donor preparation 
Due to the low solubility of amiloride, NVP-QBE170 and GD-40-QQ33 a first dilution 
(1:1) of all stock solutions (20 mM in DMSO) was made in DMSO. The secondary stock 
solution (10mM) was then diluted as appropriate with DMEM/F12 phenol free to 
make up a final concentration of 100 µM (1% DMSO) which was used as donor 
solution for the permeation assay. 
  
2.6.4 Transportation assay  
The permeation assay through Calu-3 cells was performed when the TER was 
constant. All experiments were performed in quadruplicate and inserts used for each 
compound were carefully chosen to ensure the mean TER was comparable between 
groups. Before starting the assay, cells were washed twice with 100 µl of warm PBS 
then replaced with 500 µl of DMEM/F12 in the bottom side of the Transwell, and 
100µl onto the apical side before 1h equilibration. The experiment was started by 
replacing the media from the top side with 100 µl of donor dose (pre-warmed) and 
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200 µl of samples were taken from the bottom side at: 0, 15, 30, 45, 60, 90, 120, 180, 
240 minutes. Samples were replaced with pre-warmed DMEM/F12 phenol free. 
 
2.6.5 Permeation assay though Calu-3 using 552-02 in mucin solution 
Permeation assay were performed also dissolving 20 µM 552-02 in 0.5 µM purified 
mucin. The experiment was carried out in triplicates in the way as described in the 
section 2.6.4. 
 
2.6.6  HPLC analysis 
The range of calibration curve used is show in the Table 2.3 (section 2.5.3). Standards 
and samples were prepared using DMEM/F12 phenol free. The separation was 
performed on a Phenomenex column C18 (4.6 x 250mm 5µm) equipped with 
fluorescence detector (excitation 314 nm Emission 416nm) injecting 70 µl and. 
Mobile phase used was a gradient of NaPO4 buffer 10mM pH 4.2 (solvent A) and 
acetonitrile (solvent B) at a flow rate of 1 mL/min. The gradient method used for the 
separation is shown in Table 2.5. 
 
 
 
Table 2.5. Representation of gradient method 
used to analyse Amiloride and Analogues after 
transport assay thought Calu-3. 
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2.6.7 Papp calculation 
The apparent permeability coefficient for each compound analysed through Calu-3 
and controls (without cells) was calculated as described in the section 2.3.5.3 using a 
surface area of 0.3318 cm2. 
 
2.7 Purification of porcine jejunal mucin  
2.7.1 Materials  
Porcine jejunum was sourced from the local abattoir, complete mini Tablets protease 
inhibitor cocktail were purchased from Roche, CsCl was purchased from Sigma 
Aldrich (Gillingham, UK), quick seal centrifuge tube Beckman Coulter (High Wycombe, 
UK), electric mix-paddle purchased from Qualtek Electronics Corporation (Fort Worth, 
UK), N-ethyl maleimide and Guanidine purchased from Thermo Fisher Scientific (UK), 
EDTA was purchased from Sigma Aldrich (Gillingham, UK), Cellulose Ester Dialysis 
membrane (Spectra/Por Biotech). 
 
2.7.2 PJM collection 
Porcine jejunum (Figure 2.7) was obtained from the local abattoir immediately after 
the sacrifice of the animal and placed in a container with ice. It was washed gently 
(to avoid mucus loss) with protease inhibitor buffer pH 6.5 (see Table 2.6) several 
times until the liquid passing through the intestine was clear. The gut was cut into 
sections of 20-25 cm long and open out by cutting along the line of the mesentery. It 
was store on tray on ice till mucus was scraped out.  
The mucus was scraped out using crooked finger moved along the intestine segments 
and it was placed into the rehydration buffer (10ml/g mucus). 
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2.7.3 Mucus preparation 
The mixture mucus-rehydration buffer was stirred with an electric paddle at 200 rpm. 
After 48 h the mixture was removed from the paddle and spun for 30 minutes at 3500 
rpm and temperature set at 22 °C in order to remove any insoluble material. The 
density of the mixture was then increased up to 1.4 g/mL with addition of CsCl mixing 
for 30 minutes at 200 rpm with a magnetic stirrer. The density was checked weighing 
1ml of mixture and adjusted adding CsCl, to increase, or distilled water to decrease 
the density. 
  
Sample preparation for 1st centrifugation step 
The mixture was transferred into quick seal centrifuge tube using a syringe. Tubes 
were sealed using a soldering iron which was used to slightly melt the neck of the 
Table 2.6. Buffers needed for gut mucin preparation 
Figure 2.7. Porcine Small intestine used for mucin 
extraction.  
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plastic tubes. The neck of the tube was dabbed with vegetable oil and a metallic plug 
was put onto the neck of the tubes.  
By gently pressing the solder iron on the metallic plug the tube was sealed (Figure 
2.8). The samples were then spun at 50000 rpm, 10 °C for 62 h using a Beckman 
Coulter centrifuge (LE80 Ultracentrifuge, Beckman, Ireland) and with fixed angle 
rotor type 70Ti (Beckman, Ireland).   
The neck of the tubes was then cut with a scalpel and the mixture collected in 1ml 
aliquot. The density was recorded for each aliquot and 2µl were used for Alcian blue 
staining (for more details see 2.2.3). 
 Sample preparation for 2nd centrifugation step 
For the second centrifugation step was necessary to decrease the concentration of 
guanidine from 4 to 0.5M. For this reason, aliquot that gave a blue staining were 
mixed together and dialyzed using membrane (cut-off 10kDa) against rinsing buffer 
and 0.5 M guanidine (changed 3 times per day) for 2 days. The membrane was 
warmed to 60 °C and left to cool three times to avoid bacterial contamination. The 
density was changed to 1.4 g/mL using CsCl and then centrifuged as described in the 
Figure 2.8   Sealing of centrifuge tube. A soldering iron is pressed 
on a metallic plug to seal the tubes. 
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1st centrifugation. Following ultracentrifugation the fractions were subjected to 
density determination, Alcian blue staining and absorbance measurement at 260 and 
280 nm using a Nanodrop ND-1000 spectrophotometer (Labtech, UK) for DNA 
detection. Fractions that gave a blue staining and no absorbance at 260 and 280 nm 
were collected. Half of the volume was kept in fridge increasing GdnCl to 2 M and the 
other half was kept in liquid nitrogen until needed and dialysed for 24/48 h against 
dH20 before further studies. 
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2.8 Application of STD-NMR for ligand characterization 
One of the most powerful NMR technique, the STD NMR, was applied to understand 
whether there is any interaction between mucin and drug molecules. 
 
2.8.1 Nuclear magnetic resonance (NMR) 
Nuclear magnetic resonance spectroscopy (NMR) is a useful analytical chemistry 
technique used in quality and to characterise the chemical, physical and biological 
properties of the matter. In order to achieve the desired results several kind of NMR 
techniques are available such as one and two-dimensional, solid state NMR, 
relaxometry NMR (9) and Saturation-Transfer Difference NMR for the study of 
transient receptor-ligand interaction in solution (10) 
 
2.8.1.1  Theoretical background 
NMR can be described as a physical phenomenon that occurs when atomic nuclei 
aligned with an applied field and are induced to absorb energy and change their spin 
orientation with respect to the applied field. Whether the nuclei experience this 
phenomenon depends on their spin properties. Spin, like electrical change or mass, 
is a fundamental property of particles. It is also called intrinsic angular moment. The 
spin angular momentum (I) gives a magnetic moment on a nucleus and can be zero 
or comes in multiple of ½. Yet, it can be positive or negative (11). Only the molecules 
with non-zero spin are NMR active. In the absence of a magnetic field (B0) all spin 
states are degenerate as orientations of the spin are random and have equal energy. 
When a magnetic field is applied externally, their energies are affected and nuclei 
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align themselves either with or against the field of the external magnet (Figure 2.9) 
passing from the ground state to excited state.  
 
The difference between the ground state and excited state depends on the external 
magnetic field strength (ΔE). When the spin returns to its ground state level, the 
absorbed radiofrequency is emitted at the same frequency level. The emitted energy 
is directly proportional to the strength of the applied field.                 
[ = γBo2π  
Where B0 is the external magnetic field experienced and γ is the gyromagnetic ratio 
(the ratio between the nuclear magnetic moment and angular moment). 
 
The NMR spectrum is a plot of the intensity of NMR signals versus magnetic field 
(frequency). The spectrum of a molecule is diagnostic by its chemical shift. A chemical 
shift is defined as the difference in parts per million (ppm) between the resonance 
frequency of the observed proton and tetramethylsilane hydrogens (most common 
reference compound in NMR) which is set at δ zero ppm. 
Figure 2.9. A representations of nucleus orientation. In the absence of a magnetic field, 
these are randomly oriented but when a field is applied they line up parallel to the applied 
field, either spin aligned or spin opposed. 
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2.8.2 Saturation Transfer Difference -NMR 
The STD-NMR technique is one of the most powerful NMR techniques to detect and 
characterizer weak ligand binding (Kd ∼ mM–μM), between a large molecule 
(receptor >20 kDa) and a smaller molecule (ligand) (12) (13). It is an economical method 
as it does not require expensive isotope or radioisotope labelling. Moreover, for the 
experiment a very small concentration of receptor is required (nM-pM), although an 
excess of 20–1,000 times excess ligand is 
 necessary. 
 
The setup of experiment involves the recording of two NMR spectra. Firstly, a 
reference spectrum is registered under conditions of thermal equilibrium. In the 1D 
1H NMR the irradiation frequency is set at a value that is far from any ligand or protein 
signal (off resonance) with a signal intensity I0. In the second 1H NMR, the irradiation 
condition is chosen to specifically irradiate and saturate (with cascade of Gaussian-
shaped pulses) only protons of the protein (on resonance) (see Figure 2.10) giving a 
signal intensity Isat.  For example, it is possible to choose to irradiate the aliphatic 
region (from 0 to 1 ppm) or aromatic region (around 7ppm).  The irradiation is applied 
for a period of time called saturation time that can be varied in the range of seconds. 
The intermolecular transfer of magnetization from the receptor to the bound ligand 
is the base of the STD-NMR. If the ligand is close in space to the site of binding, the 
magnetization from the receptor protons will be transferred, via spin diffusion 
through inter-molecular nuclear Overhauser effect (NOEs), to the ligand protons. As 
a result of the binding, the signal intensity of the ligand will significant reduced. In 
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particular, only the chemical group involved into the transient interaction, receptor-
ligand, will reduce. By subtracting both experiment (on resonance and off resonance) 
a positive difference signals and the STD spectrum is obtained which allows the 
identification and characterization of the binding ligand. The intensity of the signal of 
the non-binding molecules for the two spectrum will be the same and in the 
difference spectrum no signal will appear. 
 
2.8.3 Material 
Tobramycin, mucin from porcine stomach, type III, Wilmad® NMR tube 5mm and 3.3 
mm were purchased from Sigma Aldrich (Gillingham, UK), OF-80-NS22 and 552-02 
were donated by Novartis (Basel, Switzerland), Salbutamol sulfate 99% was 
purchased from Alfa Aesar (Heysham,UK). Deuterium oxide was purchased from 
Figure 2.10 Schematic representation of STD-NMR. 1D 1H NMR radiofrequency does not affect 
the molecules signal. During the Second 1H NMR saturation is transferred from the receptor to 
the ligand with a reduction of the signal of the chemical group involved into the interaction. 
STD spectra is the difference between firs 1H NMR and second 1H NMR. 
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Cambridge Isotope Laboratories Inc (Massachusetts, USA), and Dimethyl sulfoxide-
d6 (99.5% D) was purchased from VWR (Leuven, Belgium), vivaspin 6 10 kDa 
purchased from Thermo Fisher Scientific (UK) and Amicon Ultra-0.5 Centrifugal Filter 
10kDa were purchased from Millipore (UK). 
 
2.8.4 Application of STD-NMR to Salbutamol and Tobramycin using fresh PLM and 
PGM 
Fresh mucus harvested from porcine lung and bronchi sections (see section 2.2.2) 
and PGM, were used for STD-NMR experiments to study its interaction with 
salbutamol and tobramycin. 
 
Sample preparation for STD-NMR 
The fresh porcine respiratory mucus was diluted 1 out 2 with D2O. The diluted fresh 
mucus was then mixed with 10mg/ml Tobramycin to have a final concentration of 
5mg/ml. In studies using PGM, tobramycin and salbutamol (stock solutions in D2O) 
were added to 1.5mg/ml PGM to have a final drug concentration of 5mg/ml. Samples 
were left on the roller for 4/6 h before analysis by STD-NMR. Experiments were 
performed at 310 K on a Bruker digital Avance 800 MHz spectrometer using Wilmad® 
NMR tube 5mm diameter. The on-resonance and off resonance frequency was set at 
-6 and 40 ppm respectively for both compounds performed with 16 scans and 2 sec 
saturation time.  
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2.8.5 Application of STD-NMR to OF-80-NS22 and 552-02 in PGM solution and PJM 
Considering the result obtained from the ultrafiltration assay, limitation of the 
technique and compound availability, two molecules were chosen (OF-80-NS22 and 
552-02) to carrier on STD-NMR experiments to study the interaction of these two 
compounds with PGM and PJM. 
 
Sample preparation for STD-NMR 
Before being used for STD-NMR experiment, 10 ml of purified PJM mucin were 
dialysed in dH2O for 48 h at room temperature. The water was changed every 2 h and 
the volume of the mucin was reduced to 200 µl by filtration using vivaspin tube 10kDa. 
PGM, PJM, PBS pH 6.8, OF-80-NS22 and 552-02 were made up using D2O and freeze-
dried three times to exchange H2O for D2O. The deuterated PBS pH 6.8 was then 
diluted in D2O and used to dissolve PGM, PJM and compounds. For OF-80-NS22 and 
552-02 was necessary to use 25% of dimethyl sulfoxide-d6 (DMSO-D6) to allow the 
compound to be dissolved at a concentration of 10mM. 
 
2.8.5.1 Elimination of glycerol contamination from mucin 
Ultrafiltration of mucin in vivaspin tubes resulted in significant mucin contamination 
with glycerol. This resulted in the appearance of large peaks on the 1H NMR spectrum. 
Amicon Ultra-0.5 Centrifugal Filters 10kDa were used to wash the mucin and try to 
eliminate the glycerol. Amicon tubes were left soaked in D2O overnight. The day after, 
100 µl of mucin were put into the Amicon tube and washed 10 times with 400 µl of 
warm D2O (40 °C) though centrifugation at 10000 rpm. The centrifuge was stopped 
before all sample was filtered to avoid membrane drying. At the last wash the mucin 
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solution was reduced at a volume of 50 µl and volume was reconstituted to 100 µl 
using D2O 
 
2.8.5.2 STD-NMR Analyses of OF-80-NS22 and 552-02 in PGM solution 
Mucin was reconstituted in PBS pH 6.8 at a concentration of 2 µM (using nominal Mw 
of 1MDa) and left to rock for 4h before being diluted as appropriate using the same 
buffer. The mucin and drug concentrations for the STD-NMR experiment were 600 
nM and 2 mM respectively in a total volume of 500 µl. STD NMR experiments were 
performed at 283K on a Bruker digital Avance 800 MHz spectrometer using Wilmad® 
NMR tube 5mm diameter. For selective protein saturation, a field strength of 115 Hz 
was employed. The on-resonance and off-resonance frequencies were set at -0.5 and 
40 ppm, respectively. STD NMR experiments were performed with 64/256 scans, 
depending on saturation time. 
   
2.8.5.3 Competition STD-NMR for the detection of high-affinity ligands 
The mixture (250µl) mucin-OF-80-NS22 and mucin-552-02 (600nM mucin and 2mM 
drug) were mixed and used for a competition assay. The instrument was set as 
described in 2.13.4       
 
2.8.5.4 Analyses of OF-80-NS22 and 552-02 in PJM solution 
Pure lyophilised PJM was reconstituted in PO4 pH 6.8 at a concentration of 2 µM and 
left to rock for 4h. For the STD-NMR experiment, mucin and drug concentrations were 
100 nM and 2.5 mM respectively (ratio 1:25000). The experiments were performed 
at 310K on Avance 800 MHz spectrometer in Wilmad® NMR tube 3.3 mm and a field 
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a field strength of 115 Hz (as rectangular pulse equivalence) with the total saturation 
time of 1 second and the on-resonance and off-resonance frequencies were set at -
0.5 and 40 ppm. Depending on saturation time experiments were performed with 
64/256 scans using WATERGATE for solvent suppression. Saturation curves of 552-02 
were obtained by applying different saturation time (from 0.1 sec to 6 sec) to the 
mixture ligand-purified mucin and calculating for each saturation time point 
the %STD and % of magnetization transfer using Origin Pro-B programme. 
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Chapter 3 : Identification and characterisation of mucus 
models for drug permeation studies 
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3.1 Introduction  
The conducting airways of the respiratory tract are lined by viscoelastic and adhesive 
mucus layer. Mucus viscoelastic properties are manly based on mucus glycoproteins 
monomers, called mucin, being crosslinked via disulphide bonds with other 
monomers (1) (2) which helps to protect the underlying epithelium from environmental 
fine particles (3) and pathogens (4) by physical trapping and allows removal by the 
mucociliary escalator mechanism. Although it serves to protect, the barrier effect of 
mucus to both small and large molecules has been claimed in the literature (5) (6) (7) (8). 
However, a satisfactory answer has yet to be found to understand how the mucin 
glycoprotein builds a dynamic structure capable to act as barrier for drug molecules.  
 
The interaction of deposited solutes with mucus essentially due to the viscous 
properties of mucus (9). As described by Lieleg and Ribbeck (10) particles moving 
through the mucus can interact strongly with mucus components and be trapped by 
two different mechanisms: size filtering and interaction filtering mechanism. In the 
size filtering the mucus mesh dimensions and the molecular size of the diffusive 
species have an effect on the mucus permeation.  Dawson, Wirtz (11) support the idea 
of size filtering showing a decrease of neutral particle (<200nm) mobility on CF 
sputum mucus with increasing particle size. The nature and extent of interaction 
between the diffusive species and the mucus network are also determined by the 
charge and/or specific chemical groups present. This so-called interaction filtering 
has also been shown to limit the diffusion of molecules through the mucus layer. 
Experiments conducted on cervicovaginal mucus have reported a lower mobility of 
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small and negatively charged (100nm) than larger and neutral particles (200-500nm) 
(12, 13).  
The interaction of small molecules to mucus layer has been demonstrate for several 
drugs such as aminoglycosides, (14) (15), salbutamol (16). Although there are various 
mucus models described in the literature (17), no standard protocols are available for 
mucus diffusion studies. Scientists have described the use of ex vivo (18), in vivo model 
(19) or in vitro system using mucus produced by specialized cells such as Calu-3 and 
Caco-2 (20). Other research groups have described the use of simple purified pig 
gastric mucin (21) to artificial formulated using PGM, 1,2-diacyl-palmitoyl-glycerol-3-
phosphocholine and BSA (22), native human or animal (e.g. pig) mucus (23) (24) or 
pathological mucus (25). 
 
The most ideal model is the crude human mucus but is difficult to access and 
biochemical properties (mucin, DNA, lipid composition) can vary between batches. 
Mucus from pig tissue is more freely available than that of human origin but inter-
batch variability can be a problem (26). Mucus-producing cells secrete only small 
amounts of mucus and, as result, mucus has often been substituted by a commercial 
porcine mucin (PGM) model. Pathologic mucus, such as from CF, presents a high 
viscosity and the physical-chemical properties can be significant different compared 
to natural human mucus.  The high viscosity in CF people is mainly due to an 
alternated electrochemical equilibrium on the epithelium because of chloride 
channel dysfunction. 
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The work described in this chapter aimed to identify and characterise a mucus model 
that can be used to study the small molecule binding characteristics of lung mucus. 
In particular, the studies considered a primary human bronchial epithelial cell model, 
ex vivo porcine mucus and a commercially available partially purified mucin model. A 
Franz cell diffusion apparatus was used to determine the permeability characteristics 
of a 3D mucin gel to a size range of hydrophilic dextran probes as well as two model 
small molecule probes, amiloride and benzamil. 
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3.2 Materials and Methods  
Materials 
NHBE cells, B-ALI TM growth medium, B-ALI TM differentiation medium and 
supplemented were bought from Lonza. AlexaFlour-633 labelled WGA, goat anti-
rabbit AlexaFluor 488 were purchased from Life Technologies (Paisley. UK), anti-
mucin 5AC purchased from Santa Cruz (Texas, USA from life technologies, Paisley, 
UK). Porcine gastric mucin (Type II) amiloride, benzamil, gentamicin solution, FL-Na 
and FITC-dextran probes were obtained from Sigma-Aldrich (Dorset, UK). Porcine 
lungs used were donated by H G Blake, Ltd. Bull Farm Abattoir (Norwich, UK). 
Antibiotic-antimycotic mixture (100x) was from Gibco (Carlsbad, California). 
 
Methods 
NHBE cell culture and mucin identification. 
NHBE cells were cultured at an air interface on 0.33 cm2 Transwell polyester cell 
culture supports according to Novartis methods (Chapter 2 section 2.1.1). Monolayer 
integrity was evaluated by transepithelial electrical resistance (TER) (Chapter 2 
section 2.1.5). Glycoprotein secretions from air interface cultures were identified 
using Alcian Blue (Chapter 2 section 2.2.3) and immunofluorescence staining with an 
anti-MUC5AC antibody and confocal microscopy (Chapter 2 section 2.1.6). The 
microscopic structure of isolated NHBE mucus was observed by using AFM (Chapter 
2 section 2.1.8). 
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Ex vivo system 
Fresh porcine lung tissue was used to extract fresh tracheobronchial mucus as 
described in Chapter 2 section 2.2. Mucin and DNA content was determined using 2-
CAN and DAPA respectively (Chapter 2 section 2.4). Solid dry percentage of mucus was 
determinate using the following equation; 
% dry=   	
 100% 
 (see Chapter 2 section 2.2.4). 
 
Permeation assay through PGM  
A horizontal Franz-cell system was used to monitor the transport of FL-Na and FITC-
dex probes (4, 10, 40, 70kDa), amiloride and benzamil (see Chapter 2 section 2.3.5). 
The apparent permeability coefficient (Papp) for each marker was calculated using the 
equation: 
                                                              
0
app
.
1
.P
CAdt
dQ
=    
The lag time was obtained from the x-axis intercept of extrapolated linear steady 
state portion of the cumulative transport curve.  
 
FITC-dex probe, amiloride and benzamils analyses 
A microplate reader Polar Star Optima (BMG LabTech) was used to quantify FL-Na 
FITC-dex in samples (Chapter 2 section 2.3.5.1) 
Franz cell basolateral samples were analysed for amiloride and benzamil content 
using a Perkin Elmer fluorescence HPLC system equipped with a Perkin Elmer LC 240 
fluorescence detector (UK) (Chapter 2.3.5.2).  
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3.3 Results 
3.3.1 Growth and differentiation of NHBE monolayers on Transwell culture inserts  
NHBE cells were cultured at air-interface on semi-permeable Transwell inserts for 20 
days in the presence or absence of 1 ng/ml IL-13 to simulate a mucus hypersecretive 
phenotype and goblet cell hyperplasia. The cells were grown under submerged 
culture until day 7 post-seeding. From day 3-7 the TER rose from 30±13 to 760±110 
Ω cm2. After 7 days post-seeding the apical medium was removed, leaving the cell at 
the ALI, and treatment of IL-13 was started (Figure 3.1). This treatment decreased the 
TER to 281±41 Ω cm2 for (+) IL-13 and 450±100 Ω cm2 for (-) IL-13 at day 3 post-ALI.  
 
For cells not treated (-) IL-13, TER started to increase again after few days (Figure 3.1) 
whereas for (+) IL-13 decreased and from day 12-20 post-seeding the TER plateaued 
was at 550±101 Ω cm2 for (-) IL-13 and 180±35 for (+) IL-13 treatment. This TER value 
for (+) IL-13 exceeds the minimum acceptable resistance for polarised monolayers in 
monolayer transport studies (i.e. >500 Ω cm2). From day 18 post seeding, (+) IL-13 
NHBE monolayer started to detach the membrane and TER dropped to an extent 
where transport studies are not recommended.  
Statistical significance was performed using one-way analysis of variance (ANOVA) at 
95% confidence limit. Comparing TER Ω cm2 of (+) IL13 with (-) IL13 after 12 days post-
seeding the p<0.0001 indicates a significant difference (Figure 3.1 indicated with 
asterisks *). 
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After 10 days from the post-seeding monolayers appeared thickened and textured. 
The presence of mucus was visibly noticeable on both IL-13 treated and untreated 
NHBE cells as a slimy and reflective liquid on the cell surface. Figures 3.2 A and 1B 
show two different (+) IL-13 inserts at day 17 of post-seeding, with each showing a 
different phenotype. The monolayer in Figure 3.2 A is relatively smooth and 
homogenous whereas the monolayer in Figure 3.2 B is heterogeneous with four 
domed regions that are capped by cells that are distinct in appearance to the rest of 
the monolayer. This heterogeneity of cellular phenotypic is consistent with 
monolayer differentiation and the cells highlighted in Figure 3.2 B may be goblet cells.  
These features were also displayed by NHBE cell (-) IL-13 (data not shown). 
 
   
Figure 3.1. Transepithelial resistance of NHBE cells. Graphical representation of TER during 
cells seeding day. ALI and IL-13 treatment started at day 7 post seeding. Data shown are mean 
± SD, n=6 for each group. Significance at p<0.0001 determined by paired t-test is denoted 
with asterisks (***) 
        ALI 
IL13 treatment  
Mucus 
production  
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At day 10 days post-seeding, the total volume of the viscous liquid covering the NHBE 
monolayers was approximately 30µl per insert (+/- IL-13) and was firmly attached to 
the monolayer. This is a positive indicator of mucus production. To allow mucus 
harvest without damage to the monolayer PBS (100 µl) was added into each insert. 
At the same day, the presence of mucin was demonstrated by Alcian blue (AB) 
staining of the apical washes of NHBE cells. A positive AB signal was seen for samples 
taken from NHBE (+) IL-13 and (-) IL-13 (Figure 3.3). The negative control (dH2O), as 
expected, did not stain blue. 
 
 
 
 
 
 
Figure 3.2 NHBE at day 3 of Air Lift (10x). (A) Morphology of NHBE cell (+IL13) on Transwell 
with 100% confluency without presents of goblet cells. (B) Shows the presence of four goblet 
cells (indicates with arrows) on the confluent monolayer. The apical surface of inserts was 
washed with warm PBS (37°) before imaging. 
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NHBE cells +/- IL-13 at day 15 post-seeding were fixed and stained using an anti-
MUC5AC antibody which recognises the predominant mucin secreted by NHBE cell. 
Unfortunately, some mucus was lost during the wash and fixation steps as evidenced 
by a slimy viscoelastic appearance of the PBS washes. In spite of this evident loss of 
mucus, MUC5AC staining (green) (Figure 3.4) demonstrated that a near continuous 
mucus layer had formed on NHBE IL-13 treated (Figure 3.4 A & B). Control NHBE 
monolayers (no IL-13 treatment) were damaged during washes and excluded from 
analyses.  
The Figure 3.4 A reveals that the intensity of MUC5A staining is heterogeneous with 
areas of high signal intensity (central regions) as well as lower density regions that 
show intricate crosslinked strands. A zoomed image of a low density region in Figure 
3.4 A is shown in Figure 3.4 B. At higher magnification it is possible to see feint 
staining of mucins branches in the areas in between bundles of mucin branches that 
stain strongly. Figure 3.4 C is a low magnification epifluorescent image that 
demonstrates the confluent NHBE monolayer using DAPI stain (blue) and the 
heterogeneous pattern of MUC5AC staining.   
 
Figure 3.3. Alcian Blue Staining of NHBE cell +/- IL13 mucus.  Alcian blue stained 
nitrocellulose membrane dried with NHBE cells mucus sample from two inserts treated (A) 
and not treated (B) with IL13 after 10 days post-seeding. As control (C) was used dH2O. 
 
   
A               B               C            
Control 
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Feint mucin fibres 
Bundles of 
mucin  
Feint mucin fibres 
Bundles of 
mucin  
Figure 3.4 Immunofluorescence images of (+) IL-13 NHBE cells (10X). (A) & (B) show 
extracellular mucus layer. (B) Represent a zoomed picture of mucus mesh of picture (A) showing 
bundles of mucin fibres (blue arrows) and the feint fibres (white narrows). (C) Low power image 
to demonstrate confluent monolayer. (C) Cell stained with anti-MUC5AC (green) and nuclei with 
DAPI (blue). 
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Confocal imaging of the NHBE (+) IL-13 showed an added layer of mucin complexity 
(Figure 3.5). The 3D confocal reconstruction of the MUC5AC layer (Figure 3.5 A) 
includes continuous areas with high density staining and other with lower density. 
Clearly evident are mucin strands that span the Z axis of the monolayer to form an 
intricate network of mucin fibres. A zoomed image (Figure 3.5 B) was taken and it 
shows clearly bundle formation and mucus branches. The red staining in Figure 3.5 
A&B results from wheat germ agglutinin (WGA) staining of sialic acid and N-
acetylglucosamine groups within the mucus layer. 
 
 
Figure 3.5. Confocal images from NHBE cell IL-13 treated. The heterogeneity of mucus is 
evident from the dense green regions (A) (B). (B) Represent a zoomed picture of mucus mesh 
of picture (A). WGA signal (red) evident in A and B. 
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Mucus harvested from (+) IL-13 NHBE cultures after 15 days post-seeding was 
concentrated by centrifugation and analysed by Atomic Force Microscopy. Figure 3.6 
A includes a short single strand of approximately 1 µm. Figure 3.6 B includes strands 
of similar diameter intertwined with areas of inter- or intra-strand cohesion. Indeed, 
Figure 3.6 C & D show a more complex "knotted” structure. In particularly, the sample 
in Figure 3.6 C starts as a single strand and this is followed by an entanglement with 
another mucin chain. The sample shown in Figure 3.6 D has high crosslink density 
along its entire length indicating a cluster of mucin monomers. 
 
  
Figure 3.6. AFM images of mucus harvested from NHBE cells 
The images show a single strand of mucin (A), a multi-strand (B). C&D show a more complex 
network among mucins. The bright puncta dispersed throughout the samples are dried salts 
which were not removed completely by washing before sample imaging. 
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3.3.2 Investigation of porcine lung tissue as a source of respiratory mucus  
Intact lung tissue and individual tracheas from freshly slaughtered pigs were obtained 
from a local abattoir and as an alternative source of respiratory mucins. The method 
of animal sacrifice results in the entry of blood into the respiratory tract and mucus 
harvest by simple scraping of the tissue failed to give mucus without significant blood 
contamination. Gentle washing of the tissue with sterile NaCl solution caused a 
significant loss of the luminal lung mucus and a reduction in mucus yield. When the 
lung tissue was gently rinsed with NaCl solution and maintained in an ex vivo culture 
condition at RT, 4 or 37 °C with or without antibiotic/antimycotic mixture there were 
differences in the amount of harvested mucus (Table 3.1). When tissue was dissected 
and incubated on the open bench and maintained at 37°C in the absence of 
antimicrobials (Table 3.1 N° condition 7) the tissue was odorous and showed signs of 
necrosis (discolouration and uneven texture) and infection (Figure 3.7).   
 
Figure 3.7. Tissue kept in aseptic (A) and non-aseptic (B) condition. 
(A) Tissue washed with 0.9% NaCl, treated with antibiotics and dissection obtained using 
sterilized instruments.  (B) Tissue not washed with 0.9% NaCl, without antibiotic treatment 
and dissection obtained without using sterilized instruments. 
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A small amount of mucus (~100 mg/lung) was obtained after incubating the samples 
at room temperature and 4°C with (Table 3.1 N° condition 1-4) no differences seen 
between tissues cultured in low or high concentrations of antimicrobial agents.  
The highest yield of mucus was harvested after keeping the tissue at 37°C for 24 hours 
(Table 3.1 N° condition 5-6). In this condition it was possible to harvest ~600 mg of 
mucus per lung.  
The different concentration of antibiotics did not change the amount of mucus 
harvested remaining at 600 mg/lung and no more mucus was obtained after scraping 
and incubating the tissue for a further 24 hours. Moreover, after 48 hours’ incubation 
in the presence of a high concentration of antimicrobials the tissue became odorous 
and the RPMI culture media was yellowish in colour indicating infection with no 
increment of mucus harvested (Table 3.1 N° condition 8).   
 
 
 
 
Table 3.1. Condition tested for respiratory porcine mucus production. Several condition 
were tested changing temperature, time of incubation, sterile condition and antibodies 
concentration. High and low antibodies concentration; penicillin (100 or 300 Units/ml), 
streptomycin (100 or 300 μg/ml), fungizone (25 or 75 μg/ml) and gentamicin (5 or 15 μg/ml).  
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3.3.2.1 Biochemical and physical analysis of porcine mucus  
As expected, all porcine mucus samples showed a positive AB staining reaction (Figure 
3.8).  
 
Samples (~200mg) from four independent mucus harvests after 24h incubation at 
37°C were weighed and freeze-dried until a constant weight was recorded. The 
mean % dry solids resulted was 12.4%±0.9 (Table 3.2).  
 
 
Figure 3.8. Alcian blue staining of mucus harvested from fresh porcine lung tissue. 
Tracheobronchial porcine mucus from tissue treated with: (A) low concentration antibiotics 
at 37°C for 24h, (B) low concentration antibiotics at room temperature for 24h, (C) low 
concentration antibiotics at4°C for 24h, (D) high concentration antibiotics at 37°C for 24 h, 
(E) Control (dH20). Samples were spotted in duplicate. 
 
Table 3.2 Determination of % dry solids for porcine lung mucus. Determination of the dry 
weight % of four mucin aliquots samples (A, B, C, D). 
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Determination of mucin and DNA concentration 
Quantitative biochemical assays were performed to determine the concentration of 
mucin and DNA in the porcine mucus samples. Table 3.3 shows the percentage of 
mucin and DNA corresponding to the eight lung mucus samples harvested. The mucin 
content varied some 4-fold between samples (0.5-2% w/v), whereas the DNA content 
was more consistent i.e. 0.32-0.63 %w/v. The mean DNA concentration 0.5±0.11% 
was higher than expected and likely indicates a contamination of the sample with 
shed epithelial cells. The amount of DNA in PGM gels was proportional to the mucin 
concentration increasing from 0.03 to 0.13% as the PGM% was increased from 1% to 
5%. 
 
The pH of the harvested mucus after 24h of incubation was measured as 6.8±0.11 
(n=8, mean ± SD). 
Table 3.3.  Determination of mucin and DNA %.  Determination of mucin and DNA % of eight 
mucus samples (A-H) from porcine respiratory mucus and PGM. Data shown are mean ± SD 
(n=3).  
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In summary, the yield of porcine lung mucus was low and contained a significant 
amount of contaminating DNA. For practical reasons it was decided to seek an 
alternative mucin model that was more abundant and less labour-intensive to 
harvest or manipulate in the laboratory.  
 
3.3.3 Application of Sigma PGM model to mucin permeability studies 
Initial studies were performed using a horizontal Franz-cell system to determine the 
permeability profile of PGM models to FL-Na and a size range of FITC-dex probes; the 
size range was 376 to 70000 Dalton (stokes diameter from 1 to 12 nm) (Table 3.4). 
This size range include the hydrodynamic radii of many biological molecules that are 
under investigation for pulmonary administration by Novartis and other major 
Pharma companies. These include scFv, Fab fragments and minibodies (27). 
 
 
 
3.3.3.1 Validation of fluorescence-based analytical methods  
Table 3.5 shows the calibration curve ranges, coefficient of determination, limit of 
detection and limit of quantification for each of the fluorescent probes used in the 
Table 3.4. Nominal molecular weight and Stokes diameter of all fluorescent probes applied 
to PGM gels. Values of Stokes diameter supplied from manufacturer (Sigma).  
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study. From Table 5, it can be seen that all calibration curves were linear (R2 > 0.999 
for all probes) and the LOQ was ~3 fold lower than the lowest calibration standard.   
 
3.3.3.2 Permeability of reconstituted PGM gels to a molecular weight range of 
fluorescent probes  
The transport of each fluorescent probe across PGM models (1,3 or 5% w/v in PBS pH 
6.8 at 37°C) was monitored over 120 min using a Franz cell (Figure 3.9). The 
cumulative mass transport profile displayed a biphasic trend for all probes studied. 
Specifically, the rate of transport across the gel was low from 0 – 30 min after which 
the rate increased 7-fold from 30 – 120 min for FL-Na and FD4 and ~3-fold for all 
other probes. The steady state flux of each probe was linear over the 2 hour 
timecourse of the experiment. The same biphasic profile was observed for 3 and 5% 
PGM (data not shown) although the rate of cumulative mass transported decreased 
with incremental increases in PGM concentration.  
Table 3.5. Linearity and sensitivity of the method.  
The table includes a summary of the calibration curve range, analytical method used, 
coefficient of determination (R2), limit of detection (LOD), limit of quantification (LOQ).  
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Table 3.6 includes the permeability profile of PGM and a control membrane alone 
(without PGM) to the molecular weight range of solutes. The Papp was calculated 
considering 30-120 min of transportation assay except for the control (mucin free) 
membranes which displayed steady state transport across the membrane from time 
=0 min. For blank membranes the rate of solute transport reduced after 
approximately 30 min consistent with the end of steady-state flux and approach to 
equilibrium. The application of PGM reduced the rate of solute transport into the 
receiver chamber as evidenced by an iterative reduction in Papp as probes increased 
in molecular size (Table 3.6).  
 
When the Papp of each gel was calculated for different probes, there was a clear 
reduction in the permeability as the % PGM increased. This indicates that the 
Figure 3.9. Cumulative transport of FL-Na and FITC-dextran probes across 1% PGM gels 
using Franz cell diffusion cells.  
Concentration added to donor chamber was 0.20 mg/ml for FL-Na and FD4 and 1 mg/ml for 
FD10, FD40 and FD70. Solid lines correspond to linear regression fits for 0-30 min, dashed 
lines are for 30-120 min. Data shown are mean ± SD, n=6 for each probe. 
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diffusion of each probe is incrementally restricted as the mucin concentration 
increases. The Papp values for all probes across 1% PGM was significantly lower 
(p<0.0001) than that of the bare membranes. The permeability to both FL-Na and 
FD4 decreased about 7 or 8 -fold when 1% PGM was added to the bare membrane. 
The permeability to FD4 decreased further by ~ 10 and 13-fold at a gel concentration 
of 3% and 5% respectively. Intriguingly, the relative fold-decreases in Papp to FL-Na 
and FD4 was similar (p>0.05) for all three concentrations of mucin used. For FD10, 
the Papp of 1% PGM was very low (0.30+±0.09 10-6 cm/s). Yet, the permeation of FD10 
through PGM decreased further (28 and ~83-fold from the 0% control) when the 
concentration of mucin was increased to 3 and 5% (Table 3.6). The relative decrease 
in the permeability was greater when comparing 1% and 3% PGM (p<0.01) than when 
comparing 3 to 5% (p<0.05) (Table 3.6 A). 
 
From Table 3.6 C, it is evident that the lag time calculated for penetration of the bare 
membrane increased steadily with incremental molecular weight. The lag times for 
FD 40 and FD70 were identical, indicating a restricted passage of FD70 across the 
membrane as described above. FL-NA and FD4 lag time is influenced by the addition 
of mucin gel onto the bare membrane. Specifically, it increased 26-fold (p<0.0001) 
for FL-Na and ~4-fold for FD4 (p<0.001), whereas no significant increment of lag time 
was noticed for FD10, 40 and 70 (p>0.05). Following the addition of PGM gel, the lag 
time was slightly increased to 22/23 min for FL-Na and, therefore, only marginally 
 influenced by the change of PGM. The increment of lag time for higher molecular 
weight probes (4-70kDa) was of about 10 min increasing from an average of 18 to 28 
min for both 3 and 5% PGM.  
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 An inverse relationship between the molecular weight and apparent permeability of 
each PGM solution was recorded (Figure 3.10). PGM displayed higher Papp values 
when probes with smaller molecular weight (FL-Na and FD4) are considered as they 
can easily diffuse through the microenvironment of the mucin mesh. For the probes 
with highest molecular weight, (such as FD40 and FD70) the total mass transported 
was very low compared to other probes showing a low Papp Figure 3.10). Moreover, 
PGM permeability to probes with a molecular weight of >10 kDa was much lower for 
all the different PGM concentrations tested (Figure 3.10).    
 
Table 3.6. Influence of PGM concentration on FL-Na and FITC probes diffusion 30-120 min. 
A Apparent permeability mean (*10-6 cm/s) and respective SD of FL-Na and FITC probes 
though 0, 1, 3, 5% PGM gel using Franz cell system (n=6). B Fold decreased of all probes 
used compared to 0% mucin gels. C Lag time in minute of FL-Na and FITC probes. Statistical 
analysis by one-way ANOVA and multiple comparison test.  
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From Figure 3.10 A, an exponential decrease in permeability is observed for the bare 
dialysis membrane (0% PGM). In the corresponding plot of Pap versus 

√  (Figure 
3.10 D) there is a linear relationship, supporting a free diffusion of through the bare 
membrane. Figure 3.10 B and E show the 1% PGM permeability profile. Figure 3.10 C 
appears similar profile to 0% PGM although there is a more restricted difference 
between 1% PGM permeability to FL-Na and FD4 in 0% PGM. In Figure 3.10 E, this is 
visible as a non-linearity that becomes more apparent in the permeability profiles of 
the 3% and 5% PGM samples (Figures 3.10 F). This indicates that the permeation of 
FD40 and FD70 is restricted by PGM and / or the membrane filter. In the case of FD10 
there is a clear restricted diffusion in 3% and 5% PGM and a subtle indication of 
restricted permeation in 1% PGM.  
  
 
C
h
a
p
te
r 3
 
1
4
2
 
  
A B C 
D E F 
Figure 3.10. Influence of the molecular weight of probes on the Papp. The Papp decreases with increase of the molecular size of FL-Na and 
FITC dex without (A & D) and with of mucin concentration at 1 (B &E), 3 and 5% (C & F). Data shown are mean SD n=6. 
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3.2.4 Transport of amiloride and benzamil across PGM gels  
Figure 3.11 shows the cumulative mass transport of amiloride/benzamil 1% PGM.  
The transport of amiloride across the PGM gel (Figure 3.11, red) was linear and rapid. 
Approximately 40% of the applied amiloride dose was transported to the receiver 
chamber by 120 min. The cumulative transport profile of benzamil was biphasic. The 
rate of transport was slower in the first 30 minutes, 8±2.91 and 2.6±0.42% of 200 
µg/ml dose donor, compared to a more rapid permeation from 30-120 mins, 36±8.6 
and 27.1±2.08 % for amiloride and benzamil respectively, indicating a delay before 
steady state transport through PGM.  
 
 
 
Figure 3.11. Example cumulative mass transport of amiloride and benzamil across 1% PGM. 
Drugs were applied to the Franz cell door chamber at a concentration of 0.20 mg/ml. The 
biphasic profile of benzamil is showed with solid lines correspond to linear regression fits for 
0-30 min, dashed lines for 30-120 min. Data shown are mean SD n=8. Experiments were also 
performed on 3% and 5% PGM for which Papp data are shown in table 3.7. 
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As shown in Table 3.7, the steady state permeability of the bare membrane 
decreased of about 6-fold following the addition of 1% PGM gels for FL-Na, amiloride 
and benzamil (p<0.0001). The PGM Papp to FL-Na and amiloride was very similar for 
al mucin gel used. In contrast, the PGM Papp to benzamil was lower than amiloride 
and FL-Na in each condition. The permeability to benzamil was 1.5-fold lower with 
0% PGM. Interestingly, the relative difference between Papp for benzamil and 
amiloride grew (p<0.05) with incremental increases in PGM concentration i.e. the Papp 
to amiloride was 1.5-fold, 3-fold and 4-fold greater than amiloride for 1%, 3% and 5% 
PGM, respectively. This differential transport of amiloride and benzamil is 
unexpected considering their similar molecular weight (229.6 and 319.8 Da 
respectively). 
From Table 3.7 C, the addition of 1% mucin gel onto the membrane significantly 
influenced the lag-time of the molecules (p<0.001), whereas no significant increment 
of lag time was noticed for increment of mucin to 3 and 5% (p>0.05). Amiloride 
showed a lower lag-time at 1%PGM of 8 minutes which increased to 16 and 20 
minutes with the increment of mucin to 3% and 5% respectively (p>0.05). Benzamil 
lag-time at 0%PGM was about ~10-fold higher that FL-Na and amiloride and not 
significant increment of lag time were noticed with increment of mucin concentration 
to 5% (p>0.05). 
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Table 3.7. Influence of mucin concentration on Amiloride and Benzamil compared with FL-
Na. A Apparent permeability mean (*10^-6 cm/s) and respective SD though 0, 1, 3, 5% PGM 
gel using Franz cell system (n=9). B Fold decreased of Amiloride, Benzamil and FL-Na 
compared to 0% mucin gels. C Lag time in minute of FL-Na amiloride and benzamil. Statistical 
analysis by one-way ANOVA and multiple comparison test. 
 
**** 
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3.4 Discussion 
Specialized epithelial cells called goblet cells and submucosal exocrine glands secrete, 
the mucus, which serves to protect the airway. Mucin, glycosylated protein, are the 
main non-water component of mucus and the main responsible for mucus 
viscoelasticity.  
Button, Cai (28) propose a gel-on-brush model stating that different mucins are 
differentially expressed in different locations in the ASL. The mucus layer over the 
PCL is formed by secreted mucin, mainly represented by MUC5AC and MUC5B for the 
airway, while PCL comprises membrane-associated mucins, MUC1 and MUC4, 
responsible of the strong interaction of the ASL with the epithelia (29). The complexity 
of the gel-on-brush model appears impossible to recreate without mucus-producing 
cell line or tissue sections.  In vitro cell culture models are very attractive and the 
NHBE cell cultures have made important contributions to the understanding of the 
pathogenesis in CF and COPD (30, 31) thanks to their ability to reproduce a similar in 
vivo epithelial mucin and mucus production phenotype, unlike transformed or 
malignant cell lines.  
 
In this study we investigated NHBE cells as a model of the bronchial epithelial source 
of mucus. To produce fully differentiated cell monolayers capable of mucus 
production cell monolayers must reach 100% confluency before starting the air lift 
procedure. Moreover, the use of cell culture models for drug transport studies 
requires the formation of tight polarized monolayers as an essential precondition. 
The transepithelial electrical resistance (TER) is widely used as a measure of the 
resistance presented by the paracellular pathway of a confluent monolayer.  The cells 
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formed tight junctions as evidenced by the measurement of TER ~ 800 Ω cm2. 
Treatment with IL-13 was associated with a decrease in TER and a change in the 
appearance of the cells with producing of a viscous liquid, the mucus.  
 
Low passage number NHBE cell model has a proven capacity for mucus production 
(30, 31) however, the yield of mucus is low as observed in the healthy lung. Normal 
NHBE cells mucus production may be increased by inflammatory stimulation. 
Malavia, Mih (32) showed that the treatment of NHBE cells with the pro-inflammatory 
cytokine IL-13, at a concentration of 1 up to 10 ng/ml induces increasing levels of 
MUC5AC demonstrated by immunofluorescence. IL-13 has also been shown to 
increase goblet cell density on NHBE cells by Alcian blue staining by directly 
interacting the airway epithelium and with involvement of ERK, p38 MAP kinase, and 
phosphatidylinositol 3-kinase pathways (33).  
 
To avoid phenotypic drift that is associated with serial passaging of primary cells, the 
NHBE monolayers described here were performed using NHBE cell on passage 1, 
which ensure mucociliary differentiation as described by others (30, 32). In particular, it 
has been shown that NHBE cilia-genesis decreases in P-3 and P-4 cell cultures as for 
the bioelectric properties characteristic of airway epithelium  (30). 
TER is a well-established method and  a widely accepted in vitro culture technique of 
monitoring TJ integrity (tight junction), differentiation and polarisation of monolayers 
(34). Unexpectedly, environmental contamination of the (+) IL-13 NHBE monolayers 
caused cells to detach from the membrane and TER dropped before they were ready 
for the permeation assay.  
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Mucus was strongly attached to the epithelium and for collection was necessary to 
solubilise it with apical washes of PBS washes at 37°C (35) (36). Considering the volume 
added and volume collected we may state that the total mucus yield was about 
30µl/well.  To the best of our knowledge, has not been reported the amount of mucus 
produced by NHBE. This yield of mucin is insufficient for the routine performance of 
mucin binding assays that required volumes in the millilitre range. However, up-
scaling of these cultures onto larger diameter inserts in greater numbers is an 
alternative, yet costly option. 
 
Different methods have been used to show mucin presence on NHBE cell surface such 
as AB stain in detection of sialylated or sulphated groups on mucin but non-mucin 
specific (Figure 3.3) (37) where  blue staining may indicate the presence of mucin 
fractions and DNA (38) without apparent differences between the mucus from NHBE 
+/- IL13 (Figure 3.3).  
Mucus secretion is supported also by immunochemistry using antibody against 
MUC5AC (Figure 3.4) and images taken with confocal microscope (Figure 3.5), which 
show a dense green area as a result of MUC5AC stain. In fact, the use of specific 
antibodies against the MUC5AC mucin is a useful method to study MUC5AC protein 
levels (39). AFM analysis of washed mucus revealed single strands and more complex 
mesh-like strands. A major challenge in AFM imaging is the differentiation between 
mucin and DNA which appears structurally similar on the AFM length scale. A 
quantitative DNA assay was not performed on the NHBE mucus however it is not 
expected to be significantly contaminated by DNA. As a source of DNA apopototic 
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and/or necrotic NHBE cells were washed from the surface throughout the culture 
process and before harvest. This increases the likelihood that AFM images represent 
mucin glycoproteins rather than DNA. 
 
The principle secreted lung mucin MUC5AC has been studied by AFM. Round et al 
Round, McMaster (40) investigated affinity purified MUC5AC from human ocular 
origin. They showed that the intramolecular conformational of the mucin complex 
was heterogeneous; from the display of a single molecules to a complex glycoprotein 
aggregation. In fact, mucins are macromolecule with a complex organization and 
different structures due to glycosylated regions and their tendency to form different 
multimers with different length. It is evident that the 3D structural complexity of 
mucin gels cannot be studied by AFM imaging. However, AFM offers opportunities to 
understand the single molecule associations that contribute to the complex 
viscoelastic behaviour of mucins and mucus. 
 
In contrast to the in vitro NHBE cell model, ex vivo porcine lung tissue represents an 
alternative source of larger amounts of intact lung mucus. In this study, freshly 
isolated porcine lungs were incubated in different condition to minimise microbial 
contamination and degradation while maximising mucus harvest. The optimal 
conditions involved incubation at 37°C and for 24h in the presence of antibiotics 
(penicillin, streptomycin, fungizone and gentamicin). These conditions produced 
~600 mg of mucus per lung. Biochemical analyses demonstrated that the % dry solid 
and the DNA content was supraphysiological for a healthy lung mucus. In spite of this 
the mucin concentration (1%) was typical for a healthy sputum (41). The high amount 
 Chapter 3 
150 
 
of cell that come off during the mucus harvesting may have contribute to the high 
solid dry %.  
 
This high solid dry % is in agreement with Martens, Inglis (42) studies on mucus isolated 
from ex vivo porcine bronchi, cystic fibrosis human, and non-cystic fibrosis human 
bronchi. In porcine and “normal” human mucus, the solid percentage was ~8% 
increasing up to 18 % for cystic fibrosis mucus. A high percentage was also showed 
by Larhed, Artursson (43) were the solid component of undiluted pig intestinal mucus 
resulted to be between 14-17% and comparable to the dry percentage obtained from 
the rat native intestine mucus (16.2%) (44).  
The large amount of other mucus components than mucin is also in agreement with 
previous studies and could represent the presence of lipids, proteins and salts.  
DNA concentration in the PLM was about 5 mg/ml (0.5% w/v), more similar to DNA 
concentration found in CF sputum (0.5 mg/ml up to 9 mg/ml) than DNA found in 
health people sputum which is ~3µg/ml (45). Probably, during mucus collection cells 
have been damaged releasing DNA which can interfere with our analyses. In fact, as 
showed by (46) drug molecules can bind to DNA and the interaction of drugs with 
nucleic acid is a significant feature in pharmacology. Is necessary to consider the 
mucus as a heterogeneous complex containing mucin, DNA, lipids, enzymes, 
antibodies, and as a result of cells damage all this substance will be released in the 
mucus layer with a consequent variation of mucus rheology and mucus-drug 
interaction. 
Larhed, Artursson (43) studying the influence of pig intestinal mucus components, 
demonstrated that mucin dry percentage was mucin only 5% (w/w %) compared to 
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lipids (37%) and protein (39%) and the remaining 19% comprising ~6% DNA and 13% 
inorganic salts and that all mucus component may reduce diffusion of drugs in native 
intestinal mucus.  
 
In summary, the ex vivo porcine lung mucus model was low yielding, work intensive 
and, more importantly, lacking in physiological similarity to in vivo healthy lung 
mucus.  
 
Transport assay using PGM  
Porcine gastric mucin (type III) from Sigma Aldrich is a cost-effective mucin model 
that has been used by many as a mucus model for the purposes of studying 
nanoparticle transport and the formation (22) or persistence of bacterial biofilms (47). 
It is known that this crudely purified mucus model does not retain its ability to form 
a complex 3D gel matrix. However, PGM has the advantages of abundant supply, low 
cost, ease of use by rehydration and overnight swelling and a ~10-fold lower 
concentration of contaminating DNA (compared to harvested PLM) and was used for 
further transportation experiments. 
PGM because of its denatured state does not form a reliable gel structures and is 
considered a poor gel model (48) but could be used to study binding interactions (49). 
 
The Franz diffusion cell system is a well-established and simple method for in vitro 
permeation studies. It is one of the most important methods for researching 
transdermal drug administration but has been also used for studying gel, mucus 
permeations and formulation release studies. For instance, the side-bi-side diffusion 
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chamber has been used by Bhat, Flanagan (51) to studying the diffusion of p-
aminosalicylic acid, isoniazid, and pyrazinamide with a range of molecular weight of 
123-430 Da, through PGM mucin gel (4% w/v). For each compound the permeability 
of aqueous solution compared to PGM solutions decreased of ~4 (isoniazid and p-
aminosalicylic acid) and 2-folds (pyrazinamide) indicating a significant reduction in 
permeation due to the mucus solutions and that indicate that absorption of nebulized 
drugs can be reduced by drug-mucin interactions.  
 
To understand the size-filtering effect, diffusion experiments were carried out using 
FL-Na (376 Da) and FITC-dex probes at different molecular weight (4-70kDa) through 
three mucin concentration (1, 3 and 5%). Buffer permeability studies (0% PGM) were 
performed to provide a baseline to compare with mucus solution permeability. The 
physiological thicknesses of mucus layer ranges from 1 µm  in the oral cavity  to 500 
µm in the gastrointestinal tract (52) (53) (54) but the mucus thickness used for our studies 
to produce an experimental mucus layer was around 3 mm to ensure consistent 
mucus barriers that could be easily and reproducibly pipetted to form a homogenous 
layer on the support membrane.  
 
A reduction in effective diffusion was observed with the increase of probes molecular 
weight (376-70 kDa) and increment of PGM concentration (1-3%). All probes showed 
a significantly increased permeation lag-time, associated with decreased steady-state 
solutes fluxes, when buffer solution was substituted by 1% PGM. Moreover, the 
retardation of solutes appeared greatly enhanced for molecules with a molecular 
weight >10 kDa.  
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The diffusion coefficients for each probes used was defined by the Stokes Einstein 
equation. Is it possible to calculate the diffusion coefficient from the Daynes and 
Barrier lag time relationship (eq. 3.1) (55) where “D” is the diffusion coefficient, “” 
the lag time and “h” is the barrier thickness but the difficulty to use this equation 
resulted from the complexly of the barrier used represented by two different 
materials; membrane support and mucin thickness.  
Eq. 3.1    = 

 
Desai, Mutlu (56) used a Perspex diffusion chamber to study the permeation through 
native porcine gastric mucus of 125I-labelled solute in a range of 148-200000 Da (Na+, 
lysozyme, rennet, bovine serum albumin and glucose oxidase). The passage through 
mucin gels appeared greatly restricted for solute at molecular weights >30 kDa 
Daltons (5-fold decrease) and solute flux decreased of ~30-fold when comparing 
Na125I (148 Da) and glucose oxidase (200 kDa).  The membrane, to support the mucus 
solution used by Desai and co-worker, had a pore size of ~100 nm, about 10 times 
larger of the largest molecules used, glucose oxidase (13 nm), leading them to 
suppose than mucus layer may have significantly affected the molecules diffusion. 
In the experiments we performed, the largest molecules used were 9, 12 nm (FD40 
and FD70), while the membrane used had pore size of ~15 nm, so the diffusion of 
larger solutes through 3D cylindrical pores of the membrane support may have been 
retarded by the closeness between molecular size and membrane pore cut-off. 
Most inhaled drug are small molecules used for the symptomatic relief of chronic 
diseases such as asthma. To date, there is very little published data that reports upon 
mucin binding of inhaled drug solutes (15, 57). With the closure of the Novartis R&D site 
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in Horsham UK the project shifted focus to the study of small molecule interactions 
with mucus. In this chapter amiloride and benzamil were used as examples of inhaled 
experimental therapeutics for investigation of their transport through PGM. 
 
Amiloride and benzamil have similar molecular weights (229.6 and 319.8 Da 
respectively) but surprising the percentage of mass transported though the 
experiment was lower for benzamil (~27%) than amiloride (37%) and the relative 
decrease in transport rate observed when increasing PGM concentration was ~2 to 3 
times higher for benzamil than amiloride and FL-NA. A structural comparison of the 
two solutes show that the introduction of a benzyl group onto the amiloride 
guanidine group leads to a significant retardation in the transport rate through PGM. 
The increased hydrophobicity of benzamil may have enhanced the interaction with 
the hydrophobic pocket of mucus glycoprotein. 
 
The mucus lining the upper respiratory tract may adversely affect the absorption and 
action of aerosolized drugs which may lead to a dramatically change of the drug’s 
efficiency in vivo. Therefore, the investigation of drug binding to mucus is extremely 
important to understand the importance of hindered diffusion of inhaled 
compounds.  
Diffusion of solutes through mucin is an important factor in the design of drugs which 
have to diffuse through the mucus layer and the identification of parameters involved 
into the drug-mucin interaction will help the design of new drug molecules. 
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Conclusion 
In this chapter we have investigated different mucus models to be used for diffusion 
studies of solutes in a molecular range of 376-70000 Da. Following the low mucus 
production of mucus-producing cells and high DNA contamination of the ex vivo 
porcine mucus, diffusion experiments have been performed using a commercial 
mucin PGM which showed low contain of genetic material. 
In transport assay, the substitution of buffer solution with 1%PGM significantly 
affected the diffusion of all probes although, from this study, is not clear the 
relationship between solutes >10 kDa molecular weight and mucus “size-filtering” 
due to the closeness of the size of two probes used (FD40 and FD70) to the membrane 
cut-off. Although the “size-filtering” appears to not significantly affect the diffusion 
of macromolecule 376- 4000 Da, surprising the mucin gel permeation of two small 
molecules <500 Da, amiloride and benzamil, appears different with benzamil showing 
a retarded diffusion. 
The results of these studies indicate that the “interaction-filtering” may reduce 
permeation rates across mucus layers also of same size molecules and could play an 
important role in reduced inhaled drug disposition. Therefore, further studies are 
needed to investigate mucin-amiloride analogues interaction. 
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Chapter 4 : Understanding of physical-chemical relationship 
between mucin-ENaC blockers interactions 
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4.1 Introduction 
The epithelium of the respiratory tract plays a major role in in maintaining the conduit 
for air to and from the alveoli (1) and thanks to the combined function of mucus secretion 
and ciliated cells the airway epithelium has a critical role in the defenses of the lung 
against particulates and pathogens inhaled from the environment (2, 3).  The beating cilia 
of the epithelium are separated from the mucus layer by the presence of a periciliary 
liquid layer (PCL) (~7µm) and together, these two airway surface liquid components 
make up the airway surface liquid (ASL) (4). The efficiency of mucus clearance depends in 
large part on the volume and hydration state of both layers (5) which depends by the 
active action of ion transport processes involving the epithelial sodium channel of the 
glands and superficial epithelium (4, 6, 7). 
ENaC is a key element for the maintenance of sodium balance in a number of epithelial 
tissues, is thought to play a significant role in influencing mucus hydration levels (8) and 
it is a target for several diseases characterized by aberrant epithelial Na+ transport such 
as in CF patients. In people with CF, ENaC is abnormally hyperactive with increment of 
Na+ and H2O absorption, attributable to the impaired function of CFTR (9) resulting in a 
reduced Cl-/HCO3- and H2O secretion. These effects lead to mucus dehydration and 
failure of MC. 
 
A ENaC blocker would be predicted to improve hydration and MC reducing the rate of 
sodium and water absorption from the luminal aspect (10). This hypothesis is supported 
by in vitro data showing the amiloride (an epithelium sodium channel blocker) effect on 
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ASL height using confocal scanning microscopy, and variation of ASL volume measuring 
changes in concentration of blue dextran dye on primary cultures (11). However, in vivo 
clinical studies failed to demonstrate a significant improvement of MC after amiloride 
treatment (10, 12).  The failure of amiloride reflected both its low potency (IC50 0.34 µM) 
for ENaC blockade and short duration of action on airway surfaces (13) (14). 
To achieve a more favorable pharmacological potency, the amiloride drug structure has 
been modified for the development of more potent, long-acting analogues for CF 
pharmacotherapy (14). Benzamil and phenamil, two second generation amiloride analogs 
have been considered as ENaC blocker alternatives to amiloride. Both these ENaC 
blocker are significantly more potent than amiloride i.e. the ENaC IC50 values for 
phenamil and benzamil are 17- and 9-fold lower than amiloride (15) but their lipophilic 
character is associated with rapid absorption across both human and ovine bronchial 
epithelia (16). This predicts increased absorption into the systemic circulation and 
resultant hyperkalemia.  
 
Compound 552-02 and GS9411 (undisclosed structure) have been designed for inhaled 
dosing and appeared more potent than amiloride (17) and considered a lead for CF 
treatment. After that GS9411 was reported to induce hyperkalemia (18) the development 
of these compounds was halted.   
NVP-QBE170 in vitro assay in NHBE showed a longer duration of action compared to 
amiloride and 552-02 and in vivo assay in guinea pig airways, showed an enhancement 
of potency and duration of action and no hyperkaliemia problems but the clinical 
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development have been halted due to the irritancy response in the airways after 28-day 
inhalation. 
 
Defective function and expression of CFTR in CF are associated with mucus 
hypersecretion and dehydration which allow bacteria to grow leading to infection and 
inflammation. CF mucus is characterized by an increased carbohydrate content in the 
mucin, because of this, it has a highly branched oligosaccharide structure with higher 
tendency to interact and form gel which may lead to an obstruction of drug transport in 
vivo (19). This may be made worse by the presence of DNA, mostly coming from host cells  
or released from bacteria after antibody response (20), and from  alginate, a bacterial 
polysaccharides that may contribute to increase mucus viscoelastic properties (21) and 
diffusion rate of drug molecules and their efficiency of inhalation may dramatically 
decrease.  
 
The literature reports the interaction of several drug molecules to mucus. 
Aminoglycosides activity, class of drug used to treat pseudomonal infection in CF, have 
been shown to be limited by mucin (22); tobramycin was shown to interact to sputum (23) 
and porcine mucin (24), colistin or polymyxin E, polymyxin B shown interaction to porcine 
mucin (24). Braybrooks, Barry (25) reported that tetracyclines intestinal absorption was 
reduced by mucin and Bhat, Flanagan (26) showed the interaction of albuterol to porcine 
gastric mucin. 
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The mechanism of interaction between mucus and inhaled drug molecules is rarely 
studied and poorly understood. Better understanding of the physico-chemical properties 
that dictate mucin-drug interactions may lead to the development of more efficacious 
therapies that are not bound by mucus.  
 
For the determination of plasma protein binding most protocols describe the use of  
ultracentrifugation (27, 28) although improved throughput have been reported with the 
use of a 96-well equilibrium dialysis methodologies (29). These methods have also been 
applied for the studying of mucus-drug interaction (23, 26) but to investigate the 
mechanism of mucin-drug interaction is necessary to develop and introduce simple 
methods which may be used for quick screening a range of drug candidates in vitro. 
 
The aim of this chapter was to tested the hypothesis that inhaled amiloride analogues 
are bound by mucin and that the extent of binding can be correlated with standard 
physicochemical drug properties. To do so, our studies were motivated by the need to 
develop an easy method for the screening of a range of ENaC blocker designed by 
Novartis.  
Initial studies used fluorescence and ultraviolet spectroscopy explored to study the 
mucin interactions of two prototype ENaC blockers, amiloride and benzamil. The need 
for a more sensitive and higher throughput system led us to develop a 96-well 
ultrafiltration assay. This method afforded the screening of a panel of 12 amiloride 
analogues with a range of physicochemical properties against three distinct CF sputum 
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components i.e. mucin, DNA and alginate. Finally, we used restrictive Calu-3 monolayers 
to determine the effect of mucin on the rate of transepithelial transport of select 
amiloride analogues. 
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4.2 Material and methods 
Materials 
Amiloride, benzamil, rhodamine B, alginic acid sodium salt (sodium alginate, from brown 
algae), DNA from fish sperm, Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) 0.5 M 
solution, FL-Na and FD4 and PGM (type III) containing ~0.5-1.5% of bound sialic acid were 
purchased from Sigma, Aldrich. Amiloride analogues were donated from Novartis (Basel, 
CH). MultiScreen Ultracel-10 Filter Plate 10 kDa (Product # MAUF01010) were purchased 
from Millipore (UK).  
 
Methods 
Fluorescence spectroscopy  
Fluorescence spectra were recorded after mixing PGM solution (1 µM) titrated with 
amiloride or benzamil at different concentration (0.4, - 15.2 µM) (Chapter 2 section 
2.4.10). Effect of solvent polarity on the fluorescence emission 100 mM of amiloride or 
benzamil was tested as described in Chapter 2 section 2.4.11. Fluorescence spectra were 
recorded on Hitachi Fluorescence FL-4500 in 1cm Quartz cells (Chapter 2 section 2.4.10). 
 
UV-Visible spectrophotometry 
Mucin solution, 0.5 µM, was mixed with amiloride or benzamil at different concentration 
(0.0-130 µM). The absorption spectra were obtained from an Agilent technologies Cary 
60 spectrophotometer in a range of 200-450 nm using a Quartz cuvette with 1 cm path 
length (Chapter 2 section 2.4.11).     
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Ultrafiltration binding assay 
ENaC blockers were mixed with either PGM mucin solution (ratio from 1:1 to 200:1), 
alginate (ratio 20:1) or DNA (ratio 20:1) and experiments performed as described in 
Chapter 2 section 2.5.4 and 2.5.12. 
Some experiments included TCEP-treatment of mucin to study the binding of benzamil 
and 552-02 (drug: mucin molar ratio 20:1) (see Chapter 2 section section 2.5.5) 
Mass balance was determined as described in Chapter 2 section 2.5.8 and the extent of 
specific and non-specific binding was calculated as following; 
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  
 
 
Calu-3 cells culture 
Calu-3 cell culture reagents and media preparation are described in Chapter 2 section 
2.6.1. Cells were seeded onto polyester Transwell supports using a liquid covered culture 
as described in Chapter 2 section 2.6.2 and Monolayer integrity was evaluated by 
transepithelial electrical resistance (TER) (Chapter 2 section 2.1.5). 
 
Permeation assay 
Transport studies were performed as described in Chapter 2 section 2.6.4. 
Transportation studies were also performed using a mixture of purified porcine jejunal 
mucin (0.5 µM) and 552-02 (20 µM) (Chapter 2 section section 2.6.5). 
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Compound analyses by High-Performance Liquid Chromatography (HPLC) 
Amiloride and analogues were analyzed onto a Phenomenex Luna C18 column (250x 4.6 
mm 5µm) attached to a Perkin Elmer HPLC system equipped with a Perkinelmer LC 240 
fluorescence detector (UK). Analytes were resolved using an isocratic method for the 
binding assay (Chapter 2 section 2.3.5.2) and using a linear gradient for analyzing 
samples from permeation assay (Chapter 2 section 2.6.6). 
 
Compound analysis microplate fluorescence spectroscopy 
A microplate reader Polarstar Optima (BMG LabTech) a was used for FL-NA, FD4 and 
rhodamine B analysis as described in section Chapter 2 section 2.5.7. 
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4.3 Results 
4.3.1 Identification of amiloride and benzamil binding to PGM study by florescence 
and UV-Visible spectrophotometry 
Amiloride and benzamil are both strongly fluorescent molecules showing and excitation 
and emission in aqueous solution of 362 and 417 nm and 366 and 412 nm, respectively. 
Mucin is a glycoprotein which has a weak intrinsic fluorescence due to a low abundance 
of aromatic amino acids with excitation and emission maxima of 290 nm and 350 nm 
respectively. 
The interaction of mucin with amiloride and benzamil was evaluated firstly by exploring 
the fluorescence signal of the drug after titration into PGM solution (1 µM). The 
fluorescence spectra of the mixtures at different concentration are shown in Figure 4.1 
A and B. An incremental and proportional increase in fluorescence intensity was 
observed upon titration of both amiloride and benzamil. The two compounds in PBS pH 
6.8) and in absence of mucin have a strong fluorescence emission at 417 for amiloride 
and 415 nm for benzamil (data not shown) but when the mixture mucin-drug was 
considered the emission peak of amiloride did not shift significantly staying stable at 419 
nm for each concentration of drug used (Figure 4.1 Aa). In contrast, in the mixture mucin-
drug, benzamil at the lower concentration, 0.8µM, showed a maximum emission 
wavelength of 422 nm but following the addition of more benzamil there is a blue shift 
of the fluorescence emission peaks to 417 nm (Figure 4.1 Bb) which may indicate that 
benzamil is placed in a less polar environment and less exposed to the solvent (30, 31). 
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Figure 4.2 shows a linear relationship between drugs concentration and fluorescence   
intensity in a concentration range of 0-15.2 µM for both amiloride and benzamil. 
  
Figure 4.1. Fluorescent emission of amiloride and benzamil upon titration into mucin. 
Amiloride (A) and benzamil (B) was titrated with PGM (1 µM) and emission spectra recorded 
after excitation at 362 nm (amiloride) or 366 nm (benzamil). Amiloride lambda max was stable 
(Aa) whereas benzamil lambda blue shifted (Bb)as drug concentration increased. 
 
 
 
A 
B 
Aa 
Bb 
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The fluorescence of 100 nM of amiloride and benzamil were than analyzed using 
different proportions of EtOH (from 0 to 100%). As shown in Figure 4.3 the fluorescence 
intensity increases as the proportion of the less polar solvent increases from 0 to 100%.  
 
 
 
 
 
 
 
 
Another simple and applicable method to investigate the formation of a complex is UV-
Vis absorption measurement (32). The absorption spectra of mucin in absence and 
Figure 4.3. Fluorescence intensity of amiloride and benzamil in different proportions of EtOH. 
Fluorescent intensity of amiloride (red) and benzamil (blue) increase as EtOH % proportion 
increases. Data corrected for drug fluorescence at 0% EtOH.  
Figure 4.2. The linear relationship between Δ ﬂuorescence intensity and drugs concentration. Δ 
ﬂuorescence intensity increase proportionally to drug concentration (0.4-11.2 µM) during mucin 
titration (1µM). Benzamil blue circle, amiloride red circle. 
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presence of amiloride or benzamil at different concentration are shown in Figure 4.4. 
The UV-vis spectra of mucin (0.5 µM) shows a strong peak at 260 nm while amiloride 
(Figure 4.4 A m) and benzamil (Figure 4.4 B n) both display strong absorbance bands at 
290 and 366 nm which proportionally increases as the concentration of drug added is 
increases from 0.5 to 130 µM (Figure 4.4 a-l). Yet, mucin and drug compounds show a 
peak at 210 nm which increasing drug concentration appear to red-shift and the same 
was noticed increasing drug concentration in phosphate buffer solution (100mM 
NaH2PO4 50mM NaCl pH6.8) in absence of mucin (data not shown). 
 
Figure 4.5 shows an extract of the UV absorbance data for amiloride and benzamil-mucin 
mixtures at three concentrations – 10 µM, (Figure 4.4 A, C), 70 µM, (Figure 4.4 B, D) and 
130 µM, (Figure 4.4 C, F). For both drugs no peak shift of absorbance was noticed but 
comparing the spectrum of the mixture (mucin-drug) and the spectrum of a summed 
absorbance of mucin and drug alone is possible to notice differences between amiloride 
and benzamil (Figure 4.5).  
In particular, during the titration of amiloride or benzamil into 0.5 µM mucin the mixture 
spectrum (Figure 4.5 dotted line) with amiloride at 10 µM (Figure 4.5 A) is similar to the 
control spectrum (Figure 4.5 A red solid line) but with increasing of drug concentration 
to 70 µM (Figure 4.5 B) and 130 µM (Figure 4.5 C) the peak at 260 and 290 nm decreased 
in the mixture spectrum. 
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Figure 4.4. UV-Vis absorption spectra of the mixture mucin-drug in the presence of 
different concentration (a-l) of amiloride (A) or benzamil (B). The inserts in A and B are the 
spectrum of 90 µM amiloride and benzamil respectively. All spectra are buffer background 
corrected for PBS pH6.8.  
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Titration of benzamil into mucin (Figure 4.5 D, E and F) effected a larger change in 
absorbance, which is especially visible at the mucin 260 nm band and the 290 and 366 
nm bands after titration with 70 (Figure 4.5 E) and 130 µM benzamil (Figure 4.5 F). In 
fact, the absorption of the mixture appears lower compared with the summed 
absorbance of a pure benzamil and pure mucin solution (Figure 4.5 E and F, mixture solid 
blue line, control dotted line). The peak at 210 nm was noticed in the two drugs and 
mucin alone and for both amiloride and benzamil red-shift as drug concentration 
increases but not increment of absorbance was noticed. In fact, same shifting was 
noticed when increasing drug concentration in buffer solution without mucin (data not 
shown).  
 
Although UV-Vis spectroscopy is a convenient method for studying small numbers of 
compounds in a detailed manner an alternative experimental method was required for 
screening larger numbers of compounds. Towards this end a 96-well ultrafiltration 
binding assay was explored as a method to screen a panel of amiloride analogues for 
mucin binding.  
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Figure 4.5. UV-Vis absorption UV-vis spectra of the mixture mucin-drug mixture (solid line) and summed absorbance of mucin and 
drug alone (control dotted line). A-F mixture and control spectrum of three representative concentrations (10,70,130 µM) used for 
mucin titration (0.5µM) with amiloride (A-C) and benzamil (E-F). Data corrected for PO4 buffer Abs 
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4.3.2 Development of fluorescence-based analytical methods for amiloride and 
analogues using PGM 
Calibration curve ranges are shown in Table 2.3 in Chapter 2 which also includes 
coefficient of determination, excitation/emission wavelength, limit of detection, limit of 
quantification and internal standard used for each amiloride analogues for the 
ultrafiltration binding assay. From Table 2.3, it can be seen that all calibration curves 
were linear (R2 ≥ 0.998 for all compounds) and the LOQ was ~10 fold lower than the 
lowest calibration standard.   
 
4.3.2.1 Validation of ultrafiltration binding assay using a multiscreen 96-wells plate 
Ultrafiltration binding assays are widely used in pharmaceutical industry to screen 
candidate compounds for plasma protein binding (33, 34). Cognizant of the non-uniformity 
of ultrafiltration across the MultiScreen plate experiments were performed to validate 
the method. These included the determination of mass balance for each well on the plate 
and the extent of non-specific binding to the plate. 
 
The mass balance (recovery) was determined for each compound after ultrafiltration of 
the drug-mucin mixture in the ratio 1:1 to 200:1 and a mucin-free drug solution. For NVP-
QE170 the highest ratio used was 20:1 (20 µM :1 µM) due to the solubility limit (100µM). 
The method developed involved the inclusion of a known mass of internal standard in 
the receiver chamber of the plate that was chromatographically resolvable from the 
analyte under investigation. HPLC analysis of the ultrafiltrate revealed both the analyte 
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and internal control concentration. The latter was used to determine the dilution factor 
and hence filtrate volume.  The mass balance was determined for all drug-mucin ratio 
and resulted lower at the lower drug concentrations for all other compounds, due to 
NSB, but appeared to be very similar for each concentration of amiloride tested (data 
not shown). 
 
Screening of 12 amiloride-based compounds for mucin binding at 20 µM revealed a wide 
range of binding variability (Table 4.1). A concentration of 20 µM was chosen as it lies in 
the concentration range expected in lung lining fluid following inhalation delivery of 
typical low molecular weight solute. This concentration was also easily detectable by 
HPLC and was far from the expected solubility limits of each drug tested.  
Table 4.1 shows that all compounds have a recovery of over 95% with and without mucin. 
The only compound showing a low mass balance was GF-40-QQ33 which displayed a 
recovery of 66 and 72 % with and without mucin respectively and displayed also a high 
NSB (15%), possibly due to their highly lipophilic nature and low aqueous solubility. The 
NSB for all other compounds was not higher than 4.5%.   
 
GF-40-QQ33, Benzamil and OC-73-KH00 displayed a high specific mucin interaction with 
38> 33>21% respectively, followed by 552-02, JE-12-FK73 and UB-15-NR66 with 20> 18> 
15%. Amiloride appears to be the compound with lowest percentage of mucin binding 
(0.7%) similar to FL-Na used as probe control. Other molecules that displayed a relatively 
low mucin interaction (lower than 15%) were MC-12-DR04, CA-91-YE87, KF-08-NW22, 
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OF-80-NSS22, and the dimer NVP-QBE170 with 7-12%. FD4 (MW 4 kDa) displayed a low 
mucin interaction (3%) but a very high NSB (~75%) probably due to the closeness to the 
membrane molecular weight which was 10kDa.  
 
 
4.3.3 Isotherm binding and physical-chemical correlation between mucin (PGM) and 
amiloride analogues. 
Based on the variability in the extent of mucin binding for ENaC blockers at 20 µM, 
binding isotherms were constructed for each compound by plotting the free versus 
bound drug concentration across a range of drug: mucin ratios. The binding isotherms 
for 12 ENaC blockers plus two probes FL-Na and FD4 are shown in Figure 4.6 and 4.7. 
Table 4.1. Validation of ultrafiltration binding assay using PGM as mucin model. Compounds, FL-
Na and FD4 mass balance in solution +/- mucin determinate by the use of internal standard, % NSB 
and % mucin binding determined after ultrafiltration assay. Data shown are mean ± SD (n=3). 
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For all eight compounds shown is Figure 4.6 the isotherm shows that the molar ratio of 
bound drug : mucin increases sharply, reaching a maximum with increasing free 
concentration of drug. Non-linear regression analysis demonstrated that the data were 
well described by the Langmuir monolayer absorption model (Eq. 4.1) were Bmax is the  
maximal extend of binding Kd is concentration of ligand necessary for half occupancy of 
the binding sites, X is the concentration of the ligand and Y is the specific binding. 
 
Amiloride displayed the lowest molar ratio of bound drug to mucin (Bmax 1.4 mol/mol) 
very similar to the control probe, FL-Na (Figure 4.7 E). For NVP-QBE170 at the highest 
ratio used (20:1) the bound drug is 1.2 mol/mol and for all other compounds in Figure 
4.6 the bound drug was between 6 and 30 mol/mol. Langmuir monolayer absorption 
model was also followed by FL-Na and FD4 in Figure 4.7 (E-F) used as control. 
For compounds shown in Figure 4.7 (A-C) the binding isotherm displayed a distinct trend 
to other compounds. At low concentrations the binding approached a pseudo-plateau 
around 100 µM before increasing sharply at the highest tested concentration. This 
binding isotherm was not consistent with monolayer binding models such as the 
Langmuir isotherm. However, the isotherms were well described by the Guggenheim-
Anderson-deBer (GAB) isotherm model (Eq. 4.2) where y is the amount of ligand bound 
per protein (mol/mol), qm the amount of monolayer binding of ligand per protein 
(mol/mol), Ceq the free ligand concentration, and Ks and KL are the monolayer and 
multilayer binding constant.  
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This model represents a multilayer liquid phase adsorption to mucin as described 
previously (35). The non-linear regression model fit parameters for QQA using Langmuir 
isotherms gave a R2 <0.250 (data not shown). It is apparent from the model fit that the 
Langmuir model is inappropriate for application to these data.  
 
(Eq. 4.1)    $ = % .

('())
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During our studies the Millipore MultiScreen plates were discontinued and only 4 
different concentrations were used for the binding isotherm for CA-91-YE87 (Figure 4.7 
D) and parameters did not converge with any equation although appears to follow the 
trend of its stereoisomer KF-80-NS22 (for structure see Chapter 2 section 2.6). Like for 
compound in Figure 4.6 also analogues in Figure 4.7 (A-D) displayed a large difference in 
the mucin binding with compounds KF-80-NS22 and CA-91-YE87 displaying the lowest 
molar ratio of bound drug to mucin of ~12 mol/mol at a ratio of 1: 200 (mucin : drug). 
OC-73-QQ33 (Figure 4.7 C) displayed the highest interaction to mucin with 42 mol/mol 
followed by JE-12-FK73 with molar ratio of bound drug to mucin of ~22 mol/mol. 
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Figure 4.6. Drug-mucin binding isotherm(1). Data for each compound from the ultrafiltration binding assays were fitted by a langmuir model: 
y=Bmax . x/(Kd+x) using GraphPad Prism v5. Data shown are mean ±SD, (n=3)  
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Figure 4.7. Drug-mucin binding isotherm (2). Data for compound A-D from the ultrafiltration binding assays were fitted by a GAB isotherm 
model: y= qm . KsCeq/(1-KLCeq)(1-KLCeq+KsCeq) 
Data for compound E and F  were fitted bya  languir model: y=Bmax . x/(Kd+x) using GraphPad Prism v5. Data shown are mean ±SD, (n=3)  
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Seeking to correlate the extent of mucin binding with standard physicochemical 
properties we examined Log P octanol/water, molecular weight, polar surface area (PSA), van 
der Waals Volume, polarizability, H-donor, H-acceptor, and rotatable bonds as 
determinant of binding (Table 4.2).  
Taking together the 12 amiloride-based compounds there was a weak correlation 
between the extent of mucin binding and compounds physical properties. Figure 4.8 
shows two examples of poor correlates of binding:  Log P o/w (R2= 0.421) and rotatable 
bonds (R2=0.360) (Figure 4.8 A and B respectively). For the other physical-chemical 
properties the correlation was weaker, displaying a R2 < 0.200 (data not shown).  
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Table 4.2. Physical properties of amiloride and analogues; Log Po/w, PSA, MW, Van der Walls Volume, polarizability, H donor, H acceptor 
and rotatable bonds were calculated using Marvin Sketch 6.2 (Chemaxon) 
 
 
** Log P obtained from literature  
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In particular, mucin binding versus Log Po/w displayed clearly two trends. The percentage 
of mucin binding increases for compounds with a Log P o/w between -3.72 to 0 and the 
same trend can be notice considering compounds with Log P o/w in the range of ~-1 to 
2.70, which is consistent with the polarity of the two groups, quaternary amine (QQA) 
and non-quaternary amine (NQQA) analogues (Table 4.2). Considering all physical 
properties shown in Table 4.2, a strong positive correlation was observed between mucin 
binding and Log Po/w for both NQQA (R2 =0.952) (Figure 4.9 A) and QQA (R2 =0.899) 
(Figure 4.9 B). For NQQA other parameters were poor binding predictor (R2 <0. 400). 
Opposite to this, for QQA a weaker but positive correlation with almost all physical 
properties was observed; van der Waals Volume (R2 =0.770), rotatable bonds (R2 =0.838), 
PSA (R2 =0.613) (Figure 4.9 D, F, & H), polarizability (R2 =0.767), molecular weight (R2 
=0.758), H acceptor (R2 =0.730) (Figure 4.10 J, L & N). No correlation was possible to 
Figure 4.8. Mucin- binding at 20 µM correlated with amiloride and analogues physical 
parameters. A percentage of mucin binding vs Log P o/w. B percentage of mucin binding vs 
rotatable bonds. 
 Chapter 4 
 
186 
 
observe with H donor as four of the QQA considered are characterized by the same 
number of H donor (Figure 4.10 P). 
In the case of NQQA strong correlations were prohibited by a small sample set of four 
compounds. However, an inverse correlation was observable for PSA (R2=0.032) and H 
donor (R2=0.023) appear inversely correlated with the percentage of mucin binding. In 
Figure 4.9 C, mucin interaction appears to increase with increasing van der Walls volume 
for smaller molecules (amiloride, OF-80-NS22 and MC-08-DR04) but there is not clear 
correlation for benzamil, 552-02, GF-40-QQ33 and NVP-QBE170. For stronger 
correlations it would be necessary to extend the range of compound.  
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Figure 4.9. Mucin- binding at 20 µM correlated with amiloride and analogues physical 
parameters (1). Dashed lines indicate 95% confidence intervals. Mucin-binding of QQA 
(blue circle) and NQQA (red rectangles) analogues vs Log P (A-B), van der Waals Volume 
(C-D), rotatable bonds (E-F) and PSA (G-H). Data corrected for %NSB and shown are mean 
± SD (n=3) 
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Figure 4.10. Mucin- binding at 20 µM correlated with amiloride and analogues physical 
parameters (2). Dashed lines indicate 95% confidence intervals. Mucin-binding of QQA (blue 
circle) and NQQA (red rectangles) analogues vs polarizability (I-J), molecular weight (K-L), H 
acceptor (M-N) and H donor (O-P). Data corrected for %NSB and shown are mean ± SD (n=3) 
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Moreover, the retention time of NQQA (Figure 4.11 A) and QQA (Figure 4.11 B) appeared 
correlated with Log Po/w (NQQA R2=0.833, QQA R2=0.973). The elution time is governed 
by the water solubility of the analogous and the carbon content of the molecules. In fact, 
for each group as the Log Po/w increases stronger is the interaction of the compounds 
with the stationary phase of the column being retained for a longer time. 
 
 
As shown in the Table 4.1, a part from GF-40-QQ33 which displayed a 15% NSB due to 
its high hydrophobic character, the percentage of NSB was not higher of 2.6 % all other 
amiloride analogues, and mucin binding (corrected for NSB) was at least 5-fold higher 
suggesting that the binding behavior is significantly alternated in the presence of mucin. 
In fact, Log P o/w was the physical properties with strongest correlation with percentage 
of mucin binding for both QQA and NQQA but resulted not correlated with percentage 
of NSB (Figure 4.12 A) as for van der Waals Volume (Figure 4.12 B) and other physical 
Figure 4.11. Retention time of amiloride and analogues correlated with LogP o/w.  
Dashed lines indicate 95% confidence intervals. (A) NQQA, (B) QQA. 
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properties (data not shown) indicating that the results of mucin binding were not 
affected by the devise used.  
 
 
4.3.4 Influence of Alginate and DNA in ENaC blocker disposition. 
ENaC blockers, as experimental therapeutics for CF, would encounter a complex cocktail 
of macromolecules in the airway lumen of a CF patients. Alginate and DNA are two 
macromolecule components of CF sputum that have been shown to sequester and 
attenuate the activity of inhaled molecules (36) (23). Moreover, amiloride is known to be a 
DNA binding molecule (37) (38). The ultrafiltration method was exploited to screen for 
binding of amiloride analogues to calf thymus DNA and brown algae alginate to 
understand whether also these two macromolecule may modulate the disposition of 
inhaled ENaC blockers.  
Figure 4.12. Non Specific Binding at 20 µM correlated with amiloride and analogues physical 
parameters. A % NSB vs Log P o/w. B % NSB vs van der Waals Volume. Data shown are mean ± 
SD (n=3). 
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Figure 4.13 shows the specific and non-specific binding of amiloride analogues to 
alginate. It is possible to see that the %NSB for NQQA non significantly changes the 
extend of binding in the presence of alginate staying under 5% for all range of 
compounds but GF-40-QQ33 displayed the highest %NSB at about 30%. The specific 
binding to alginate, calculated as the difference between binding in the presence and 
absence of alginate, was consistently less than 5% except for UB-15-NR66, JE-FK-73 and 
OC-73-HK00 that shown a specific interaction of 12, 15 and 18% respectively (Figure 
4.13). The total and non-specific binding of the two quaternary ammonium 
stereoisomers, KF-08-NW22 and CA-91-YE87, were near identical (p>0.05).  
 
No strong correlations were observed between specific alginate at 20 µM and eight 
commonly considered physicochemical parameters (Figure 4.14 and 4.15, red rectangle). 
Interestingly, a plot of alginate binding against QQA physical properties (Figure 4.14 and 
4.15) displayed a similar positive correlation obtained for percentage of mucin (Figure 
4.9 and 4.10). For example, Log P o/w (R2= 0.875) and rotatable bonds (R2= 0.794) (Figure 
4.14 B & F) appear strongly correlated and weaker correlation was found for van der 
Waals Volume, polarizability, H acceptor and molecular weight (Figure 4.14 and 4.15) 
with R2< 0. 680. No strong correlation was observed for PSA (Figure 4.14 H) and H donor 
(Figure 14.15 P) (R2<0.450). This observation would suggest that similar binding 
interactions may occur between amiloride analogues and alginate as those that drive the 
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binding to mucin. However, it is noticeable that the extent of binding is greater for mucin 
than alginate. 
 
 
 
  
Figure 4.13. Alginate binding (gray bar) and non-specific binding (black bar) at 20 µM of 
NQQA and QQA after ultrafiltration assay. Data shown are mean ± SD (n=3). 
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Figure 4.14. Alginate-binding at 20 µM correlated with amiloride and analogues physical 
parameters (1). Dashed lines indicate 95% confidence intervals. Alginate-binding of QQA 
(blue circle) and NQQA (red rectangles) analogues vs Log P (A-B), van der Waals Volume (C-
D), rotatable bonds (E-F) and PSA (G-H). Data shown are corrected for %NSB represent the 
mean ± SD (n=3). 
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Figure 4.15. Alginate-binding at 20 µM correlated with amiloride and analogues physical 
parameters (2). Dashed lines indicate 95% confidence intervals. Alginate-binding of QQA (blue 
circle) and NQQA (red rectangles) analogues vs polarizability (I-J), molecular weight (K-L), H 
acceptor (M-N) and H donor (O-P). Data corrected for %NSB and shown are mean ± SD (n=3). 
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Amiloride analogue binding to DNA 
Figure 4.16 shows the total and non-specific binding of amiloride analogues to DNA. At 
first glance it is possible to notice that the %NSB appears lower compared the extend of 
binding for amiloride analogues in the presence of DNA, staying under 6% for all range 
of compounds but GF-40-QQ33 which displayed the highest %NSB at about 35%. 
Compounds that appear to be extensively bound by DNA are Benzamil and 552-02 
displaying a specific binding of ~32%, followed by JE-12-FK73 and OC-73-HK00 at ~23%. 
Amiloride, which showed the lowest mucin binding and not significant interaction to 
alginate, displayed a 16% of specific interaction to DNA. The analogues least bound by 
DNA were OF-80-NS22, CA-91-YE87 and KF-80-NW22 showing a specific binding of about 
5%.  
 
The plot of specific DNA binding (corrected for NSB) against physical properties (Figure 
4.17 and 4.18) appear poor binding predictor for NQQA with all R2 <0.305. Regarding 
QQA, seeking for correlations, was noticed a strong positive correlation with most of the 
physical properties considered; Log P o/w, van der Waals Volume, rotatable bonds, PSA, 
polarizability, molecular weight and H acceptor (R2 ≥0.700) (Figure 4.17 and 4.18). A poor 
correlation was found for H donor (R2<0.400) (Figure 4.18 P). 
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Figure 4.16. DNA binding (gray bar) and non-specific binding (black bar) at 20 µM of NQQA 
and QQA after ultrafiltration assay. Data shown are mean ± SD (n=3). 
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Figure 4.17. DNA- binding at 20 µM correlated with amiloride and analogues physical 
parameters (1). Dashed lines indicate 95% confidence intervals. DNA binding of QQA 
(blue circle) and NQQA (red rectangles) analogues vs Log P (A-B), van der Waals Volume 
(C-D), rotatable bonds (E-F) and PSA (G-H). Data corrected for %NSB and shown are mean 
± SD (n=3). 
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Figure 4.18. DNA- binding at 20 µM correlated with amiloride and analogues physical 
parameters (2). Dashed lines indicate 95% confidence intervals. DNA -binding of QQA (blue 
circle) and NQQA (red rectangles) analogues vs polarizability (I-J), molecular weight (K-L), 
H acceptor (M-N) and H donor (O-P). Data corrected for %NSB and shown are mean ± SD 
(n=3). 
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4.3.5 Effect of TCEP on Benzamil and 552-02 mucin binding 
A positive correlation between Log Po/w and mucin binding was consistent with a 
hydrophobic binding interaction. To probe this further the mucin binding of select ENaC 
blockers was evaluated in the presence of TCEP which is capable of reducing the mucin 
disulfide bonds which tether together mucin chains to form cross-linked hydrophobic 
pockets (39). As can be seen from the results in Figure 4.19, when TCEP is added into 
mucin mixtures containing benzamil or 552-02 there is a significant reduction of mucin 
binding for both benzamil (10-fold, p<0.0001) and for 552-02 (3-fold, p<0.001).  
   
Figure 4.19. Mucin binding of benzamil and 552-02 at 20 µM with (gray bar) or without (black 
bar) 50mM TCPE treatment. Significance at p<0.0001 denoted with asterisks (****) and 
p<0.001 with (**) determinate by unpaired t-test. Data shown are mean ± SD (n=3).  
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4.3.6 Permeability characteristic of calu-3 monolayer: in-vitro correlation to predict 
amiloride and analogue absorption in the lung 
In this thesis the Calu-3 lung adenocarcinoma cell line was used to generate a restrictive 
lung epithelial barrier model suitable for studying the transport of ENaC blockers across 
the airways. Four days after seeding onto 6.5mm Transwell inserts the Calu-3 cell 
monolayers reached 100% of confluence and TER (Ω•cm2) was measured post-
confluence up to day 18 post-seeding (Figure 4.20 A). TER increased sharply from the 
first day it was measured (4-6) and between day 14 and 18 the TER reached a plateau 
around 1200 Ω cm2 for each plate a part for plate 4 which displayed a higher TER of 
1305±45 Ω cm2, for each plate the Papp for F-Na was determined to judge the 
restrictiveness of the monolayers (Figure 4.20 B). At TER plateau monolayer permeability 
to FL-Na was measured. All four plates used for permeation studies displayed a Papp value 
between 0.349 and 0.495 x10-6 cm/s.   
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Apical to basolateral (AB) transport of all amiloride and analogues, except OC-73-
HK00, across polarized Calu-3 monolayers and cell-free Transwell inserts was monitored 
over 4 h.  
The cumulative mass transport profile for both NQQA (Figure 4.21 A) and QQA (Figure 
4.21 B) across Calu-3 increased linearly throughout the experiment. Table 4.3 shows the 
permeability coefficients for Calu-3 across the cell layer and control (cell-free insert) 
varied greatly across the range of amiloride and analogues which comprised NQAA and 
QQA. Notably, the permeability to NQQA was ~3-fold higher than that of QQA analogues. 
Compound MC-08-DR04 displayed the highest mass transported with 6.4 nmol 
transported in 4 h. This was ~3 fold higher than benzamil (1.8 nmol / 4 h) (p<0.0001) and 
over 50-fold higher than 552-02 (p<0.0001), which alongside amiloride, displayed the 
lowest mass transported; amiloride 0.123 nmol / 4 h, 552-02 0 0.103 nmol 4 h (p>0.05). 
Figure 4.20. Transepithelial resistance of calu-3 cells. (A) Graphical representation of TER during 
cells seeding day. (B) mean TER and summary of FL-Na Papp for each plate of calu-3 monolayer 
used. Data shown are mean ± SD, n=4.  
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The AB transport for UB-15-NR66 and JE-12-FK73 was very similar (~0.16 nmol / 4 h) 
(p>0.05) and about 4-fold lower than CA-91-YE87 and KF-80-NW22 (Figure 4.21 B) 
(p<0.0001). 
 
Figure 4.21. Cumulative transport of amiloride and analogues across Calu-3 monolayer. 
(A) NQQA and (B) QQA. Concentration added to apical chamber was 100 µM. Data shown 
are mean ± SD, n=4. 
A 
B 
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Compound 552-02 displayed slower transepithelial transport than amiloride i.e. 0.28 for 
552-02 versus 0.69 10-6 cm/s for amiloride. The Papp of blank Transwells was determined 
because of the extensive NSB recorded for some compounds in ultrafiltration studies. 
The presence of Calu-3 cells on the Transwell insert resulted in a decreased Papp of 72-
fold for 552-02 similar to FL-Na (88-folds) and 56-folds for amiloride. Surprising, although 
MC-08-DR04 shows a low Log Po/w 0.02, appears the fastest amiloride analogue to cross 
the cell monolayer having a Papp that decreased of only 3-fold compared with the control. 
The most hydrophobic QQA and NQQA compounds, OC-73-HK00 and GF-40-QQ33 
Table 4.3. Permeability of Calu-3 monolayers or bare Transwell inserts to amiloride and 
analogues. Data are mean ± SD, n=3-4. 
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respectively, showed extensive binding to the Transwell insert as evidenced by a low Papp 
in the absence of cells (Table 4.3). Notably, the Papp measured for Calu-3 to GF-40-QQ33 
was less than 2-fold lower than the cell-free Transwell: 2.81x 10-6 cm/s versus 1.61x 10-6 
cm/s. Unfortunately, OC-73-HK00 appears to have a high NSB showing a very low Papp 
even without monolayer (0.007 x 10-6 cm/s). When applied to Calu-3 monolayers the 
mass transported to the receiver chamber was lower than the LOD. These data were 
excluded from further analysis. 
 
Compounds were prepared as 20 mM stocks in DMSO and before dilution to 100 µM for 
permeation experiment. HPLC analysis of drug dose solution, before and after 
experiments, excluded the possibility of precipitation for all amiloride analogues 
included GF-40-QQ3.  
 
4.3.6.1 Relationship between drug physicochemical properties and transport across 
Calu-3 cell 
When seeking correlation between drug properties and Calu-3 permeability the QQA set 
contained only 4 compounds, of which two were isomers (KF-80-NW22 and CA-91-YE87). 
Figure 4.22 A-F demonstrates that there are no strong correlates for transport across 
restrictive Calu-3 monolayers (R2<0.200 for all parameters). Distinct from the trends seen 
for mucin binding, Log Po/w correlated poorly with Calu-3 transport for both groups, 
notwithstanding a ~4-Log range of lipophilicity for both groups. 
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Figure 4.23 shows the Papp of amiloride and analogues across insert cell-free and is 
possible to observe a negative correlation between filter permeability and amiloride 
analogues standard physical properties. In particular, is observed a strong correlation 
with van der Waals Volume for Papp of both NQQA (R2=0.9001) and QQA (R2=0.7762) 
(Figure 4.23 C and D respectively) and also correlation with QQA Papp versus Log Po/w 
Figure 4.22. Apparent permeability of amiloride and analogues at 100 µM correlated vs 
physical parameters. Papp of QQA (blue circle) and NQQA (red rectangles) analogues vs Log P 
(A-B), molecular weight (C-D) and van der Waals Volume (E-F). Data shown are mean ± SD (n=4). 
 
A
C
B 
C
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(R2=0.8001) (Figure 4.23 B) which may indicate that the filter used to seed Calu-3 cells 
may have affected the Papp of amiloride analogues. 
 
4.3.6.2 Statistical analysis of mucin binding and Papp across Calu-3 with SPSS. 
Correlations between physical parameters and Papp were also determined by calculating 
the Pearson correlation coefficient. As shown in Table 4.4 A, correlations displayed for 
QQA are comparable (green rectangles) to those obtained from linear regression (Figure 
4.9 and 4.10) showing a strong positive correlation with all physical parameters, except 
H-donor number, for which it was not possible obtain any correlation due to a low 
Figure 4.23. Apparent permeability of amiloride and analogues at 100 µM across cell-free 
Transwell inserts correlated vs physical parameters. Papp of QAA (blue circle) and NQAA (red 
rectangles) analogues vs Log P (A -B) and van der Waals Volume (C-D). Data shown are in mean 
± SD (n=3). 
A B 
C D 
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number of compounds. For QQA transport across Calu-3 correlated negatively with Log 
P o/w and rotatable bonds (R2=873 and R2=821, respectively) and weaker correlation for 
other physical properties. In Table 4.4 A it is possible to notice that all physical 
parameters appear correlated to each other displaying a R2 >0.749. For example, 
rotatable bonds were strongly correlated with Van der Waals Volume (R2= 0.997) and 
polarizability (R2=0.990). 
For NQQA (Table 4.4 B), the Pearson’s correlation, displayed also a negative correlation 
with rotatable bonds (red rectangle) and opposite to QQA, NQQA physical properties 
displayed a very variable correlation to each other. For instance, Log Po/w resulted 
strongly correlated to rotatable bonds (R2=0.818) but correlated poorly with PSA, 
molecular weight and H-acceptor (R2<0.100). 
 
C
h
ap
ter 4 
 
2
08 
  
Table 4.4. Statistical analysis of mucin binding and Papp across calu-3 with SPSS. % mucin binding at 20 µM and Papp at 100 µM correlated 
versus amiloride analogues parameter A QQA B NQAA s: molecular weight, Log P o/w, PSA, van der Waals Volume, polarizability, H-donor, H-
acceptor and rotatable bonds. Yet, each physical parameter correlated versus each other. 
Green rectangle indicates pearson correlation comparable to linear regression results. 
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Variance inflation factor (VIF) quantifies the severity of multicolinearity measuring the 
impact of colinearity among the variable in a regression model and a value >10 indicates 
the presents of multicolinearity. In our analysis VIF resulted to be 12<and>35 for QQA 
and 22<and>286 indicating that early analysis of multivariate regression indicates 
multicollinearity and insufficient population size for both groups of compounds. 
 
4.3.7 Influence of porcine purified jejunal mucin on 552-02 apparent permeability 
across Calu-3 monolayer 
To assess the effect of mucin-binding on the transport rate of amiloride analogues across 
the lung epithelium experiments were performed in which 552-02 (a high binding drug) 
was pre-equilibrated with purified porcine gut mucin before application to restrictive 
Calu-3 monolayers. Surprisingly, the rate of 552-02 transport increased 20-fold 
(p<0.0001) compared to control monolayers (Figure 4.24). The resistance of mucin-
treated monolayers was reduced by ~80% (from 1125 to 217±82 Ω cm2) after 4h 
treatment compared to a 25% (from 1201 to 899±151 Ω cm2) for mucin-free treatment 
(p<0.05). 
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Figure 4.24. Transport of 552-02 across Calu-3 cell monolayers in the presence and 
absence of purified mucin.  Papp of 552-02 dissolved in aqueous solution (black bar) 
and 552-02 dissolved in 0.5 µM purified mucin (gray bar) after 4 h experiment. 
Significance at p<0.0001 denoted with asterisks (****) as determined by unpaired t-
test. Data shown are in mean ± SD (n=3). 
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4.4 Discussion 
CF is a genetic disease and the abnormal anion transport in the respiratory conducting 
epithelia leads to impaired MC. The use of ENaC blocker may help to reconstitute mucus 
hydration on the airways an improve people with CF quality of life. Developed in the 
early 1960s to act as ENaC blocker at the lumen of distal renal cortical collecting duct, it 
was several decades before nebulized amiloride was studied for its effect on the 
pulmonary function of CF patients. Its poor PK/PD properties led to the synthesis of more 
potent and durable ENaC blockers like benzamil and 552-02 but the low solubility of 
these compounds lead to further attempts to develop improved amiloride analogues (40). 
To better design inhaled CF therapeutics it is imperative to better understand if mucus 
binding in the lung can negatively affect the inhaled disposition of solutes.  
 
Work in this chapter aimed to determine if a panel of inhaled ENaC blockers (12) undergo 
non-specific binding to secreted mucin. We supposed that mucin binding can reduce the 
free concentration of drug available for transport to the epithelial surface and therefore 
reduce the pharmacological activity of the drug. 
 
Many methodologies exist for determine the extent of drug-DNA and drug-plasma 
protein binding but no standard method is available for specifically study drug-mucin 
interactions in industry. This chapter explored the use of fluorescent and UV-Vis 
spectroscopy for the study of interaction between mucin and small molecules in a similar 
way to that described previously (35, 41). The fluorescent spectroscopy study aimed to 
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observe changing of amiloride and benzamil spectrum following titration of drugs (0.4 to 
15.2 µM) into 1 µM mucin. The absence of any mucin-induced changes in the amiloride 
spectrum (Figure 4.1 and 4.2) indicate no measureable binding in this experimental 
condition. In contrast, in the fluorescence spectrum of benzamil a maximum blue shift 
of 5 nm was noticed after mucin titration with benzamil at highest concentration (15.2 
µM). 
The interaction of one molecule with another molecule can result in a bathochromic or 
hypsochromic shift of the fluorescence peak implying that the conformation of one 
molecule was changed (42), or in a fluorescence quenching where a fluorescence intensity 
of a given substance is reduced as a consequence of molecular rearrangements, energy 
transfer, collision or complex formation (43).  
The binding of a ligand to a macromolecule may causes changes in their structure which 
may have an effect on the environment around the fluorophore. The recorded blue shift 
may be due to a reorientation of the solvent molecules around the fluorophore when 
excited which leads to a change in the dipole moment of the solvent in the binding site 
compared to free solution. Moreover, the exposition of the fluorophore to a less polar 
environment leads to the increment of the fluorescence intensity (quantum yield 
increased) as we observed when adding ethanol to a ligand solution (Figure 4.3). The 
interaction of the ligand to a hydrophobic region of the mucin may lead to an increment 
of the quantum yield. Therefore, the shift observed may be due to molecular interaction 
but more investigation was necessary.    
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The use of UV spectroscopy allowed further investigation of the formation of a drug-
mucin complex. To achieve analytical sensitivity, the mucin and drug concentrations 
were 0.5 µM and 130 µM (maximum), respectively. Comparing the absorbance of the 
control (sum of mucin and ligand absorbance) and the absorbance of the mixture, a 
distinct reduction of absorbance in the spectrum in the UV spectra of both compounds 
was observed using a mucin: drug ratio of 1:140 for benzamil and 1:260 for amiloride 
(Figure 4.5) which is evidence that they have formed a mucin-drug complex (42). An 
explanation for these changing in absorption for amiloride and benzamil may come from 
the formation of a drug-mucin complex. In particular, the absorbance spectra after 
benzamil titration into mucin displayed a greater suppression of absorbance bands than 
amiloride indicating that there was differential mucin binding for two structurally similar 
compounds. This mucin: drug ratio is higher than that used in the fluorescence 
spectroscopy assay and indicates that the binding interaction is of low-affinity. 
 
A new method was sought that facilitated work towards two distinct objectives: to 
screen for mucin binding in a range of related compounds; and to investigate in detail 
drug-mucin binding events. At present, pharmaceutical companies do not screen for 
mucin binding, however plasma protein binding (PPB) screening is a routine step in the 
drug development pathway. Fung, Chen (44) showed the determination of plasma protein 
binding using a new method. Commercially available compounds with different structure 
(12 in total) were mixed with plasma and unbound and bound fraction were separated 
by a 96-well plate filtrate assembly. The unbound percentage obtained using the 
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Microcon-96 assay was plotted with literature data and resulted to have a good 
correlation (R2=0.900), although no information regarding the physical-chemical 
parameters and NSB of compound used are indicated. 
 
The donor plate and receiver plate of the multiscreen 96-well plate are separated by a 
membrane filters at a cut-off of 10 kDa which have been used for several years  to 
separate unbound drugs from protein-bound drugs (45). The optimization of the 
ultrafiltration conditions used in the centrifugation process were necessary to improve 
the separation of the free and bound drug. For instance, spin time and temperature were 
chosen to avoid sample evaporation in a non-temperature controlled centrifuge. Sample 
evaporation was experienced in preliminary experiments and caused a sizeable 
reduction in the donor and filtrate volume. This made mass balance determination very 
challenging and could have resulted in drug precipitation in greatly reduced volumes of 
solvent (data not shown).  
A drawback of any multiwell plate-based assay is heterogeneous activity across the plate. 
The manufacturers of the Multiscreen plate used here recognise this heterogeneity and 
state explicitly in the manual that filtrate rates are particularly variable in the peripheral 
wells of the plates. Although the extent of binding can be determined by comparison of 
drug concentrations in control (mucin free) and treatment (drug + mucin) wells it is 
prudent to determine the mass balance of analytes within experiments. To calculate the 
filtrate volume and to determine the mass balance a precise volume of internal standard 
at known concentration was “spiked” into each well. The volume of the filtrate which 
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dilutes the standard can be determined by calculating the dilution factor of the standard 
through simultaneous HPLC detection of analyte and standard in the retentate. The same 
procedure was performed for the determination of the retentate volume after 
centrifugation. Using this approach, the mass balance was 96-104% for 11 out 12 
amiloride analogues. The low mass balance and high NSB for GF-40-QQ33 is most likely 
attributable to membrane- and plastic plate -binding.  
NSB has been reported to be correlated to lipophilic molecules (46)  and is typically 
estimated by measuring the Log Po/w but this is a gross simplification of a complex 
phenomenon as showed by Dickson, Gee (47) who demonstrated, using a quantum 
mechanical calculations, a correlation between NSB and drugs whose interacting with 
lipid molecule whereas the water-octanol partition coefficient did not show good 
predictive power.  High non-specific binding is a poorly understood phenomenon and 
has been reported as a particularly challenging issue for the determination of plasma 
protein binding (27) due to the lipophilicity of these molecules. Lee, Mower (48) 
demonstrated that pre-treating the filter membrane with 5% tween 80 or 5% 
benzalkonium chloride, the interactions with lipophilic drug molecules (such as 
vinblastine, hydrocortisone and propranolol), is reduced of over 70%. The surface-active 
agent did not cause significant damage of the membrane resulted by a serum protein 
leakage of 0.7 and 1.2% without and with treatment. 
 
Using the 96 well ultrafiltration assay the binding isotherm was determined for 12 
amiloride analogues. Midway through the studies the Millipore MultiScreen plates were 
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discontinued by the manufacturer. As a result, for four compounds isotherms were 
constructed with 4 concentrations rather than 8. From the binding assay it was found 
that all ENaC blockers bound to mucin, with the extent of binding at 20 µM ranging from 
0.7 to 37.5% (Table 4.1). The variability of drug binding between amiloride analogues of 
varying structure indicates that binding is determined by drug physicochemical 
properties that vary between the compounds, rather than any consistent structural 
features such as the pyrazinoyl group (Figure 4.6 and 4.7). Further evidence of a non-
specific binding event is the observation of identical binding between the stereoisomeric 
pair of compounds, CA-91-YE87 and KF-80-NW22 (Table 4.1).  
Mizushima, Takanaka (49) investigated the metabolic kinetics of R and S-oxybutynin 
showing that were slightly different and that R-oxybutynin in human plasma was 
approximately two-fold higher than that its S-enantiomer. The stereoselectivity of chiral 
drug metabolism and pharmacokinetic profiles have been reported in several studies (50)  
(51) (52) and the binding of chiral drugs to plasma proteins appears to exhibit 
stereoselectivity.      
Albani, Riva (53) studied the binding of propranolol enantiomers to human albumin and 
human α-AGP by equilibrium dialysis demonstrating the preference of (S) propranolol to 
bound α-AGP displaying a free fraction of 30 % and 23 %for (R) propranolol. 
Ofori-Adjei, Ericsson (54) using equilibrium dialysis, determinate the protein binding of 
racemic chloroquine to human albumin and α-AGP showing that (R) chloroquine strongly 
binds to albumin whereas, (S) chloroquine strongly binds to α-AGP. 
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The binding isotherm showed two different trend of absorption model. Amiloride 
analogue in Figure 4.7 suggested a multilayer binding to mucin rather than a simple 
monolayer binding as showed by compounds in Figure 4.6. The multilayer absorption 
may appear to be combined with QQA in amiloride analogue structure although UB-15 
NR66 showed a monolayer absorption.  
 
The binding isotherm allows the determination of binding properties between the 
equilibrium concentrations of bound and free ligand over a certain concentration range 
by fitting the Langmuir or GAB adsorption integral (Eq 4.1 and 4.2) to generate the 
corresponding affinity distribution. Langmuir isotherm is used to describe ligand-protein 
monolayer binding (55) and the assumption of the model consist in; the absorbed layer 
should be a monolayer, there are finite number of equivalent (identical) site, each site 
can hold at most one molecule, there are no interactions between adsorbate molecules 
on neighbouring sites. Due to these assumption, Figure 4.25 A shows a theoretical 
Langmuir isotherm binding where increasing the ligand-protein ratio the ligand binding 
reaches a maximum as all site on the protein are occupied by a ligand molecule. 
This is not the case of a GAB isotherm (multilayer liquid phase adsorption) (Figure 4.25 
B) which is used to describe a multilayer binding equilibrium. GAB isotherm assumes a 
random distribution of sites that are empty or that are covered by one or more 
monolayers. In contrast to the monolayer model, increasing the ligand-protein ratio the 
ligand binding does not reach a maximum but keeps increasing.  
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Hydrophobicity and solubility in water are often inversely correlated (56). In our studies 
before each experiment the solubility of compounds was accurately tested to avoid 
precipitation issue in experimental condition. Different concentration of drug-mucin 
mixture and pure drug solution at same concentration were diluted as appropriate and 
analysed through HPLC. The maximum concentrations of drug used in ultrafiltration 
experiments were 5/10 fold lower than the solubility provided by Novartis or determined 
by HPLC (data not shown). No solid formed was noticed with indication of absence of 
analyte precipitation. 
 
GAB isotherm was used by Zhao, Chen (35) to describe the multilayer binding of 
epigallocatechin gallate (EGCG) to purified porcine gastric mucin. EGCG-mucin 
interaction was studied using a combination of UV-Vis spectroscopy, transmission 
electron microscopy and ultrafiltration isothermal titration microcalorimetry (ITC). Using  
Figure 4.25. Theoretical representation of monolayer binding fitted by Langmuir model  
and multilayer binding fitted by GAB model. 
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ITC, Zhao, Chen (35) noticed a decreasing in the binding energy while increasing 
temperature affirming that the multilayer binding may imply hydrogen bonding but 
there is no a clear picture of the drug-mucin interactions at the molecular level (57) (58).   
 
To gain an insight into the intermolecular forces governing the mucin interactions of 
ENaC blockers we correlated standard physicochemical parameters with the extent of 
binding. The extent of drug binding at 20µM was chosen as a concentration that could 
be expected after delivery of a therapeutic amiloride aerosol (59).The extent of mucin 
binding varied greatly across the range of amiloride analogues which comprised QQA 
and NQQA analogues. Amiloride displayed the lowest mucin specific interaction (0.7%) 
and GF-40-QQ30 the highest (37.5%). The data indicate that drug hydrophobicity is could 
be a key factor in determining whether ENaC blockers bind extracellular mucins.  Values 
of Log P o/w used in this study were generated in silico. However, HPLC analysis using a 
consistent eluent program confirmed the ranking of cLogP values for both groups of 
compounds. Yamagami, Kawase (60) used a range of heteroaromatic compounds such as 
thiophenes, furans and (di)azines with a Log Po/w in the range of -0.8-1.84, reported the 
use of reversed phase HPLC retention times to provide a convenient method for 
estimating drug hydrophobic character. 
 
In contrast to NQQA, QQA compounds showed correlation also with other physical 
parameter, (such as H-acceptor, van der Wall Volume). The NQQA group compounds 
were characterized by a wide heterogeneous structure, presenting a wide range of 
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molecular weight (230-756 g/mol) and van der Waals Volume (251-938 Å3). Since our 
analysis is based on a small dataset, the drawn of correlation between percentage of 
mucin binding and ENaC blocker physical-chemical properties may require the extension 
of the range of model drug analyzed. 
Komiya, Park (61) studied mucus binding of 7 steroids (testosterone, progesterone, 
androst-4-ene-3,17-dione, deoxycorticosterone, corticosterone, hydrocortisone and 
dexamethasone) in a range of 1.53-3.99 in Log P o/w demonstrating that following rat 
intestinal perfusion, steroids binding to mucus may be due hydrophobic regions of the 
glycoprotein.  
 
Bhat, Flanagan (62) used a diafiltration system, which combines characteristics of 
equilibrium dialysis and ultrafiltration in a continuous system, to study the extent of 
binding to porcine gastric mucus fractions (400 kDa) and BSA of six compounds 
(albuterol, rifampicin, p-amino-salicylic acid, isoniazid, pyrazinamide and pentamidine). 
This compound set includes a molecular weight range of 123-822 g/mol, and a clogP from 
-1.23 to 2.85. The model compounds used were structurally diverse and selected on the 
basis of their potential therapeutic application for pulmonary route rather than on their 
physico-chemical parameters. Despite the structural variability within the group the 
association constants, as determined by Scatchard analysis, were within one order of 
magnitude, suggesting that the binding events were non-specific and that similar binding 
forces may be involved. In comparison to drug binding to BSA the association constants 
for mucin were lower (for 3 of the 5 reported drugs). The authors proposed that 
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hydrophobic binding to mucin polypeptide cores could explain the binding phenomenon, 
although there was no clear trend between cLogP and the Ka of binding to mucin.  
Kearney and Marriott (63) studied the tetracycline interaction nature to mucin using 
equilibrium dialysis in different pH condition (1 to 11). The percentage of drug bound 
increased from 15 to 60% when pH was increased from 1 to 3. Around pH 3 the mucin 
and tetracycline have opposite charge and an electrostatic interaction may occur. At 
higher pH tetracycline are neutral due to the ionization of the acid group and the drug 
bound gradually decreases back to 15% which ma due to hydrophobic interaction of drug 
molecule with the globular protein region of mucin. Following this observation, they 
attributed the binding of compounds to gastric mucin to a combination of electrostatic 
forces and hydrophobic interactions. 
Several studies demonstrated that positively-charged, low-molecular weight drugs bind 
electrostatically to the negatively charged components in mucus. In particular, Niibuchi, 
Aramaki (64) using equilibrium dialysis studied the interaction of 13 β-lactam and 3 
aminoglycoside antibiotics to rat intestinal mucin demonstrating a strong interaction of 
gentamicin to the mucin sugar moiety resulted from a significant decrease of the bound 
drug after treating the mucin with glycosidase.  
 
Mucin forms a complex gel network that presents both un-glycosylated non-polar 
domains that may serve as drug binding pockets and polar glycosylated domains with 
oligosaccharide chains that confer negative charge to the mucins through carboxyl and 
sulfate groups, therefore, the interaction of NQQA and QQA may fall within different 
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drug with the disulfide reducing agent, TCEP. Due to the limited availability of 96-well 
plate, the treatment with TCEP was used only with benzamil and 552-02. As can be seen 
from Figure 4.19, there is an increase of free drug concentration when TCEP was used to 
reduce mucin for both benzamil (10-folds) and 552-02 (3-folds). These observations 
support the assumption that disulfide bridges could potentially increase the ability of 
mucin to interact with ENaC blockers. The difference between the similar binding but big 
difference in effects of TCEP on benzamil and 552-02 may be due to a different binding 
modes. Different Log Po/w values mean different baseline affinities for mucin.  
 
Influence of other sputum components on ENaC blocker disposition 
The inhalation of amiloride analogues into the CF lung will lead to drug exposure to wide 
range of complex anionic macromolecules that may sequester drug extracellularly. 
Alginate is bacterially-derived anionic polymer with carboxyl end groups that forms 
highly viscous aqueous solutions that contribute to obstruction of small airways and 
respiratory congestion in patients with CF and chronic pulmonary infection. The most 
widely studied alginate secreting bacterium is the opportunistic pathogen, P. aeruginosa 
and the concentration in CF sputum has been reported to range from 4 to ~100 µg/ml 
when measured by enzyme-linked immunosorbent assay (65). 
Bacterial polymer differ from the algal alginates in that mannuronate residues may be 
modified with O-acetyl groups (66). Pseudomonas aeruginosa activates the algD operon 
in response to environmental conditions such as high osmolarity, nutritional deprivation 
and the presence of ethanol,(67) (68) (69, 70) leading to the biosynthesis and secretion of 
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alginate as a self-defense mechanism against host immune clearance and also enhances 
adhesion to solid surfaces. 
Like mucin, alginate is an anionic carbohydrate polymer with mucoadhesive properties, 
but unlike mucin, lacks a protein hydrophobic core.  Similarly, extracellular DNA is an 
abundant extracellular macromolecular component of sputum. The concentration of 
DNA found in lung sputum from healthy people is ~3µg/ml (71) but is often present at high 
levels in CF sputum (0.5 mg/ml up to 9 mg/ml) (71) (72). 
 
As showed in Figure 4.13 and 4.16, QQA showed similar correlation obtained with mucin 
for both alginate and DNA, while for NQQA the extent of binding to alginate was lower 
than observed for mucin and equivalent concentrations but resulted higher for DNA 
binding.  The similarity of correlation between mucin and alginate may lead us to think 
that are due to interaction of model drug to the polysaccharide chain of mucin and 
alginate. 
Evans and Linker (66) found that P. aeruginosa polysaccharide differ from the algal 
alginates for the presence of 0-acetyl instead of mannuronate residues. Although this 
difference  Gordon, Hodges (36) studied, with equilibrium dialysis, the binding of 
aminoglycosides antibiotic to alginate (β-lactams, gentamicin and tobramycin) to two 
alginate model; commercial alginate and that extracted from a cystic fibrosis-derivate 
mucoid strain of P. aeruginosa. The similar results obtained with these two alginate 
model support the use of commercial alginate as a model for P. aeruginosa 
polysaccharide. 
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Moreover, all amiloride analogues appear to bind DNA with 552-02 and benzamil 
showing the highest binding (~35 %), and OF-8-NS22 and the two stereoisomer (KF-80-
NW22 and CA-91-YE87) showing the lowest binding (~5%). NQQA compounds are 
characterized by a strong correlation between percentage of mucin binding with LogPo/w, 
but there is no correlation between percentage of DNA binding and Log P o/w for NQQA 
(Figure 4.17). As show in Chapter 3, PGM used as mucin model for our studies contains 
DNA (Chapter 3 Table 3.3). The application of the 96-wells plate binding assay was also 
used to understand whether the DNA contamination has affected the results of 
percentage of mucin binding. The absence of correlation with Log Po/w may be an 
indication that percentage of mucin binding was not affected by DNA. 
In 1987, the interaction of amiloride to DNA was demonstrated by  Besterman, Elwell (73). 
They studied the relationship for 12 amiloride analogs to DNA demonstrating that 
amiloride can intercalate into DNA and inhibit the catalytic activity of DNA 
topoisomerase II. In 1993 Bailly, Cuthbert (74), using the technique of foot-printing, 
demonstrated that the interaction of amiloride with DNA involves a sequence-specific 
recognition process. In particular, amiloride was shown to bind selectively to sites rich in 
A-T residues using three DNA restriction fragments of defined sequence. The 
intercalation of amiloride into ds-DNA was then confirmed by Mirmomtaz, Ensafi (38)  
who developed a sensitive DNA biosensor for the determination of amiloride in vitro 
using a pencil graphite electrode.  
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High-sensitivity calorimetric techniques have allowed the thermodynamics studies of 
drug–DNA interactions demonstrating that this complex is stabilized by a number of 
noncovalent interactions such as van der Waals interactions, hydrogen bonds and 
hydrophobic forces. Drugs that exhibit a binding preference for A-T base pairs appear 
favorable to hydrophobic contacts between the adenine C2 hydrogen atoms and the 
aromatic rings in the drug. Moreover, the hydrogen bond acceptors on the A-T base pairs 
(C2 carbonyl oxygen of thymine or N3 nitrogen of adenine) appeared to interact with any 
hydrogen bond donors on the drug (such as amide groups) (75).  
 
Permeability characteristic of calu-3 monolayer: in vitro correlation to predict 
amiloride and analogues absorption in lung. 
The pulmonary epithelium is considered the most significant barrier to the absorption of 
compounds delivered into the lungs (76). Calu-3 cell line forms tight monolayers (77, 78) and 
is considered a good cell culture model that mimics the transport and metabolic 
properties of human bronchial epithelium. In spite of its good barrier properties the Calu-
3 line does not form fully pseudo-stratified differentiated, mucus secreting monolayers 
as found in NHBE cells. However, their cost, reproducibility and high proliferative 
capacity allows for easy application in academic laboratories. 
 
In our studies, the Calu-3 model showed TER and FL-Na paracellular permeability of 
~1200 Ω cm2 and ~0.400x10-6cm/s, respectively. This is comparable to other published 
works that employed the submerged Calu-3 culture (79) (80).   
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Our results show a higher cell monolayer permeability to amiloride compared to 552-02, 
which is in agreement with Hirsh, Zhang (17). However, contrast the idea where more 
hydrophobic molecules are predicted to be absorbed more rapidly (14). For the QQA 
compounds, Calu-3 Papp decreased with increment of Log Po/w. However, the range of 
compounds is very limited (Figure 4.22) and three of the four quaternary compounds are 
1-3 Log units more hydrophilic than the most hydrophilic NQQA. The hydrophilic 
character of QQAs is likely to limit the transport pathway into / across the epithelia to 
the passive paracellular or active/facilitated transport pathways.  
 
Mathia, Timoszyk (80) evaluated the potential of Calu-3 cells as a permeability screen to 
predict in vivo absorption of hydrophobic (such as propranolol, antipyrine) and 
hydrophilic solute (such as caffeine, mannitol and theophylline) showing that Calu-3 cell 
line has low permeability to hydrophilic drugs and that hydrophilic drugs transport across 
the cell line via paracellular or active uptake. Saha, Kim (81) used primary cultured rat 
alveolar epithelial cell monolayers to investigate the influence of lipophilicity on the 
penetration of β-blockers. A combination of hydrophilic β-blockers (sotalol and atenolol) 
and lipophilic probes (propranolol, metoprolol, timolol, betaxolol) were used to 
demonstrate that lipophilic compounds were translocated primarily via the transcellular 
route whereas hydrophilic β -blockers traverse the alveolar epithelium via paracellular 
route. 
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As a corollary of this the permanently cationic character of QAA compounds should 
decrease epithelial permeability which is a major limitation for the airway efficacy of 
amiloride (Log P -0.89) and benzamil (Log P 1.45). Contrary to expectations, in our studies 
compound MC-08-DR04 which is a NQAA with cLog Po/w 0.02 was the most permeant 
ENaC inhibitor.  
Unexpectedly, as showed in Figure 4.23, although the filter used in Transwell insert had 
a diameter of 0.4 µm appears to affect the permeation of molecules. This is obviously 
not size-restricted diffusion but instead binding to plasticware.  
 
Correlation of percentage of mucin binding and Papp versus physical parameter of drug 
model were analyzed also using SPSS which did not show significant correlation between 
Papp and physical properties was found. SPSS was used to calculate the VIF which 
describes the extent of multicollinearity (or correlation between predictors) that exists 
in a regression analysis. The presence of high correlation between predictors can 
increase the variance of the regression coefficients, making them unstable and difficult 
to interpret. Our results indicate that both group of compounds, quaternary and NQQA, 
have a high multicollinearity indicating the need to extend significantly the range of 
compounds analyzed. 
 
Sakamoto, Matsumaru (82) reported the protein expression of 7 membrane transporters 
on human trachea bronchial Cell lines (Calu-3); OCT1, OCT3, OCTN1 and OCTN2 for the 
solute carrier transport family (SLC), and for ABC transporter family multidrug resistance 
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associated protein (MRP) 1, 2 and breast cancer resistance protein (BCRP). As shown by 
Horvath, Schmid (83) OCTNs transporters appear to be involved in the uptake of inhaled 
drugs, such as albuterol have a high interaction with charged compounds. Furthermore, 
Biermann (84) using fluorescence microscopy, provided supporting evidence for the role 
of OCT2-faciltated uptake of amiloride into cells using an OCT2-overexpressing HEK293 
cell model. Future investigations should investigate further the role of OCT(N) 
transporters in the uptake and transport of ENaC blockers across lung epithelial cells such 
as Calu-3 monolayers.  The use of intact, ex vivo or in vivo lung models (85) would provide 
an optimal model for studying drug disposition in a complex multicellular architecture. 
 
Influence of porcine purified mucin on 552-02 apparent permeability across Calu-3 
monolayer. 
The guanidine-containing analogue 552-02 showed extensive mucin-binding (20% at 20 
µM) and was available in good amounts from our collaborators. Moreover, preliminary 
NMR experiments (described in Chapter 5) had shown promising results. For these 
reasons 552-02 was chosen to investigate the effect of mucin-binding on Calu-3 
permeability. The hypothesis of this work was that extensive mucin binding would 
reduce the free concentration of 552-02 available for transepithelial transport which 
would be observed as a reduction in the Papp of Calu-3 monolayers. Unexpectedly, the 
addition of highly purified and extensively dialyzed mucin (see Chapter 5) severely 
disrupted Calu-3 monolayer and increased transport some 20-fold. Although this effect 
was unexpected, others (86) have reported an increased Caco-2 intestinal epithelial 
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permeability after exposure to biosimilar mucus. This mucus model was composed of 
polyacrylic acid, mucin (5% w/v), lipid mixture with linoleic acid content ranged 0.06-
2.46% (w/v), cholesterol, phosphatidylcholine and polysorbate 80. The permeability 
enhancing effects of the biosimilar model was attributed to the high concentration of 
linoleic acid which has been demonstrated to be highly cytotoxic on human umbilical 
vein endothelial cells (87, 88). When the linoleic acid content was restricted to 0.06-0.11% 
w/v resulted fully compatible with the Caco-2 cells following MTS assay. Only at 
concentration above 2.4 % Caco-2 cell viability was reduced. 
In the CsCl density gradient centrifugation lipids are expected to display a buoyant 
density of 1.00-1.200 g/ml (89) and distinct from the fraction at ~1.4 g/ml from where 
mucin was harvested. The persistence of guanidine in purified mucin is a more likely 
cause of decreased monolayer viability. In spite of a 24 hours dialysis regime it is feasible 
that the concentration of guanidine did not reduce sufficiently from 4M guanidine to 
avoid a toxic effect of Calu-3 monolayer. Cytotoxicity effect of polyhexamethylene 
guanidine hydrochloride on human alveolar A549 cells was demonstrated by (90) who 
showed that cell death after treatment with polyhexamethylene guanidine 
hydrochloride was associated with formation of intracellular reactive oxygen species and 
apoptosis at even 2 μg/mL concentration. 
Alternatively, fatty acid contamination could have imparted a cytotoxic effect. For 
example, Hansson and coworkers Hansson, Sheehan (91) reported that the fatty acid 
content of human airway, human cervix and pig stomach mucin after CsCl purification 
ranged from 0.4 to 0.9 µg of fatty acid/mg of glycoprotein. 
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Conclusion 
In conclusion, we developed and applied a sensitive and quantitative ultrafiltration 
mucin binding assay with opportunity for automated screening of drug-mucus binding. 
We have shown that mucin-binding may affect the lung disposition of inhaled ENaC 
blockers in the CF lung. Hydrophobicity is generally considered to be a key determinant 
of drug absorption from the airways. Taken alongside the observed effect of hydrophobic 
character is determining mucin-binding it is feasible to conclude that the lung 
transepithelial transport of hydrophobic solutes could be retarded by mucin-binding.  
Moreover, DNA and alginate binding appeared extensive for QQA but NQAA drug 
physical properties appear not correlated to DNA and alginate binding. The extension of 
the range of drug model may elucidate the involvement of other physical properties into 
the interaction as for better understand the correlation between Papp and drugs physical 
parameters.   
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Chapter 5 : Investigation of drug-mucin interaction by STD-NMR 
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5.1 Introduction 
Mucociliary clearance (MC) is a coordinated system of epithelial mucus secretion, cilia 
action, and cough, used to preserve the healthy environment in the lung (1). MC is 
impaired in respiratory disease such as in COPD (2) CF (3) bronchiolitis (4) and asthma (5) 
leading airway inflammation and obstruction due to mucus hypersecretion and 
dehydration. 
Therapy to maintain ASL hydration is important during not only in CF patients but in all 
chronic airway diseases (3, 6). It has been shown that MC in people with COPD and 
bronchiolitis is enhanced with administration of aerosolized salbutamol, (7, 8) a 
bronchodilator agent that significantly increases ciliary beat frequency of human nasal 
and bronchial epithelial cells after stimulation of adenylyl cyclase and the subsequent 
rises of cAMP (9). Although the disposition of salbutamol appears to be unchanged in 
asthma and COPD (10) it appears improved in CF patients showing a faster increment of 
concentration peak in serum (11). 
 
For CF it is thought that inhalation of ENaC blockers may enhance MC due to a reduction 
in water reabsorption which, in turn, re-establishes appropriate airway hydration (12, 13). 
The prime cause of patient morbidity in CF is associated with chronic lung infection with 
pathogens such as Pseudomonas aeruginosa (14). Aggressive antibiotic treatment can 
only temporarily reduce P. aeruginosa (15) and it is inevitable that chronic re-infection  
will occur. Tobramycin is an aminoglycoside antibiotic used to treat various types of 
bacterial infections, particularly Gram-negative infections and the nebulised formulation 
 Chapter 5 
239 
 
is indicated in the treatment of chronic infection with P. aeruginosa in patients with 
cystic fibrosis (15, 16).  
 
The efficacy of aerosol therapy in CF may be limited by the interaction of drugs with 
mucus components. For example, early studies of Saggers and Lawson (17) showed that 
mucus affect the activity of antibiotics. Several techniques have been used as tool to 
characterize the nature of drug–mucin interactions such as mucus diffusion assays (18),  
dialysis and ultrafiltration assays (19) (20), UV-vis absorption and fluorescent 
spectrophotometry technique (21). Bhat, Flanagan (22) using an in vitro diafiltration 
technique (combination of dialysis and ultrafiltration) showed the presence of 
interactions between salbutamol and commercial porcine gastric mucin, and   Ramphal, 
Lhermitte (23) demonstrated the interaction of tobramycin with whole CF mucus sputum 
using  ultrafiltration technique. Chapter 4 detailed the development and application of a 
96-ultrafiltration assay which showed the presence of interaction between ENaC 
blockers and commercial partially purified mucin, PGM.  These techniques afford the 
detection of binding kinetics and stoichiometries, however It is necessary to employ 
complementary high resolution structural techniques to better understand the nature of 
mucin-drug interactions the at the molecular level. 
 
NMR spectroscopy has been used to obtain structural insights and binding properties of 
the ligand-protein complexes (24) using a variety of methods such as transfer NOEs to 
asses conformational analysis of the bound ligand  (25) and pulsed-gradient spin-echo 
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NMR (PGSE-NMR) to examine the diffusion of polymers through mucus solutions (26) (27) 
(28). STD-NMR (29) is a relatively new technique that has been used to provide ligand 
structural information when bound to its target (30) (31). Initially used to study transient 
protein-carbohydrate interactions, the STD-NMR applications for detection and 
characterization of transient ligand-macromolecule interaction has steadily increased 
and was rapidly used to characterize interactions between nucleic acid and ligands (32), 
proteins and peptides (33) and also used by Mari, Serrano-Gomez (34) to study the 
interactions between ligands and extracellular membrane proteins using living cells. STD 
-NMR can be also used to have confirmation of drug-mucin binding and allow the 
identification of the “binding epitope” or the hydrogen atoms of the ligand involved in 
the interaction with its cognate receptor (35), and may lead to the design of more 
powerful molecules and the improvement of inhalation therapies. 
In the mucin research field STD-NMR has been applied to determine the target epitope 
of short MUC1-derived tumour-associated glycopeptides when bound to the breast 
cancer-selective monoclonal antibody SM3 (36) and to identify the binding properties of 
MUC1 interactions with human macrophage galactose type lectin (37). 
 
The aim of this chapter was to apply, for the first time, the use of STD-NMR technique to 
study mucin-ENaC blocker interactions. Pilot studies included studies on the binding of 
tobramycin to fresh, unpurified PLM. Significant DNA contamination in PLM supported 
the use of PGM as a more refined mucin model to examine mucin binding interactions 
for salbutamol, tobramycin and two amiloride analogues; OF-80-NS22 and 552-02. The 
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structural features of these drugs allowed for the mapping of drug structural domains as 
“interacting” and “non-interacting”. Studies on these ENaC blockers were extended to 
include the use of highly purified porcine jejunal mucin (PJM). 
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5.2 Material and methods 
Materials 
Porcine lungs and jejunum tissue were sourced freshly after slaughter from H G Blake, 
Ltd. (Norwich, UK). Mucin powder from porcine stomach (type III), tobramycin, EDTA, 
CsCl and Wilmad® NMR tube 5mm and 3.3 mm were purchased from Sigma Aldrich 
(Gillingham, UK), Salbutamol sulfate 99% was purchased from Alfa Aesar (Heysham, UK), 
deuterium oxide was purchased from Cambridge Isotope Laboratories Inc 
(Massachusetts, USA). Dimethyl sulfoxide-d6 (99.5% D) was purchased from VWR 
(Leuven, Belgium), Vivaspin 6 (10 kDa), N-ethyl maleimide and guanidine were purchased 
from Thermo Fisher Scientific (UK) and Amicon Ultra-0.5 Centrifugal Filter 10 kDa were 
purchased from Millipore (UK). Quick seal centrifuge tube Beckman Coulter (High 
Wycombe, UK), Cellulose ester dialysis membrane MWCO 10 kDa (Spectra/Por Biotech). 
Compounds OF-08-NS22 and 552-02 were donated by Novartis (CH). 
 
Methods 
Harvest of fresh porcine respiratory mucus  
Respiratory porcine mucus was collected as described in Chapter 2 section 2.2.2. 
 
Isolation and purification of jejunal porcine mucus 
Jejunal porcine mucus was collected and purified purification as described in Chapter 2 
section 2.7.2. 
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Determination of biochemical properties 
Mucin and DNA content were determined using 2-CAN and DAPA respectively (Chapter 
2 section 2.4).  Mucus solid %dry was determinate using the following equation; 
% dry=   	
 100% 
 
Pilot STD-NMR studies of tobramycin and salbutamol binding to fresh porcine respiratory 
mucus and PGM 
Mucin and drug preparation for STD-NMR studies are described in Chapter 2 section    
2.8.4.  
 
STD-NMR studies of OF-80-NS22 and 552-02 binding to PGM and purified PJM 
Mucin and drug preparation for STD-NMR studies are described in Chapter 2 section 
2.8.5.4.  
Glycerol contamination was eliminated as described in chapter 2 section 2.8.5.1. 
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5.3 Results 
5.3.1 Tobramycin binding to PLM and PGM studies by STD-NMR 
Initial STD-NMR studies involved the study of the aminoglycoside antibiotic, tobramycin 
binding to fresh PLM. The use of 800MHz NMR instrument afforded a well resolved 1H 
spectrum of tobramycin. Although a full structural assignment was not performed the 
spectrum was consistent with low field NMR structural data (38). The reference spectrum 
(I0) for the tobramycin and mucus are shown in Figure 5.1 A and B respectively. 
Tobramycin-mixture reference spectrum  (Figure 5.1 C) showed evidence of several 
overlapping peaks. Notably, two well-resolved and non-overlapping tobramycin peaks at 
~5.5 and 5.6 ppm shifted upfield by 0.2 ppm. In the STD-NMR spectrum, very weak STD 
signals were observable (indicated by dashed lines in the Figure 5.1 D) which is an 
indicator of mucin-tobramycin interaction. The shifting of tobramycin peaks upon mixing 
with mucin in addition to the complex and broad peaks of mucin precluded the 
assignment of the tobramycin binding motif.  
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Figure 5.1. STD-NMR spectroscopy for the study of tobramycin-porcine respiratory 
mucus binding.  A: reference 1H NMR of 5mg/ml tobramycin solution in D2O; B reference 
1H NMR of mucus. C: 1D 1H reference spectrum of mixture tobramycin-mucus; D: 1H NMR 
(on-resonance) transfer of saturation from protein to ligand. Solvent (D2O) peak at 
chemical shift of 4.7 ppm. 
 
ppm 
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Figure 5.2 shows the reference spectra and STD spectra of PGM and tobramycin-PGM 
mixtures. Figure 5.2C includes some non-overlapping peaks (0.88 and 2.36 ppm) that are 
attributable to mucin in spite of a vast molar excess of ligand (10 mM versus 1.5 µM 
mucin assuming mucin MW of 1 MDa). Integration of the STD spectrum peak (Figure 
5.2D) illustrates that tobramycin protons receive saturation from the glycoprotein but 
are very weak STD signal with intensities of 1.1%. 
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Figure 5.2. STD-NMR spectroscopy for the study of tobramycin-PGM mucin binding.  
A: reference 1H NMR of 5mg/ml tobramycin solution in D2O B: reference 1H NMR of 
mucin 1.5 mg/ml (w/v) in D2O; C: 1D 1H reference spectrum of mixture tobramycin-
mucin, arrows indicates residual mucin signal; D: 1H NMR (on-resonance) transfer of 
saturation from protein to ligand.  
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The mucin spectrum did not include any measurable downfield resonances from 
aromatic amino acids but instead included resonance peaks restricted to the region 
between 0.8-5 ppm. A large residual water peak remained in the mucin spectrum as 
expected from a highly glycosylated and hygroscopic glycoprotein 
 
5.3.2 Salbutamol binding to PGM mucin study by STD-NMR  
STD-NMR analysis of salbutamol-mucin mixtures offered a less complex and highly 
resolved NMR spectrum.  In Figure 5.3, a standard 1H NMR spectrum is shown for 
salbutamol (top spectrum) and the mixture (middle spectrum). The 1D 1H NMR spectrum 
of salbutamol indicated that the two protons on the benzyl alcohol group were missing 
from the structure. This was confirmed by COSY and TOCSY NMR spectra (performed by 
Dr C. McDonald, data not shown). The commercially sourced salbutamol sample was 
used regardless for the purposes of validating the STD-NMR approach. The STD appears 
lower for protons at 1.4 and 2.4 ppm (~1.9%) and aromatic protons at 7.0 and 7.5 ppm 
appear to have a stronger interaction as for proton at 5.0 ppm. This identifies a binding 
event with PGM. Moreover, the differential STD values for individual resonances indicate 
preferential binding of the phenolic ring to the PGM “receptor”.  
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Figure 5.3. STD-NMR spectroscopy for the study of salbutamol-PGM mucin binding.  
Top: reference 1H NMR of 5mg/ml salbutamol solution in D2O; Middle: 1D 1H 
reference spectrum of mixture salbutamol-mucin; Bottom: 1H NMR (on-resonance) 
transfer of saturation from protein to ligand.  
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5.3.3 Analysis of OF-80-NS22 and 552-02 binding to PGM mucin by STD-NMR 
STD-NMR studies were performed with OF-80-NS22 (Figure 5.4 A) and 552-02 (Figure 5.4 
B) which displayed low and high mucin binding in the ultrafiltration studies described in 
Chapter 4. The top spectrum of Figure 5.4 A and B shows the reference spectrum of 
ligands, showing all the non-exchangeable protons of their structure highlighted by red 
circle for OF-80-NS22 and blue triangles, rhombus and hexagon for 552-02 whereas the 
pyrazinoyl protons appeared exchangeable and invisible. 
 The 1H NMR reference spectrum of the model drug and mixture ligand-mucin (ratio 
3300:1) are the top and middle spectrum respectively. Drug-binding is seen as resolved 
peaks in the STD spectrum of ligand-mucin mixtures (bottom panel Figure 5.4 A and B). 
The STD spectrum for OF-80-NS22 (Figure 5.4 A) indicates that the interaction with 
mucus glycoprotein involves all four of the aliphatic non-exchangeable protons which 
are detectable by NMR. This is corroborated by noticeable broadening of the signals at 
1.15 and 3.3 ppm (Figure 5.4 A, red circle bottom spectrum).  
Greater peak broadening was observed in the STD spectrum of the mixture 552-02– PGM 
mixture. Three distinct regions of 552-02 were identified on the STD spectrum (Figure 4B 
bottom spectrum); benzene ring moiety represented by two resonance peaks at 7.0 and 
6.7 ppm (blue triangles), glycerol-like side chain at 3.5 ppm (blue rhombus) and the 
central butyl group (blue hexagon) at 2.4 and 1.5 ppm. Significant differences were 
identified in the extent of STD for the two molecules. In both experiments there was a 
residual mucin signal in the STD spectrum at 1.8 ppm (dashed line, Figure 5.4A and B). 
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The extent of saturation transfer for each of the OF-80-NS22 resonances was 2%. This 
extent was 5-fold higher for all resonances in 552-02. This result is consistent with the 
difference in mucin-binding of these compounds in the ultrafiltration assay (Chapter 4).  
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Figure 5.4. STD-NMR spectroscopy for the study of drug-mucin binding.  A and B mucin 
binding of OF-80-NS22 and 552-02 respectively. Top: reference 1H NMR of ligand solution in 
D2O; Middle: 1D 1H reference spectrum (off resonance) of mixture ligand-mucin (ratio 
3300:1); Bottom: 1H NMR (on-resonance) transfer of saturation from protein to ligand. 
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STD-NMR competition studies were performed to understand whether OF-80-NS22 and 
552-02 bind to the same site on the mucin molecule. Towards this aim, 2 mM of OF-80-
NS22 and 2 mM 552-022 where mixed in 600 nM mucin and subjected to STD analysis. 
Figure 5 A shows reference spectrum of mixture ligands-mucin while Figure 5D shows 
the STD spectrum for the mixture ligands-mucin. It is possible to see in Figure 5.5, that 
the STD spectrum of the mixed ligands (panel D) is very similar to the composite STD 
spectra for the individual ligands i.e. OF-80-NS22 (spectrum B), 552-02 (spectrum C) 
suggesting that the two ligands do not compete for the same site of binding of the mucus 
glycoprotein. 
 
Figure 5.5. STD-NMR spectroscopy for the competitive study of ligands-mucin binding.  A 1H 
NMR reference spectrum (off resonance) of mixture ligands-mucin. B 1H NMR (on-resonance) 
transfer of saturation from mucin to OF-80-NS22. C 1H NMR (on-resonance) transfer of 
saturation from mucin to 552-02. D 1H NMR (on-resonance) transfer of saturation from mucin 
both ligands, OF-80-NS22 (red) and 552-02 (blue). 
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5.3.4 PJM purification and biochemical analysis 
Mucin was purified from porcine jejunal tissue was denatured and purified by density-
gradient centrifugation in CsCl/4M GdnCl. The sample showed a thick layer of insoluble 
material (pellicle) at the top of the tube which was separated from lower layers and was 
not possible to distinguish the mucin layer from the DNA layer (Figure 5.6). 
 
 
 
  
Figure 5.6. 1° Schematic of the mucin product from CsCl gradient centrifugation. Two layers 
are distinguishable; insoluble material and yellowish layer. Fractions were collected in a 
volume of 1ml from the top to the bottom. 
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Samples of forty CsCl fractions were stained with AB (Figure 5.7A). The intensity of AB 
staining increased from fraction 16 to 40. In contrast the buoyant density of the fractions 
increased progressively from the top to bottom fractions (Figure 5.7B). AB positive 
fractions 16-27, displaying densities of 1.35 - 1.48 g/ml were collected in accordance with 
to published density of mucin.  
 
Mucin-containing fractions were subjected to a second density-gradient centrifugation 
step in CsCl/0.5 M GdnCl. After ultracentrifugation at least three layers were visible. A 
darker layer at the top of the tube corresponding to insoluble material, yellowish layer 
corresponding to the one containing mucin and a clearer layer, with high density at the 
bottom of the tube (Figure 5.8).  
Figure 5.7. 1° CsCl gradient centrifugation. (A)  Alcian blue staining of ultra-centrifuge fractions. 
(B) Density of fractions. Blue stained fractions with density between 1.35-1.48 g/ml were 
collected. 
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Fractions from the second centrifugation step were analysed for absorbance at 260 and 
280 nm (Figure 5.9 A), stained with AB (Figure 5.9 B) and measured for density (Figure 
5.9 C). The A260/A280 for fractions 1-25 were consistently recorded as 0.2-0.3 AU but 
increased sharply to > 1.0 AU from fractions 26-30 and above 2.0 AU in the remaining 
fractions. AB staining revealed strong staining for fractions 21-39 and weak staining for 
fractions 18-20. The measured density for the fractions increased linearly from 1 to 40 
as expected from a CsCl gradient. Taken together these three methods allowed the 
identification of fractions 19-25 as the mucin-positive fractions. The buoyant density of 
these fractions was between 1.37-1.49 g/ml and the total volume collected was 25 ml.  
Figure 5.8. 2nd CsCl density-gradient ultracentrifugation. Three layers are distinguishable; Top: 
insoluble materials. Middle: Mucin. Bottom: DNA. Fractions were collected in a volume of 1ml 
from the top to the bottom.  
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Figure 5.9. 2nd CsCl density-gradient ultracentrifugation. A Fractions absorbance at 260 and 280 nm. B Fractions alcian blue staining. C fractions 
density (g/ml). 
 Chapter 5 
258 
 
Purified PJM was dialysed for 48 h against water to remove CsCl and the chaotropic 
guanidine salt. The fractions yielded four aliquots of PJM of (~180mg) and freeze-dried 
until a constant weight was recorded. The mean % dry solids resulted was 0.51%±0.09 
(Table 5.1).  
 
 
The mucin concentration of the purified PJM samples after dialysis was 380 ± 45.1 µg/ml 
and DNA was undetectable (LOD was 2 µg/ml). The molecular weight of the PJM was 
approximately 4.6 x 106 g/mol, as determined by analytical ultracentrifugation (data 
supplied by Dr Balazs Bajka from the Institute of Food Research). 
 
5.3.5 STD-NMR studies of OF-80-NS22 and 552-02 binding to PJM 
Before use in STD-NMR experiments the PJM was dialysed against water for 48 h then 
subjected concentration in vivaspin tubes, exchange into deuterated buffer and 
concentration in Amicon tube to have a final volume of 100 µL at a concentration of 
~2.5µM. 1H NMR analysis of the mucin solution (Figure 5.10) showed a small but 
Table 5.1. Determination of % dry solids. Determination of the dry weight % of four mucin 
aliquots samples (A, B, C, D). 
 
 Chapter 5 
259 
 
significant NMR signal for glycerol which is used to extend the shelf-life of the filtration 
membrane devices. The glycerol NMR signals spanned the range 3.5 to 4.5 ppm - the 
region in which some OF-80 and 552-02 resonances are found. The contaminated mucin 
was washed with D2O using Amicon tube and glycerol was successfully eliminated from 
mucin (data not shown). 
 
 
Off and on-resonance spectrum NMR of OF-80-NS22 mixed with purified PJM is shown 
in top and bottom spectra of Figure 5.11 A, respectively. Due to the different 
temperature condition used for STD-NMR experiment for PGM (283 K) and PJM (310 K), 
STD spectrum of OF-80-NS22 in Figure 5.11 shows peaks at 3.5 and 1.25 ppm with 
chemical shift slightly down moved of 0.15 ppm compared to the same drug model mixed 
with PGM in (Figure 4 A, bottom spectrum). Inspection of the 1D NMR spectrum reveals 
evidence of an interaction between OF-80-NS22 and mucin. Subtraction of the on-
Glycerol 
Figure 5.10. Glycerol contamination of PJM. 2.5 mM porcine mucin after washing using 
vivaspin tubes resulted contaminated with glycerol (arrow). 
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resonance spectrum in which the protein was selectively saturated from the off-
resonance spectrum produces the difference spectrum (1H STD-NMR spectrum, Figure 
5.11). The percentage of STD and magnetization transfer at 1 s saturation time (Figure 
5.11B) was identical for all protons except B; %STD for B was 1.60 cf. 2.02 for others. This 
was matched by a reduction in magnetization transfer of 20% compared to other signals 
(Figure 5.11 B). 
  
Figure 5.11. STD-NMR spectroscopy for the study OF-80-NS22 and purified mucin binding.  
A Top: reference 1H NMR of mixture drug-mucin; Bottom: 1H NMR (on-resonance) transfer 
of saturation from mucin to OF-80-NS22. Methyl group (M) at chemical shift 1.25 ppm, 
aliphatic group (A1 and A2) chemical shift at 3.5 ppm, proton (B) at chemical shift 3.5 ppm. 
Solvent suppression applied. B percentage of STD and magnetization transfer for each 
proton involved into the interaction with mucin. STD NMR experiments were performed 
using WATERGATE for solvent suppression. 
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1H STD NMR spectra of PJM mixed with 552-02 is shown in the top spectrum and the STD 
spectrum is shown in the bottom spectrum of Figure 5.12. The extent of STD observed 
with purified mucin is comparable to the data recorded for PGM (compare Figure 5.12 
with Figure 4 B). Also in this case three chemical regions were identified to be involved 
into the interaction with the mucin: A1, A2, G1-3, L1-4 (Figure 5.12 bottom spectrum). 
The peak corresponding to G1 and G3 protons, appear to be split in up and down signal 
and opposite to this, proton L2 and L3 were identified as a unique peak. Studies with PJM 
were performed at 310 K whereas PGM studies were conducted at 283 K. As a 
consequence, some resonances shifted. For example, benzyl (A1-2) and butyl group (L1-
4) showed down and up shift respectively. In particular, with the increment of 
temperature at 310 K, the benzyl ring down shifted at 7.4 (A2) and 7.1 (A1) and butyl 
group up shifted to 2.9 (L4), 2.3 (L1) and 1.1 ppm (L2 and L3), whereas the glycerol group 
(G1-3) did not change showing a chemical shift at 3.4 and 3.7 ppm. In general, greater 
peak broadening was observed for 552-02 and the extent of STD was about 15% at a 
saturation time of 1 second (Figure 5.12 B).  
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To probe for differential mucin-binding activities across the 552-02 structure a variable 
saturation time experiment was performed ranging from 0.1 seconds to 6 seconds. The 
Figure 5.12.  STD-NMR spectroscopy for the study 552-02 and purified mucin binding. (A)  
Top: reference 1H NMR of mixture drug-mucin; Bottom: 1H NMR (on-resonance) transfer of 
saturation from mucin to 552-02. Solvent suppression applied (B) percentage of STD and 
magnetization transfer for each proton involved into the interaction with mucin. STD NMR 
experiments were performed using WATERGATE for solvent suppression. 
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saturation curve in Figure 5.13 shows that all protons appear to reach the saturation at 
same STD percentage at about 2 seconds. The initial slope of the saturation curve was 
consistent among all assignable protons bind equally to mucin.  
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5.13. Saturation curve of 552-02 and percentage of magnetisation transfer. 
STD intensities build-up curves for 552-02 in the presence of 100 nM purified mucin. 
Saturation applied from 0.1 to 6 sec. Initial slope calculated using Origin Pro-B Program 
Percentage of magnetisation transfer resulted similar for each proton. 
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5.4 Discussion 
Towards a better understanding of whether mucin may limit the access of inhaled drugs 
to the lung mucosal epithelium we used NMR spectroscopy to gain a molecular level 
insight into mucin-binding events. Several studies report the interaction of inhaled drugs 
molecules to mucus such as aminoglycosides, (39) (23) (40), colistin (40), salbutamol (22) and 
steroid (41) but still little is known about the chemical interaction between drugs and 
mucus components. NMR spectroscopy is a widely used technique to study molecular 
recognition of a small molecule by a macromolecule, be it a receptor, enzyme or 
membrane protein (42). The STD-NMR methodology has emerged over the last 10 years 
to offer new insights and structural information on the binding of a ligand to its receptor 
without the need to perform complex and time-consuming structural deconvolution of 
the entire ligand-receptor complex (43). However, no published studies exist to support 
the use of this technique in studying drug-mucin binding interactions. 
 
In this work, STD-NMR was initially used for studying the transient interaction of mucin 
to tobramycin, drug used for the treatment of Gram negative bacterial infection in CF. In 
preliminary studies whole PLM was used for the investigation of tobramycin-mucin 
interaction but the drug showed negligible STD signal attributable to the drug. 
Tobramycin was chosen as a probe in initial NMR studies because of published evidence 
that indicates that mucin antagonises its antibiotic activity (23) (40). These unexpected 
results could be explained in a number of ways. Firstly, the absence of STD could be due 
to a high affinity interaction, in the sub micromolar Kd range, which would prevent 
 Chapter 5 
265 
 
efficient saturation transfer from mucin to ligand and therefore be recorded as no STD 
(43). Alternatively, tobramycin may serve as a poor ligand for the mucin component of the 
intact porcine lung mucus (PLM). Mucin quantification assays in PLM revealed an amount 
of mucin of 1% (Chapter 3), for STD-NMR experiments is necessary have a large molar 
excess of ligand (1:10 to 1:1000 or more). To probe again whether tobramycin interacts 
with mucin future experiments would involve working with a purified lung mucin 
preparation or whole mucus with a defined mucin concentration that afford calculation 
of optimal ligand:protein ratios. Moreover, a confounding issue in these experiments is 
the impure nature of the lung mucus. The porcine lung mucus used here was a 
heterogeneous solution with significant DNA contamination by DNA (0.5% of dry weight 
as per Chapter 3). Commercially available PGM was trialled in subsequent NMR studies 
due to the 10-fold lower DNA contamination and greater product availability but 
notwithstanding the different biological origin and partially purified nature of the 
product.   
 
Mucus is an heterogeneous material containing not only mucins but also DNA, proteins, 
lipid, and cellular debris (44). The amount of DNA in PLM resulted to be 0.5 % (Chapter 3). 
Scraping of the tissue could have caused significant epithelial shedding and DNA release. 
The interaction of tobramycin to mucin and other mucus component, DNA, has been 
shown by Hunt, Weber (45). They analysed, after dialysis of the drug-mucus mixture, the 
kinetics of tobramycin efflux mixed with sputum from CF patient and ‘‘mock sputum’’ 
which consisted of porcine gastric mucin and +/- calf thymus DNA. Treatment of these 
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models with recombinant human DNase (rhDNase) indicated that rhDNase increases but 
not significantly the tobramycin bioactivity. Moreover, the free tobramycin in the 
dialysates resulted dependent on the concentration of gastric mucin suggesting that 
mucin may play a role in tobramycin binding. 
Tobramycin inhibits the translation of mRNA into protein preventing formation of the 
70S complex by binding to a site on the bacterial 30S and 50S ribosome. The interaction 
of tobramycin to the genetic material was also showed by Wang and Rando (46)  who used 
a tobramycin affinity column to select from a RNA library sequences capable to bind to 
tobramycin demonstrating the specific interaction of the antibiotic tobramycin to RNA 
molecules.  
The interaction of tobramycin with mucus macromolecules was also demonstrated by 
Ramphal, Lhermitte (23) who used sputum from cystic fibrosis patients and separating the 
sputum macromolecules with Sepharose CL 4B column chromatography. Mucus 
macromolecules were mixed with tobramycin +/- treated with DNase and pronase. 
Following equilibrium dialysis, the drug concentration was marginally above the LOD 
even when 100 µg/ml were mixed with 10 mg/ml of the mucus macromolecules 
indicating a strong interaction. 
 
 
To reduce the potential impact of DNA binding STD-NMR experiments were repeated 
using PGM, which displayed a lower DNA concentration compared to the whole porcine 
mucus (Chapter 3). In Figure 5.2 B the mucin spectrum did not include any downfield 
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chemical shift over 5 ppm, consistent with a low abundance of Phe, TYr and Trp residues 
and a highly glycosylated structure (47). Under these condition the STD spectrum (Figure 
5.2 D) displayed this time a weak signal of ~1% STD for all protons which, is consistent 
with weak binding interactions. This in in contrast to the significant tobramycin binding 
to mucin showed by Ramphal, Lhermitte (23) although in our experiment drug 
concentration was 50-fold higher (5mg/ml versus 0.1 mg/ml) and a mucin concentration 
~7-fold lower (1.5mg/ml versus 10 mg/ml).  
 
Mucin glycoproteins are large polyanions and so their negative charge may form an 
electrostatic interaction with aminoglycosides which are cations as demonstrated for 
gentamicin by Saggers and Lawson (48). This glycoprotein in CF is characterized by an 
increased carbohydrate content (49) with higher content of fucose, N-acetyl-glucosylated 
and galactose but no changes in sialic acid. The increase of highly branched 
oligosaccharide structure  may lead to the formation of a stronger interaction with 
tobramycin as shown by Ramphal, Lhermitte (23) without excluding the presence in CF 
sputum of another anionic polymer, alginate. 
 
In contrast to tobramycin, STD-NMR experiments with salbutamol-mucin mixtures 
revealed clear interactions with PGM (Figure 5.3 bottom spectrum) as shown by STD 
signals of 1.9 to 4.95 %. The chemical diversity of the probe ligand allowed for rapid 
identification of specific regions of salbutamol which display higher binding that others. 
The phenolic protons and the adjacent methylene protons displayed a stronger 
 Chapter 5 
268 
 
interaction with mucus (STD 4.9 %) compared to the tert-butyl and “side-chain” portion 
of the molecule (STD 1.9 %). These data support well the published data from Bhat, 
Flanagan (22) who investigated mucus binding of salbutamol (under the US name, 
albuterol) with other 5 compounds (rifampicin, p-amino-salicylic acid, isoniazid, 
pyrazinamide, and pentamidine). Specifically, gastric mucus was used to test the 
development of a purified model mucus system for its application in drug binding studies 
by diafiltration. Salbutamol and the others compounds were shown to display low 
binding with gastric mucin with 80-95% of the applied drug detectable in the reservoir.  
The low salbutamol binding (~10%) finds agreement with our results (STD ~2-5%). To 
date, no other published studies have reported date pertaining to salbutamol-mucin 
binding interactions.  
Vaisman, Koren (11) studied the disposition of inhaled salbutamol in both CF people and 
healthy adults showing that the peak of serum concentration of drug after inhalation was 
reached faster, 15-30 min, and was higher (4 ng/ml) in CF than health people for who a 
peak of salbutamol (2ng/ml) was reached at 30 min (p<0.05). The reason for the higher 
system concentration of salbutamol in CF people may be that diseased tracheobronchial 
tree in CF patience reduces the mucociliary clearance rate with consequent higher 
permeation of salbutamol. In contrast, it has been shown that the inhalational PK of 
salbutamol is similar in both asthmatic and COPD patients (10) (50). 
 
Results from Chapter 4 highlighted a significant variability in the extent of mucin binding 
across a range of experimental ENaC blockers. Our studies moved then onto the 
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investigation of the physical-chemical interaction of mucin and ENaC blockers and we 
sought to gain information on the receptor-ligand binding as well as detailed information 
about the binding epitope of the ligand and the extent of binding. Two ENaC blockers 
were chosen for investigation in these NMR studies. Factors influencing the choice of 
probe molecule included the following factors: 
1) The extent of mucin binding from ultrafiltration studies. The drug-mucin binding 
varied greatly across the range of compound. To allow the detection of 
differences was decided to study molecules that showed low and high binder. 
The low-throughput nature of the technique and project time-limitation limited 
us to study two molecules.  
2) The chemical diversity of the molecules. The range was structurally diverse and 
drug molecules were chosen considering STD-NMR limitations which require the 
use of compounds with nonexchangeable protons. 
3) The solubility and availability of probes. Experiments with STD-NMR require the 
use of compounds with high solubility without the need for high concentrations 
of co-solvents such as DMSO which may denature mucin or interfere with binding 
pockets. 
 
Taking into consideration these points, amiloride, as a low-binding drug, could not be 
used due to absence of visible protons, so OF-80-NS22 was chosen for STD-NMR 
experiments. GF-40-QQ33 and benzamil, which showed the highest binding, were 
discarded due to their high low aqueous solubility and limited availability of compound.  
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552-02 was easily soluble in the mucin solution when added at concentration up to 4 
mM from a DMSO stock (~6% DMSO final concentration). It was not possible to 
determine quantitatively the dissolved concentration of 552-02 in the mucin solution but 
there was no evidence of drug solubility issues e.g. precipitation in the sample tube. The 
solubility of OF-80-NS22 in aqueous buffer was highly favourable but to avoid DMSO-
induced changes in mucin behaviour the co-solvent was added at a concentration 
equivalent to that used for 552-02.  
 
Consistent with the ultrafiltration binding data from Chapter 4, 552-02 gave a 5-fold 
more intense STD signal than OF-80-NS22 at equivalent conditions and drug : mucin 
molar ratios (3300:1). That STD-NMR is based upon the Nuclear Overhauser Effect (NOE) 
which unequivocally supports the close contact (< 5 Å) of the ligand with mucin. The 
observation of comparable STD intensities for each proton resonance in both ENaC 
blocker molecules it is appropriate to conclude that the binding interaction is non-
specific in nature. Furthermore, a competitive assay was carried out to infer whether 
these two ENaC blockers bind to the same site. If the two ligands compete for the same 
site of binding, no STD signals of the “weaker” ligand (OF-80-NS22) should be observable, 
since it would have no opportunity to make close contact with the receptor (mucin).  
Alternatively, if the two compounds bind at different sites, the STD-NMR intensity of the 
“weaker” compound will not be affected. In our results (Figure 5.5 spectrum D) the 
ligands interaction to mucin appears non-competitive as signal of both ligands are 
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observable. This observation serves as further confirmation of a non-specific binding 
event that involves interactions across the ligand structure. 
 
Amiloride has been shown to intercalate into DNA (51) (52). For example, Bailly et al used 
DNA foot-printing to demonstrate sequence-specific DNA-amiloride interactions, 
specifically in AT-rich sites. The chemical interaction amiloride-DNA appears to involve 
the amino group at position 5 of the drug molecule (53). The proposed binding portion, in 
the pyrazinoyl group, is conserves across all analogues so DNA binding would be 
expected to be seen for all amiloride analogues.  
 
Within the probe molecule structures there are a number of exchangeable protons 
including amino and guanidine protons in addition to, and most notably, the pyrazinoyl 
group. These protons are invisible in the 1H STD-NMR experiment because of a lack of 
magnetization transfer onto them therefore we are not able to determine their 
involvement into the interaction with mucin. The pyrazinoyl guanidine group of 
amiloride and analogues was thought to be a privileged structure for ENaC blockers (54) 
but the replacement of the guanidine group with amino group (55) or quaternary amine 
(56) has also been shown to be capable to inhibit ENaC blocker. OF-80-NS22 is an example 
guanidine group substitute with an amine but also resulted invisible to STD-NMR 
experiment. 
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To better deconvolute the drug-mucin binding processes and to eliminate interference 
from DNA, lipids and other protein a multi-step mucin purification procedure was 
performed. As highlighted in Chapter 3, the yield of crude mucus isolated from porcine 
respiratory tract was only ~ 600 µl/lung with approximately 1 % mucin. Therefore, PJM 
was used instead of a plentiful supply of lung mucus. Mucin purification was performed 
using a standard method (57) (58) (59) which involves the dispersion and denaturation of the 
mucus in a solution of 4-6 M of GdnHCl. The combination of Alcian Blue staining, UV 
absorbance and buoyant density determination allowed for the identification and 
resolution of mucin- and DNA-rich fractions. For example, AB staining is not mucin-
specific. AB-positive DNA fractions were excluded by UV spectroscopy analysis. Mucin 
fractions were separated from DNA, absorbing at 260 nm, and material with a high 
absorbance at 280 nm. Although mucin has a protein core, aromatic amino acid 
constitute less than 5% of the protein which represents 25% of the total molecular 
weight of this high glycosylated mucin (47)  (58). Greater resolution of DNA and mucin 
fractions is also facilitated through use of a lower GdnCl concentration because of a 
greater difference in the buoyant density of mucins and DNA (58).  The purified mucin 
showed a isopycnic point between 1.38-1.49 g/ml and in agreement with previous 
observations for MUC5AC mucin purification from human trachea (60), MUC5AC and 
MUC5B sputum from individual chronic bronchitic patients (61), porcine jejunal  mucin  (62) 
and cervical mucin (58). Biochemical analyses were applied on the purified PJM for the 
determination of the dry solid %, mucin concentration and DNA contamination. The 
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purified mucin was devoid of nucleic acids, as judged by the non-detectable DNA with 
fluorimetric assay using DABA.  
 
The major secretory mucin synthesized and secreted by goblet cells in the small and large 
intestine is MUC2  (63). The molecular weight of PJM was 4.6 x106 g/mol obtained by 
sedimentation velocity in an analytical centrifuge. This results concurs with that obtained 
by Herrmann, Davies (64) i.e. ~4.0 × 106 g/mol using analytical ultracentrifugation and 
laser light scattering. However, earlier work by Mantle and Allen (65) described 
sedimentation coefficients of PJM equating to a molecular weight of 1.72 x106 g/mol. 
 
Purified PJM was used to perform STD-NMR experiments using OF-80-NS22 and 552-02. 
These studies also showed a shorter inter-proton distance between 552-02 protons and 
mucin in bound state compared to OF-80-NS22 protons. The extent of STD for 552-02 
was 7-fold stronger than that of OF-80 which is comparable to the results of 
ultrafiltration binding studies where the percentage of binding of OF-80-NS22 and 552-
02 was 6.9 and 32.5% respectively. These data validated the STD-NMR results with PGM 
and prove that the observed binding is attributable, to some degree, to mucin and not 
the DNA component of PGM. Mucus is a complex heterogenic solution also containing 
lipid (glycolipids, phospholipids, fatty acid, etc), plasma proteins (such as serum albumin) 
and secreted antibodies (IgA) (66) that enhance protection against specific pathogens (67).  
All these component have been shown to be significant important for the rheology 
properties of mucus capable to dramatically influence the viscosity of the mucus 
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glycoprotein (68) (69). Reid and Bhaskar (70) suggested that both physical and chemical 
properties of bronchial epithelial mucus depend on its special mix of macromolecules 
and lipid constituents which can be variable between normal airway and disease (71). 
Therefore, the in vivo mucus barrier is a complex, heterogeneous anisotropic system and 
neither PGM nor PJM are appropriate for studying mechanistic details of drug binding.  
 
We next sought to confirm the non-specific nature of ENaC blocker- mucin binding using 
552-02. A saturation curve was constructed over different saturation time scales from 
0.1 to 6 seconds. The resultant saturation curve indicated that each assignable proton 
increased at similar rates and indeed plateaued at similar point (Figure 5.13). The STD 
signal depends on the duration of the radiofrequency irradiation of the receptor and the 
saturation received from the ligand protons increases with this time (saturation time) 
(29). Gradually increasing the irradiation time, protons with a tight interaction to mucin 
are expected to reach higher saturation transfer % compared to protons with weaker 
interaction. Increasing the saturation time all 552-02 protons produced very similar 
saturation transfer which leads to the conclusion that all protons bind equally to mucin. 
In the case of 552-02, if one particular region of the molecule had displayed specific 
binding to a defined region of the mucin glycoprotein it would be detectable as an 
increase in maximal STD for the corresponding peaks. For instance, the hypothetical 
scheme in Figure 5.14 reflects a situation in which protons in the red chemical region 
undergo a stronger interaction with mucin, resulting in a higher saturation transfer %, 
compared to others in the green or pink chemical region. Moreover, it is possible to 
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identify the specific protons that has a tight interaction to mucin. For instance, Figure 
5.14 B shows a theoretical strong interaction of proton “a” in the butyl chemical region 
displaying the highest STD% compared to others protons of the same chemical region.  
STD-NMR was applied by Moller et al (36) to determine the binding epitope of the SM3 
monoclonal antibody to partially deglycosylated MUC1 glycoprotein which is highly 
enriched on breast cancer cells but there is no information on the literature regarding 
the application of STD-NMR ligand binding to intact mucin. 
 
Conclusion 
This chapter includes data supporting the use of STD-NMR to study the binding of small 
molecular probes to three different mucus / mucin models to the best of our knowledge, 
there has not yet been any literature reporting the chemical detection of the interaction 
between amiloride and mucin using STD-NMR technique. This afford to perform a 
detailed epitope mapping of the ligand bound to mucin and identification of the chemical 
group which contribute to the sequestration of drug in the airway luminal mucus and 
negatively impact on lung disposition. Amiloride and analogues are all characterised by 
a pyrazinoyl group which protons are exchangeable and invisible in SDT-NMR but 13C 
NMR could be used to check the extent of binding. 
The understanding of chemical group limiting the access of the drug to its receptor will 
give a very important contribute to the development of drug in the future. 
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Figure 5.14. Theoretical saturation curve of 552-02. 
Theoretical interaction of 552-02 butyl (red) benzyl (green) and glycerol group (pink) to 
mucin. (A) stronger interaction (red) of 552-02 protons of the butyl group where proton “a” 
displays a stronger STD% (B). 
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Pulmonary delivery of therapeutics is a growing market and offers a variety of 
opportunities in drug delivery for systemic and local delivery for the treatment of lung 
disease. In 2012 the Business Communications Company market research reviewed the 
global markets for drug delivery technologies highlighting a pulmonary drug delivery 
technologies market in wide increment with a valuation of $20 billion in 2010 with a 
forecasts trends to about $40 billion in 2016.  
In spite of an expanding of literature on the absorption of inhaled therapeutics, there is 
still a lack of knowledge about the detailed processes that occur after drug deposition in 
the airways. This is principally due to the scant availability of tools to visualise and 
quantify these processes post-inhalation. For the treatment of patients with airflow 
obstruction the inhaled route is considered an optimal way of administration of drugs 
such as corticosteroids, β-agonists and aerosol administration of antibiotics against P. 
aeruginosa is commonly used in CF.  
The delivery of molecules by aerosol must overcome the MC mechanism so the 
molecules must rapidly diffuse though the mucus layer lying the epithelium. 
Alternatively, inhaled antibiotics must penetrate the mucus barrier sufficiently to bind 
the target bacterial colonies within the sputum.  
 
From the late 80s and early 90s, the retention of lipophilic polycyclic aromatic 
hydrocarbons (PAHs) within the mucus layer on the respiratory tract of dogs has been 
studied  by Gerde, Muggenburg (1) (2). The studies consisted of installation on the airway 
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of benzo[a]pyrene (BaP) or phenanthrene and consequent determination of their tissues 
concentration. Results showed that the highly lipophilic toxicant BaP was higher retained 
by the mucus layer with about 35% of BaP retained after 1 min of exposure whereas only 
3% of phenanthrene was retained at the same time. The authors speculated that the 
retention of PAHs is due to lipid content of mucus but no proof of this hypothesis was 
shown. The influence of the mucus and MC system on PAH retention would be expected 
to serve a protective role by avoiding prolonged retention of these lipophilic toxicants at 
the epithelium surface and reduced absorption across the airways. It should be noted 
that this mechanism would serve principally to protect the lung mucosa but would not 
prohibit exposure of the gastric/intestinal mucosae to mucus-bound BaP that is cleared 
from the lung and swallowed.  
The consideration of drug-mucus interactions in the lung has received very little 
attention. In the oral drug delivery field a series of studies have indicated that drug-
mucus interaction may limit the bioavailability of therapeutics via any mucosal surface 
reducing the efficiency with which drugs can access their target receptor which may be 
critical determinant of a drug’s efficacy in vivo (3) (4) (5). 
For example, Karlsson, Wikman (6) used the mucus-producing human goblet cell model 
HT29-H to investigate steroid transport across polarised cell monolayers. Notably, the 
transport rate of the lipophilic steroid, testosterone, increased ~50% following removal 
of mucus from the apical side of the monolayer.  
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Chapter 3 of this thesis was mainly focused on the identification of an appropriate mucus 
model for the investigation of inhaled molecule-mucus interactions.  Firstly, NHBE cells 
were cultured with the aim to harvest human mucus and to ensure mucociliary 
differentiation were chosen NHBE cell passage 1 (7, 8). Mucus production was confirmed 
by AB staining for the detection of sialylated or sulphated groups on mucin (9) (10) and also 
using immunocytochemistry staining of MUC5AC (11). Harvested mucins from NHBE cell 
were also analysed by AFM to confirm the mucin polymer morphology.  
 
The harvest of mucin from in vitro lung models offers the advantages of homology to the 
in vivo mucus barrier, the expression of appropriate MUC isoforms and facile availability 
of the model without the need for ethical approval for human tissue harvest. 
Furthermore, NHBE cells mimic the in vivo bronchial epithelium through mucociliary 
differentiation (12) and the formation of two discreet layers of ASL (PCL and mucus layer) 
(13) . Recent development of the gel-on-brush model of airway mucus and penetration of 
drugs through these epithelial barriers will rely on this model in coming decades. 
However, the model’s high cost and the low mucus yield significantly confound these 
advantages and led us to explore an ex vivo porcine mucus model as an alternative. 
Biochemical analysis of PLM harvested revealed a high DNA contamination which could 
have influence the viscosity of the mucus glycoprotein (14) affecting mucus rheology. 
Therefore, diffusion assays were performed using a commercially available mucin, PGM. 
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Diffusion assays were performed using a Franz-cell system, for probes spanning a 376-
70 kDa molecular weight range through three mucin gels (1, 3 and 5%) with the aim of 
identifying size-filtering phenomena within the model. The substitution of aqueous 
solution with mucin significantly reduced solutes directional transport. As also showed 
by Desai, Mutlu (15) using porcine gastric mucus, the diffusion of FL-NA and FITC dex 
probes resulted significantly retarded in presence of mucin and appeared inversely 
correlated with increment of solutes molecular weight. We noticed a reduction of solutes 
diffusion with increased mucin concentration mostly for probes >10kDa. Desai et al 
noticed a significant reduction of diffusion rate for molecules >30kDa, however the 
disparity on the results could be explained by the ~7-fold larger pore diameter in the 
support membranes used in Desai’s studies (15). For example, our data indicates that 
FD40 (size 9 nm) displayed restricted diffusion across the bare dialysis membrane which 
bore a ~15nm pore diameter. FL-Na, FD4 and amiloride did not show significant 
difference in mucus diffusion but benzamil, which structure differs from amiloride only 
by the addition of benzyl group, showed a significantly retarded diffusion through mucin 
solution. This observation led us to speculate about the involvement of hydrophobic 
forces between benzamil and mucus glycoprotein.  
 
In Chapter 4 we showed the application of fluorescence and UV-vis spectroscopy 
techniques to further investigate amiloride and benzamil interaction to mucin. 
Consistent with Franz cell transport data benzamil demonstrated greater evidence of 
mucin binding than the less lipophilic amiloride. Technical limitations, including the use 
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of large concentration ranges of drug and mucin as well as the time-consuming nature 
of titration experiments, prohibited further UV/fluorescence spectroscopy investigation. 
Spectroscopy techniques have been used to study small molecules’ interactions with 
mucin (16, 17) but such techniques are not routinely used for screening compound binding 
to protein / glycoprotein targets. Chapter 4 also describes the development and 
validation of a 96-well ultrafiltration assay as a method to study the extent of binding of 
a wider range of solutes. This approach benefits from a wider range of sample numbers 
per experiment and the ease of transfer to robotic system that are widely used in 
pharmaceutical industry. Mass balance calculations using an internal standard approach 
afforded the precise detection of mucin binding and non-specific binding to the ultra-
filtration plates. Consistent with the published literature there was an increased extent 
of non-specific binding to the plasticware yet binding to mucin could be determined after 
subtraction of NSB from each experimental condition.   
Binding isotherms constructed for amiloride and analogues showed most frequently a 
monolayer binding model, but a multilayer binding was also noticed for three QQA.  This 
self-promoted binding site may have a significantly effect on drug disposition leading to 
a significant increment of drug molecules retained on the airways. To better understand 
the pre-determining factors for multilayer binding future work will involve the study of 
further analogues and unrelated compounds. Solubility of drug candidates in aqueous 
solvent is one of the critical physicochemical properties for the successful development 
of oral drugs (18), although solubility of compounds was accurately tested to avoid 
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precipitation issue it could be further probed by looking for the solid form of the 
precipitant in the sample by studying under polarised light microscope. 
 
We next sought to identify physical parameters that correlated with the extent of mucin-
binding at a 20 mM concentration, which is appropriate considering the deposition of 
therapeutic ENaC dose into the human lung. Both NQQA and QQA showed a strong 
correlation with Log P o/w and QQA also displayed correlation with PSA, rotatable bonds, 
van Der Waal volume, polarizability and H-acceptor number.  A series of publications by 
Matthes, Nimmerfall (19) (20) analysed binding of a series of polar and non-polar drugs to 
pig intestinal mucus showing that more lipophilic drugs displayed slower diffusion 
through mucus and higher affinity for mucus compared to more hydrophilic ones, the 
authors concluded that hydrophobicity may be an important factor for drug-mucin 
interaction. Other authors, including Kearney and Marriott (21) performed equilibrium 
dialysis of the tetracycline-mucin mixtures in different pH condition (1 to 11) and 
attributed the tetracycline interaction to mucin to a combination of electrostatic forces 
and hydrophobic interactions. In particular, the binding process was considered to be 
non-specific through a hydrophobic process at neutral pH, whereas at acidic pH was 
proposed a more specific electrostatic interaction between the negatively charged sialic 
acid residues on mucin and the positively charged tetracycline due to the net charge of 
dimethyl-amino group. Gordon, Hodges (22) using an equilibrium dialysis, demonstrated 
the binding bacterial alginate to positively charged aminoglycosides antibiotic (β-lactams, 
gentamicin and tobramycin). 
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This 96-well ultrafiltration approach for screening drug-mucin presented here was 
methodologically similar to those used by Fung, Chen (23) and Wang (24) for the 
determination of PPB and data presented in Chapter 4 reinforce the benefits of 
ultrafiltration for the determination of drug-macromolecules interaction.  
 
Further work should be focused on the deeper elucidation of ENaC-mucin interaction. 
Such as, the 96-well ultrafiltration assay may be performed pre-treating the mixture with 
DNase to exclude DNA influence of the results obtained using PGM as mucin source. 
Furthermore, the binding characteristics of the mixture in different pH condition may 
help in understanding the involvement of hydrophobic or electrostatic interaction 
interactions. For example, if the binding is governed by positive charge of ENaC blocker 
and negative charge of sialic acid residues of mucin at low pH we should see a more 
specific interaction. The increment of the pH up to 7 should causes the fall in the binding 
level in coincident with the reduction in the amount of the neutral species.  
Pronase digestion of mucin may be used to further study hydrophobic interaction. If 
binding sites are on the non-glycosylated, the digestion of the mucin protein core will 
lead to a reduced extend of drug-mucin interaction. 
Hydrophobic interaction may be further explored by studying the effect of different NaCl 
concentration on drug-mucin interaction. The increment of NaCl concentration will lead 
mucin unfolding with a higher number of hydrophobic sites exposed which may be 
observed with changing in fluorescence intensity. 
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Hydrophobic molecules have been shown to be absorbed more rapidly through 
epithelium (25) (26). Tronde et al., (26) studied the diffusion to nine drugs with range cLog P 
of -0.4- 3.5 to Caco-2 cell monolayers and the drug absorption in the isolated and 
perfused rat lung demonstrating a good correlation of both in vitro and in vivo model to 
drug lipophilicity. In our studies, the hydrophilic character of QQAs appeared to limit the 
transport of ENaC blockers and no clear in vitro correlation was found for NQQA probably 
due to the different transport pathway involved.  
Hydrophilic drugs have been shown, in some cell types, to traverse the epithelium via a 
paracellular route whereas hydrophobic molecule appear translocated via the 
transcellular route (27) (28) and there are evidence of a cation transporters for amiloride 
(29).  
With evidence of mucin binding in hand it was desirable to determine whether the 
presence of mucin at the apical membrane side of lung epithelia would reduce the rate 
of solute transport across the lung. The influence of purified PJM on 552-02 apparent 
permeability across Calu-3 monolayer was measured showing a 20-fold increase of 
monolayer permeability with increased transport of 20-fold. This effect was also 
reported by Boegh, Baldursdottir (30) after exposure of Caco-2 cells to biosimilar mucus 
composed of purified gastric mucin, lipids and protein and was associated to the 
presence of high concentration of linoleic acid. And so, further work is required to further 
delineate the transport pathway into / across the epithelia or passive paracellular or 
active/facilitated transport pathways used from amiloride and analogues. Taken 
together with published reports these observations indicate that the application of 
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exogenous mucin/mucus to intact monolayer systems is very challenging. In spite of cost 
and labour intensiveness the primary NHBE model presents an intact, endogenous 
mucus layer, albeit one that is significantly less voluminous than that found in the 
diseased lung. 
 
In Chapter 5 a relatively new NMR technique, STD-NMR, was used to probe mucin 
binding. STD-NMR analysis of 552-02 and OF-80-NS22 demonstrated a noticeably 
stronger interaction of 552-02 to mucin compared to OF-80-NS22. These data closely 
matched the ultrafiltration binding assay. Published evidence of amiloride-DNA binding 
prompted us to repeat STD-NMR studies on CsCl-purified jejunal mucin. Intriguingly, the 
results were consistent with those of PGM which indicates that DNA binding was not 
responsible for the binding observed in PGM studies. This allowed the mapping of 552-
02 and OF-80-NS22 protons as “interacting” and “not-interacting” (Figure 6.1) and gave 
further confirmation of the stronger interaction of 552-02. The invisibility of the pyrazine 
protons in all amiloride analogues is a key deficiency of the 1H STD-NMR technique. A 
number of alternative NMR protocols could be employed to better understand their 
binding. These include 15N or 13C based pulse sequences. Drawbacks include lower 
sensitivity and the need for isotopic enrichment.  
 
New formulations, for more controlled drug delivery, are necessary to promote particles 
dissolution in the airway. Drugs disposition may be limited by mucin and other mucus 
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component (DNA, lipid and alginate) and more studies are needed to better understand 
transport pathways across the pulmonary epithelium. 
 
In conclusion, the results obtained from this thesis have provided an insight into the 
physical-chemical properties between drug-mucin interaction. 
The development of a new drug is a complex process and the estimation of the extent of 
inhaled drug interaction to mucin is a step of great value in drug candidates selection.  
The sensitive and quantitative 96-well ultrafiltration binding assay developed may find 
industrial application for screening of a number of drug model with opportunity of 
automation for the screening and detailed investigation of drug binding to mucin and 
other macromolecules.  
We also report the use of STD-NMR to probe mucin-drug interaction and results 
confirmed that ENaC blocker access to epithelial targets may be negatively affected by 
non-specific mucin binding.   
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Figure 6.1. 552-02 “Interacting” and “non-interacting” protons.  
STD-NMR of mucin-552-02 mixture showed Interacting-H to mucin and Non-interacting-H/Non-
detectable-H. 
Interacting-H 
Non-Detectable H  
Non-Interacting-H (?) 
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